Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
1
Confidentiale
CLINICAL STUDY PROTOCOL
Protocol Title A Phase 2b, Dose-Ranging, Randomized, Double-Blind, 
Placebo-Controlled, Multicenter Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension
Protocol Name/Number ELEVATE 2 / RVT-1201-2002, Version 4.0 (Amendment 3)
Approval Date 19JAN2022
Compound Name/Number Rodatristat ethyl / RVT-1201 
Indication Treatment of Pulmonary Arterial Hypertension
Study Phase Phase 2b
Sponsor Name Altavant Sciences GmbH
Legal Registered Address Sponsor:
Altavant Sciences GmbH
Viaduktstrasse 8
CH-4051 BaselSwitzerlandU.S. Agent:
Altavant Sciences, Inc.
6501 Weston Parkway
Suite 330Cary, North Carolina 27513United States of America
Study Region(s) United States, Canada, Poland, United Kingdom, France, Spain, 
Germany, Italy, Belgium, Bulgaria, Ukraine, Latvia, Austria, 
Republic of Moldova, Bosnia and Herzegovina, Serbia, and Czech 
Republic
Regulatory Agency Identifier Number(s)IND: 126945 File Number: HC6-24-c223565
EudraCT: 2020-004971-42
1:  All sites outside the United States are subject to the requirements of 21 CFR 312.120 and not under the IND 126945
CONFIDENTIALITY STATEMENT
The confidential information in this document is provided to you as an investigator, potential 
investigator, or consultant for review by you, your  staff, and applicable  Independent Ethics 
Committee/Institutional Review Board. It is und erstood that the inform ation shall not be 
disclosed to others without written authorizat ion from Altavant Sciences GmbH except to the 
extent necessary to obtain informed consent fr om those persons to whom the investigational 
product may be administered.




		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
2
ConfidentialProtocol Amendment Summary of Changes Table 
DOCUMENT HISTORY
Document Date
Amendment 3, Version 4.0 19JAN2022
Amendment 2, Version 3.0 21DEC2021
Amendment 1.9, Version 2.9 (Serbia Specific 
Amendment)21DEC2021
Amendment 1.8, Version 2.8 (Germany Specific 
Amendment)07SEP2021
Amendment 1.7, Version 2.7 (Poland Specific 
Amendment)23AUG2021
Amendment 1.6, Version 2.6 (France Specific 
Amendment)20JUL2021
Amendment 1.5, Version 2.5 (Czech Republic
Specific Amendment)14JUL2021
Amendment 1.4, Version 2.4 (Poland Specific 
Amendment)14JUL2021
Amendment 1.3, Version 2.3 (France Specific 
Amendment)22JUN2021
Amendment 1.2, Version 2.2 (Italy and Germany 
Specific Amendment)17JUN2021
Amendment 1.1, Version 2.1 (UK and Bulgaria 
Specific Amendment)28MAY2021
Amendment 1, Version 2.0 19NOV2020
Original Protocol 18SEP2020



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
3
ConfidentialAmendment 3 (19JAN2022)
Section# and Name Description of Change Brief Rationale
1.3 Schedule of 
Assessments (Main 
Study)
1.4 Schedule of 
Assessments (First 
24 Weeks of OLE)Week 8 of the Main Study and OLE have been changed 
from a telephone/teleme d visit to a clinic visit.  Weight, 
vital signs, ECG and collection of safety laboratories are 
being added to Week 8 of both the Main Study and the 
OLE.Assessments are 
being added to 
Week 8 as an additional safety 
measure so there 
is not 8 weeks between visits.
1.3 Schedule of Assessments (Main 
Study)
1.4 Schedule of 
Assessments (First 
24 Weeks of OLE)Additional unscheduled safety assessments may be 
conducted at any time during th e study if the Investigator 
or Sponsor deems it necessary  for the safety of the 
patient.Additional 
wording added 
to clarify 
unscheduled visits.
3.0 Objectives and 
EndpointsDeletion of the following from additional objectives:
RPeptide (NT-proBNP)This is a 
discrepancy â€“
this objective is under Secondary 
endpoints 
already and so deleted here.
9.2.5.5 Other Tests Additional wording added to end of section:
Additional unscheduled laboratory assessments may be 
conducted at any time during th e study if the Investigator 
or Sponsor deems it necess ary for the safety of the 
patient.Additional 
wording added 
to clarify 
unscheduled visits.
Amendment 2 (21DEC2021)
Section# and Name Description of Change Brief Rationale
1.1 Synopsis
4.2 Number of 
PatientsAddition of Serbia, Republic of Moldova, Austria,
Bosnia
Addition of new sites fro m the original 45-50 sites,
approximately 68 sites.Additional 
countries and 
sites added for 
enrollment



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
4
ConfidentialEx-US clinical sites are subject to 21 CFR 312.120 
(acceptance of foreign data) and are non-IND sitesClarify ex-US 
sites are not 
under the US IND
1.1 Synopsis
3.0 Objectives and 
EndpointsObjectives and Endpoints subheadings were added 
(safety, additional and PK/PD).  No changes to actual Objectives or Endpoints were done.Clarification of 
type of 
objectives and 
endpoints.
Included in 
Amendment 1.9 (Serbia, RA 
request)
1.1 SynopsisIn synopsis only: title change from Primary and 
Secondary Endpoints to Primary and Secondary Objectives and update to Exploratory Objectives Change to reflect 
the synopsis 
wording is all Objectives rather 
than Endpoints.  
Both Main Study Objectives and 
End Points are 
found in Section 3 of the Protocol.
1.1 Synopsis
5.1 Inclusion CriteriaChange to #7 Inclusion criteria
From (changes in italics):
a. Forced expiratory volume in one second (FEV 1)
Â•60% of predicted normal, and
b.)(9)RUFHG9LWDO&DSDFLW\)9&UDWLRÂ• 0.70, and 
c. Total lung capacity (TLC) Â•70% of predicted normal 
(high-resolution com puted tomography [HRCT] required 
for7/&Â• 60% and < 70%)
To (changes in bold):
a. Forced expiratory volume in one second 
(FEV 1Â•60% of predicted normal, and
b.7RWDOOXQJFDSDFLW\7/&Â•RISUHGLFWHG
normal RU)9&Â•SUHGLFWHGLI7/&LV
not available; For subjects with CTD DVVRFLDWHG3$+LI7/&LVÂ•RIChange in 
wording to clear 
up ambiguity. 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
5
Confidentialpredicted but < 70% of predicted or if 
)9&Â•Rf predicted but < 70% of 
predicted, high resolution computed tomography [HRCT] obtained within 6 months of screening may be utilized to demonstrate limited interstitial lung disease
1.1 Synopsis
5.1 Inclusion CriteriaFrom:
3. Body mass index (BMI) Â•18 kg/m2DQGÂ” 38kg/m2
To:
3. Body mass index (BMI) Â•18 kg/m2DQGÂ” 40kg/m2Increase in BMI 
to be more inclusive of 
patient 
population.
1.1.Synopsis
5.1 Inclusion CriteriaFrom (changes in italics):5. Confirmed diagnosis of  PAH and meet ALL the
following hemodynamic criteria  by means of a screening
RHC completed prior to randomization:a. mPAP of > 20mmHg
b.395Â• 400dyneâ€¢sec/cm5
c. Pulmonary capillary wedge pressure (PCWP) or left
ventricular end diastolic pressure (LVEDP) ofÂ”12PP+JLI395Â• 400 and <
500 dyneâ€¢sec/cm5, or
3&:3/9(
'3Â” 15PP+JLI395Â• 500 dyneâ€¢sec/cm5
d. 6MWD of 100 to 550 meters at Screening
To (changes in bold):
5. Confirmed diagnosis of  PAH and meet ALL the
following hemodynamic criteria  by means of a screening
RHC completed prior to randomization:a. mPAP of >2 0mmHg
b.395Â• 350dyneâ€¢sec/cm
5
c. Pulmonary capillary wedge pressure (PCWP) or left
ventricular end diastolic pressure (LVEDP) ofÂ”12PP+JLI395Â• 350and <
500 dyneâ€¢sec/cm5, or
3&:3/9(
'3Â” 15PP+JLI395Â• 500 dyneâ€¢sec/cm5Updated 
guidelines for
pulmonary 
hypertension (PH) is defined 
as a mean 
pulmonary arterial pressure 
(mPAP) greater 
than 20 mmHg,confirmed by 
right-sided heart 
catheterization,therefore this 
update is being 
made.
The selection of 
a minimal PVR of 400 dyn.sec.cm-5was selected for the ELEVATE-2study based upon precedent of recent phase 2 clinical trials of other agents, given the 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
6
ConfidentialBelow criteria was separa ted out from Inclusion #5
6. 6MWD of 100 to 550 meters at Screeningmechanism of 
action of rodatristat ethyl, there is no scientific evidence to suggest that subjects with lower, yet substantial pulmonary vascular disease will not demonstrate a treatment response, thus the lower limit of PVR is changed to greater than or equal to 350 dyn.sec.cm-5.
6MWD is not a 
hemodynamic criteria and 
therefore now a 
stand alone inclusion 
criteria.
1.1 Synopsis
5.2 Exclusion 
CriteriaBolded wording added:
4. Three or more of the foll owing risk factors for left 
ventricular disease:
a. BMI > 30 kg/m2
b. Diagnosis of essential hype rtension that is actively 
treated
c. Diabetes mellitusAlternative 
diagnostic 
criterion if LAVinot available.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
7
Confidentiald. History of significant co ronary artery disease
(e.g., chronic stable angina, history of coronary intervention within the last  3 months, or a stenosis 
> 70% at coronary angiography)
e. Atrial fibrillation
f.Left atrial volume index > 41 mL/m2[or left atrial 
diameter (LA) > 4 cm if LAVi unavailable]
1.1 Synopsis
5.2 Exclusion 
CriteriaExclusion criteria changed from (in italics ) to (in bold )
15. Patients with:Uncontrolled arterial hyperten sion (Systolic Blood Pressure 
[SBP] > 180 mmHg and/or Diastolic Blood Pressure [DBP] > 110 mmHg), or hypotension (SBP < 90 mmHg and/or 
DBP < 50 mmHg)
15. Patients with (during Screening):
a. Severe hypertension (SBP > 180 mmHg and/or 
Diastolic Blood Pressure [DBP] > 110 mmHg), and 
patients with severe hypotension (SBP < 90 mmHg and/or DBP < 50 mmHg)
b. Hypertension or hypotension considered not controlled 
in line with clinical standardsUpdated to 
clarify 
â€˜uncontrolledâ€™
Included in 
Amendment 1.8 
(Germany, RA 
request)
1 Synopsis
5.2 Exclusion 
CriteriaAdded wording in bold :
26.Use of any investigational drug within 30 days or 
5 half-lives (whichever is longer) prior to Screening 
or 90 days if an investigational drug for PAH, unless local health authority guidelines mandate a longer 
period , or in consultation with the medical monitor,
will not interfere with the safety or efficacy of the 
studyAdded wording 
to allow for 
flexibility.
1.1 Synopsis
5.2 Exclusion 
CriteriaAddition of exclusion criteria #27. Any history of 
hypersensitivity to rodatr istat ethyl, any of its 
components, or any components in the placebo preparation.Exclusion 
criteria missed in 
original protocol
Included in 
Amendment 1.2 
(Germany, Italy and Czech 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
8
ConfidentialRepublic RA
request)
1.1 Synopsis
5.2 Exclusion CriteriaThe following exclusion criteria has been added:
28. Patient is deprived of th eir liberty by a judicial or 
administrative decision, or is  receiving psychiatric care, a nd is admitted to a health 
or social institution
29. Patient is subject to lega l protection or is unable to 
express consentCriteria was 
added at request 
of Regulatory Authority.
Included in 
Amendment 1.3 (France RA 
request)
Schedule of Assessments (Main 
Study)
9. Study 
Assessments and 
Procedures
9.1.6 Pulmonary 
Function Tests 
(PFTs)Addition of Assessment:
Pulmonary Function Tests (PFTs)
(unless completed in last 24 weeks)
Wording added in bold:
Once all screening procedures are complete and the 
Investigator determines that the patient is eligible, the 
site must upload/send the required supporting 
documentation for approval by the Sponsor. The required information will include the RHC report (including 
tracings), PFTs obtained (may use PFTs completed 
within the 24 week peri od prior to screening or 
obtained at Screening) , the screening echocardiogram, 
as well as specific information about the patientâ€™s 
medical history and disease st ate to further ensure the 
appropriateness of each patient  being enrolled into this 
study. Approval from the Sponsor  must be obtained prior 
to randomization.
9.1.6. Pulmonary Function Tests (PFTs)
PFTs (performed with or without bronchodilation) 
should be completed at Screening if there are no historical results from tests completed within 24 
weeks prior to Screening.PFTs were 
already part of 
the Inclusion Criteria but were 
not in the 
Schedule of Assessments or 
described in 
Study Assessments and 
Procedures 
section.
1.3 Schedule of Assessments (Main Study)Dispensing IP via IRT deleted from Week 8 and 18.
Echocardiogram assessment  moved from Day 1 to 
ScreeningEnough IP will 
be dispensed at Week 4 and 
Week 12 to 
enable dosing 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
9
ConfidentialPlasma NT-proBNP level has been deleted from 
Screening.
New wording in bold: 
Rodatristat Ethyl and Rodatrista t PK: At Day 1 and Week 4, a 
predose PK sample will be collected (patients will take study medication in the clinic). At Week 12, a postdose PK sample 
will be collected between 1 to 8 hours after the morning dose 
(patients will take the morning dose in the clinic and the time of dose will be recorded â€“ all other assessments can be done pre or post dose). At Week 24, no study medication 
will be taken prior to the clinic visit (the last dose in the 
Main Study will be the evening before the Week 24 visit)
and a PK sample will be collected . If the subject enrolls in the 
OLE, this PK sample will be collected prior to the first dose of study treatment in the OLE. through to Week 
12 and Week 24.
Echocardiogram 
is needed as a 
Screening tool.  
Plasma NT-
proBNP level only needs to be 
performed on 
patients who are eligible for the 
study, not at 
Screening.
Clarification on 
when to take dose at Week 12 
visit and when 
the last dose for the Main Study 
is completed.
1.3 Schedule of Assessments (Main 
Study)
9.2.6
Pharmacogenetic 
TestingAdditional wording in Bold/ addition to Schedule of 
Assessment table:
A separate and specific informed consent form will be 
provided to patients to allo w the sponsor to obtain and 
test a patientâ€™s blood sample taken at the Baseline/Day1 
and the Week 24 visits for pharmacogenetic markers 
that may be predictive of the natural history of the 
disease, response to therapy and tolerability of therapy. Addition of a 
pharmacogenetic 
blood draw at Week 24.
1.1 Schedule of 
Assessments (Main Study)
9.1.10 Registry to 
Evaluate Early and Long-term 
Pulmonary Arterial 
Hypertension Disease Management REVEAL Lite 2.0 has been deleted from the table.
Added wording in bold :
REVEAL Lite 2 includes 6 non- invasive variables: FC, 
vital signs (SBP and HR), 6MWD, NT-proBNP, and renal insufficiency (by eGFR). REVEAL Lite 2 will be 
a calculated parameter (by statistician) at Baseline 
and Week 24 of the Main Study and Week 24 of the OLE (this score will not be in the eCRF).This is a 
calculation that will be 
performed by the 
Statistician.  This is not an 
assessment that 
the site performs and therefore 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
10
ConfidentialLite 2 Risk 
Assessment 
Calculatordoes not need to 
be in the table.
1.4 Schedule of 
Assessments â€“ Open-Label Extension â€“
(First 24 weeks of 
Open Label Extension)First 24 weeks of OLE has been updated to mirror the 
Main Study (with the exception of PK, PD, and actigraphy)Up to one-third 
of the patients will receive 
rodatristat ethyl 
for the first time in the OLE.  
Safety and 
efficacy procedures have 
been updated to 
ensure patient safety.
Included in 
Amendment 1.1 (UK and 
Bulgaria RA 
request)
Included in 
Amendment 1.8 
(Germany RA request)
1.3 Schedule of Assessments â€“ Main 
Study
1.4 Schedule of 
Assessments â€“ First 
24 Weeks of Open-
Label Extension
1.5 Schedule of 
Assessments â€“ Open-
Label Extension Post 24 Weeks
5.4.1 Contraception
9.2.1 Pregnancy 
TestingInsertion of requirement for additional pregnancy testing 
in women whose menstruation is delayed or who have 
infrequent or irregular menstrual cycles.
Wording added in bold:
Serum pregnancy tests will be obtained for all female 
patients of childbearing potential at Screening and every 
4 weeks while on IP.
Pregnancy tests will be co mpleted in women of child-
bearing potential every 4 weeks while on study. Weeks 
8, 16 and 20 will be performed at home (with a kit 
given to the subject by the site) and the results will be 
confirmed with the subject by a phone call.Adding 
instructions for 
sites to perform 
pregnancy testing per 
CTFG 
Guideline,contraception 
and pregnancy 
testing recommendation.
Included in 
Amendment 1.7 
(Poland RA 
request)



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
11
ConfidentialIncluded in 
Amendment 1.4 
(Czech Republic RA request)
Included in 
Amendment 1.8 (Germany RA 
request)
2.1 Background
9.5 PharmacokineticsAddition to background:
Rodatristat ethyl is a prodrug for the active tryptophan 
hydroxylase 1 (TPH1) inhibitor rodatristat.  In vitro, 
nonclinical, and human pharmac okinetic (PK) studies to 
date have provided valuab le information on the PK 
properties of rodatristat et hyl and its active moiety, 
rodatristat. Rodatristat ethyl has low to moderate oral 
bioavailability in nonclinical  species and is rapidly 
converted to rodatristat in vivo. Both rodatristat ethyl 
and rodatristat are highly protein bound and little is 
excreted in the urine.  Bilia ry excretion predominates in 
rats and no further metabolism of rodatristat has been detected in human hepatocyte preparations. However, 
preliminary investigations have also identified a 
metabolite, M15, in the plasma  of dogs and humans after 
administration of rodatrista t ethyl. After single-dose 
administration, the half-life of rodatristat ethyl and 
rodatristat are approximately 5 and 12 hours, respectively, reaching steady-state exposure, according 
to trough concentrations, by Day 5.  The highest 
exposures achieved in healt hy subjects to date were 
reached on Day 7 following 800 mg twice daily (BID) 
doses of rodatristat ethyl.
Addition of M15 metabolite in PK section.A metabolite 
profiling study 
performed in dogs led to the 
identification of 
an additional major 
metabolite, M15, 
in plasma after the start of this 
study.  Blood for 
PK samples will analyze for M15 
in addition to 
rodatristat ethyl and rodatristat.
4.5 Criteria for Study TerminationAdditional wording in Section 4.5:
The study may resume once concerns about safety, 
protocol compliance, and data quality are addressed and the IRBs/ECs and co mpetent authorities are 
satisfied. The study will only resume after prior submission and approval of the substantial amendment (if required) by the competent authority.Clarification of 
procedures
Included in 
Amendment 1.1 (UK and 
Bulgaria RA 
request)



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
12
Confidential4.8 End of Study 
DefinitionNew wording in bold:
A patient is considered to ha ve completed the study if 
he/she completed 24 weeks of treatment including the Week 24 visit and the Follow-up Visit (for patients that 
complete the study through Week 24 but decide not to 
rollover to the OLE), or the last scheduled procedure shown in the Schedule of Assessments(SoA; 
Section 1.3).If the patient decides to continue into the 
OLE, subject must not participate in another 
interventional study until completing the final follow-
up visit (4 weeks after the last dose of study drug) 
according to the Schedule of Assessments OLE 
(Section 1.4 or 1.5).Sentence added 
to define end of 
study for patient participating in 
OLE.
Included in 
Amendment 1.3 
France RA 
request
5.3 Other Eligibility CriteriaWording updated to reflect change in process:
From 
To determine patient eligib ility at Screening, a single 
repeat of certain tests such  as laboratory values, vital 
signs, or ECGs may be allowed, with consultation of the 
Medical Monitor.
To:
To determine patient eligib ility at Screening, a single 
repeat of certain tests such as laboratory values, vital 
signs, or ECGs will be allowed .Clarification on 
updated 
procedure for 
single repeat Screening 
procedures.
5.4.1 ContraceptionCorrection of inconsistenc ies in the protocol.  
-Inclusion 1a has contraception beginning 4 weeks prior 
to first dose of IP and Section 5.4.1 has contraception 
starting at Screening.  Corre ction of Inclusion 1a to 
match Section 5.4.1., contrace ption should start at 
Screening.
-Inclusion 1a and 1b have contraception ending for 
women 4 weeks after the last  dose of IP and for men 100 
days after the last dose of IP and Section 5.4.1 has 
contraception ending for women 4 weeks after the last study visit and for men 100 days after the last visit.  The 
protocol now has contracep tion ending for both women 
and men 4 weeks and 100 days af ter the last dose of IP, 
respectively.Correction of 
inconsistency



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
13
Confidential5.4.1 ContraceptionAddition of contraception method:
Sexual abstinence â€“ (refraining from heterosexual 
intercourse). If study patient chooses this option, site 
staff must follow-up to r econfirm throughout the study.  
If patient becomes sexually active, one of the above 
choices must be utilized and documented.Clarification on 
highly effective 
method of birth control
Included in 
Amendment 1.2 (Germany, Italy 
and Czech 
Republic RA request)
Included in 
Amendment 1.4 (Poland and 
Austria RA 
request)
Included in 
Amendment 1.6 
(France RA request)
5.4.1 Contraception Deletion of contraception method:
Cervical cap or diaphrag m (double barrier) plus 
spermicideCervical cap or 
diaphragm with 
a condom and 
spermicide is not a method that 
can achieve a 
failure rate of less than 1% per 
year
Included in 
Amendment 1.1 
(UK and 
Bulgaria RA request)
Included in 
Amendment 1.2 (Germany, Italy 
and Czech 
Republic RA request)
Included in 
Amendment 1.4 (Poland and 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
14
ConfidentialAustria RA 
request)
Included in 
Amendment 1.6 
(France RA 
request)
6.1 Table 3 Footnote* The components in rodatristat ethyl are provided in 
Section 3.2.2, Table 1 of the Investigatorâ€™s Brochure.The active and placebo are formulated with the same excipientsClarifying 
statement
Included in 
Amendment 1.2 
(Germany, Italy and Czech 
Republic RA 
request)
6.4 Measures to Minimize bias: Randomization and 
BlindingAdded wording in bold:
This is a double-blind study. The Sponsor, Investigator,
patient, and study site personne l will be blinded to all
treatment group assignments. The Investigator will have 
the ability, in the IRT sy stem, to unblind a patient, and 
the decision will reside sole ly with the Investigator.
Prior to unblinding, if safety allows, the Investigator 
should contact the Medical Monitor to discuss the 
reasons for unblinding.
At the time of Screening fo r entry into the OLE, all 
patients will be re-randomi zed to receive either 300 
mg BID or 600 mg BID rodatristat ethyl in an open-label fashion.  Patients will not know what they received in the Main Study until all patients have completed the Main Study and the database is locked.
At the time of re-randomizati on in the OLE, patients 
will be assigned a new randomization number.  Once this number has been assigned, it cannot be reused/reassigned.Additions to 
paragraph to reduce 
ambiguity.
Wording added 
to section to 
make clear the 
process for randomization 
and dose level in 
the OLE.
6.5 Investigational Product ComplianceStatement added: Statement added 
to clarify what is considered IP 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
15
ConfidentialFull compliance with the IP regimen, per subject, will 
be considered to be >80%.compliance in 
this study.
1.1 Synopsis
4.1 Overall Design7.1.4 Open-Label 
Extension DesignWording added in bold :
Patients who participate in the OLE will continue to 
receive rodatristat ethyl for 6.5 years, until the 
Investigator or patient ch ooses to stop the IP, any 
stopping criteria in the Main Study are met, IP becomes 
commercially available, or the Sponsor stops the study 
for lack of efficacy  or a safety signal (whichever 
preceding criteria comes first). In no case will a 
patient be allowed to exceed 10 years of exposure 
unless the product is approved for a chronic 
indication.
Deletion of: 
Investigator or patient chooses to stop the IP, any 
stopping criterion in the Main Study is met, IP becomes 
commercially available, or the Sponsor stops the study 
for lack of efficacy or a safety signal.
Addition to Overall Design section:
Female patients of childbearing potential will 
undergo pregnancy testing every 4 weeks and will be 
required to use 2 reliable me thods of contraception to 
reduce the risk of pregnancy, starting at Screening,during the course of the study and for at least 4 weeks 
following the last dose of rodatristat ethyl.
If there is not a clinic visit,  a urine pregnancy test will 
be sent home with the patient and results will be 
followed up with a phone call.A stop date for 
the total time a subject can be on 
rodatristat ethyl 
has been established and 
added to the 
protocol.
Included in 
Amendment 1.2 
(Germany, Italy,and Czech 
Republic RA 
request)
8.1. Discontinuation of Investigatrional ProductWording added in bold:
The Investigator must al so discontinue/withdraw a 
patientâ€™s participation in the study if any of the following 
criteria apply:Updated to 
define stopping criteria for IP 
non-compliance.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
16
ConfidentialxPregnancy
xSignificant protocol violation/lack of 
compliance with the study and/or study procedures - non-compliance with IP for 
discontinuation of patient is defined as < 
50%.
xSevere constipation (e.g., obstipation with 
manual evacuation indicated) and/or severe, 
persistent, or worsening abdominal pain
xAny significant worsening on postdose 
C-SSRS indicative of active suicidal ideation 
with intent to act (defined as C-SSRS Suicidal Ideation category score of 4 or 5) or behavior 
(either preparatory act s/behavior, aborted 
attempt, interrupted attempt, or actual attempt)
xSevere depression or  anxiety based on a 
+$'6'HSUHVVLRQRU$Q[LHW\VFRUHÂ• 15, or a 
QIDS-&7RWDO6FRUHÂ• 16.
xAny severe psychiatric or CNS AE as
determined by the Investigator.
9.2.1 Pregnancy TestingClarification that if FSH does not confirm 
postmenopausal status, in addi tion to pregnancy testing, 
patients must use approved contraceptionClarification of 
pregnancy testing and use 
of contraception 
in patients where post-menopausal 
status is not 
confirmed by FSH.
Included in 
Amendment 1.1 (UK and 
Bulgaria RA 
request)
9.2.8 Suicidal Ideation and Behavior Risk 
MonitoringWording updated to reflect the immediate 
discontinuation of investigati onal product in any patient 
who experiences suicidal idea tion or behavior, following 
a risk assessment.Updated wording 
to be consistent with Section 8.1 
and reflect the 
procedures to be taken if patient 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
17
Confidentialexhibits suicidal 
ideation or 
behavior while on
investigational 
product.
Included in 
Amendment 1.1 
(UK and Bulgaria RA 
request)
9.3.2 Time Period and Frequency for 
Collecting Adverse Events, Adverse 
Events of Special 
Interest, and Serious Adverse EventsWording added:
Adverse events of special interest should be reported to 
the sponsor should they meet the definition of an SAE, 
and all timelines for repo rting of SAEs should be 
adhered to.Clarification of 
reporting of 
Adverse of Special Interest
Included in 
Amendment 1.1 (UK and 
Bulgaria RA 
request)
9.1.1 Right Heart CatheterizationAll of the following wording has been deleted from this 
section:
Parameters measur ed during the RHC:
Ð¬Heart rate (HR) - HR should be determined at the 
time of the cardiac output measure preferably by
thermodilution. HR should  be measured until 
2 consecutive values do not differ by more than 10%; the last value will be recorded in the eCRF.
Ð¬Cardiac Output by the Thermodilution or Fick (if 
thermodilution is not available) Method -Thermodilution is the pr eferred method for the 
estimation of cardiac output. At least 3 determinations that are within 10% variability of one another must be measured. Measurements must be repeated until this  reliability is met. The 
mean cardiac output will be defined as the average of these 3 measurements and used for the calculation of PVR. The mean value will be recorded in the eCRF. Investigators must ensure There is a Right 
Hearth Catheterization 
Manual sites 
should be referring to, so 
this list of 
parameters is being deleted so 
there are no
discrepancies.
There will not be 
a core imaging laboratory for 
adjudication of 
the RHC endpoints.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
18
Confidentialthat the individual values and the calculation of 
the mean are recorded in the source documents.If the mean cardiac output is auto-generated, investigators must ensure that the measurements used to calculate the mean are within the 10% variability and are available to be recorded in the source documents and in the eCRF. The last value will be recorded in the eCRF.
Ð¬Systemic arterial pressure  (systolic, diastolic, and 
mean) - Systemic arterial pressures should be taken just prior to entry of the catheter and should 
be measured until 2 consecutive mean values do not differ by more than 10%. The last value will be recorded in the eCRF. All values should be available in the source documents.
Ð¬PAP (systolic, diastoli c, and mean) - Pulmonary 
arterial pressures should be measured at end expiration and should be measured until 2 consecutive mean values do not differ by more than 10%. The last value will be recorded in the eCRF. All values should be available in the source documents. Mean PAP as determined by the siteâ€™s medical instrument (automatically generated) will be entered into the EDC system.If the siteâ€™s medical instrument does not 
automatically generate the mPAP, it should then 
be calculated manually using the following equation: mPAP = ([diastolic PAP Ã— 2] + systolic PAP) Ã· 3.
Ð¬Mean right atrial pressure (RAP) - Mean RAP 
should be measured until 2 consecutive values do 
not differ by more than 10%. If mean RAP values are less than 10 mmHg, the 2 consecutive values must not differ  by more than 1 mmHg.
The last value will be recorded in the eCRF. All values should be available in the source documents.
Ð¬PCWP or LVEDP - The PCWP or LVEDP 
should be recorded as the mean of 3 separate measurements taken at end-expiration, involving 
balloon deflation and re-wedging of the balloon 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
19
Confidentialfor these separate measur ements. It is strongly 
preferred that the same assessment (PCWP or LVEDP) be performed for both RHC assessments. In situations where this is not possible, the Investigator should provide an explanation in the eCRF. All values should beavailable in the source documents.
Ð¬SvO
2- Blood gas by pulmonary artery mixed 
venous blood sample should be measured and recorded in the eCRF. All values should be available in the source documents.
Ð¬Calculated parameters:
RPVR (dyneâ€¢sec/cm
5) = [(mPAP â€“ PCWP) 
Ã· mean CO] Ã— 80 or [(mPAP â€“ LVEDP) Ã· mean CO] Ã— 80
RCardiac Index = CO Ã· BSA
RStroke Volume (SV) = CO Ã· HR
RPAC = ratio of SV to pulmonary artery
pulse pressure
R(Weight) kg0.425 x (Height) cm0.725 x
0.007184 = BSA in M
2
9.1.9 Pulmonary 
Arterial Hypertension-
Symptoms and 
Impact QuestionnaireDeleted wording in italics :
Prior to departing the study site at the Day 1 Baseline 
Visit, patients will be instructed and trained on how to 
complete the questionnaire.
Added wording in bold:
Prior to departing the study site at the Screening Visit,
patients will be instructed and trained on how to complete the questionnaire. Patients will start the PAH-
SYMPACT questionnaire 6 days prior to the visit for 
which PAH-SYMPACT is collected, with the Day 7 being completed on the day of the visit.Clarity on how 
the PAH-Sympact 
questionnaire is 
being administered.
1.3 Schedule of Assessments (Main 
Study)Deleted wording in italics :
Coagulation testing will be done at Baseline ,Week 12,
and Week 24 for all patien ts on the Main Study and 
every clinic visit post  24 weeks in the OLE.Clarification of 
when 
coagulation test 
will be 



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
20
Confidential 1.4 Schedule of 
Assessent (OLE â€“
First 24 Weeks) 
9.2.5.2 Coagulation Added wording in bold:
Coagulation testing will be done at Screening, Week 12, 
and Week 24 for all patients on the Main Study and at 
Week 12 and Week 24 of the OLE in the first 
24 weeks  and every clinic visit post 24 weeks in the 
OLE.   completed under 
the new design. 
9.2.5.5 Other tests Urine Creatinine (for calculation of 5-HIAA) at each 
5-HIAA collection timeAddition of urine 
creatinine for clarification.
Appendix 1. Concomitant and 
Prohibited 
Medications Marketed drugs known to prolong QT/QTc AND which 
are also clearly associated w ith a known risk of Torsades 
de Pointe 
source: www.CredibleMeds.org (Woosley, 2021)An update to the 
list of marketed 
drugs known to 
prolong QT/QTc AND which are 
also clearly 
associated with a known risk of 
Torsades de 
Pointe was made in 2021.  
Amendment 1 of 
the protocol included the 
2019 version.  
This protocol has been updated 
with the new list.
Appendix 1 
6.6.1. Rodatristat 
Drug Interaction 
Potential Amodiaquine, Pimozide, and Quinidine were deleted 
from the Narrow Therapeutic Drug table as acceptable 
concomitant medications. Amodiaquine, 
pimozide, and quinidine are 
drugs that are 
known to prolong QTcF 
and therefore not 
allowed in this study. 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
21
ConfidentialAmendment 1 (19NOV2020)
Section# and Name Description of Change Brief Rationale
1.1 Synopsis Words deleted in italics and 
added in bold :
Study center(s):
United States, Canada, 
Poland, United Kingdom, 
France, Spain, Germany, Italy, Belgium, Bulgaria, 
Russia, Ukraine, 
Netherlands, Czech 
Republic, LatviaFinal country list completed
1.1 Synopsis Addition of Objective and 
Endpoint to evaluate the 
effect of rodatristat ethyl on selexipag/ACT-333679 PKAdditional PK assessments to further 
evaluate interaction between rodatristat 
ethyl and selexipag/ACT-333679 
1.1 Synopsis
5.1 Inclusion Criteria2.Added wording in 
bold :
3.Male and female 
patients must be at 
least 18 years of age 
at the time of signing 
the informed consent.Clarification of age of patient who can be 
enrolled.
1.1 Synopsis  
5.1 Inclusion CriteriaDeleted wording in italics : 
A male patient is eligible to 
participate if he does not
have a female partner who is pregnant or who intends to 
become pregnant during the study.Wording deleted as conflicting with intent 
and contraception wording.
1.1 Synopsis
4.1 Overall Design
6.4 Methods to Reduce 
Measures to Minimize 
Bias: Randomization and 
BlindingAdditional wording in Bold
added:
Eligible patients will be 
stratified during the 
randomization process based on the number of background 
PAH therapies they are 
receiving (1, 2 or 3) and use 
of selexipag (yes/no). The The results of a drug interaction with 
rodatristat ethyl and selexipag in healthy volunteers is available.  The new criteria 
in stratification and capping of patients on 
selexipag are due to the results of this 
study. 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
22
Confidentialnumber of patients who are 
receiving a prostanoid 
infusion will be capped at 50% of the total number of 
patients enrolled.  The 
number of patients who are receiving selexipag will be 
capped at 20% of the total enrolled.
1.2 Study Schematic Figure 1 updated to reflect 
accurate study visitsFigure 1 Study Schematic was not aligned 
with correct study visits
1.3 Schedule of 
Assessments â€“ Main 
StudyWeek 18 (Day 140) changed 
to Week 18 (Day 126)The number of days for Week 18 was 
wrong in original protocol
1.3 Schedule of 
Assessments â€“ Main 
StudyPhysical exam will not be 
conducted at Follow-up VisitChange is being made to accommodate a 
home visit, if needed.
1.3 Schedule of Assessments â€“ Main 
Study and Section 9.2.7, Optional Sample for 
Future ResearchOptional Sample for Future 
Research was added to the protocolThe addition of this 
optional future 
research sample will be used to 
increase our knowledge and understanding of the biology
,
pathogenesis, progression and/or treatment 
outcomes, including efficacy, AEs, and the 
process of drug absorption and disposition. 
1.3 Schedule of 
Assessments â€“ Main 
Study Footnote #5Amendment 1 wording 
(wording in italics are deleted) 
Weight only (no height or 
BMI) will be performed at Weeks 4, 12, 18, 24, and 28Weight does not need to be collected at 
Week 18.  This change in the footnote 
reflects what is in the table.
1.3 Schedule of 
Assessments â€“ Main 
Study Footnote #9 and 
Morning Dose Taken in Clinic with Food in the 
TableAmendment 1 wording
(additions in bold ):
IP must be taken daily, 
morning and evening until 
the night before the Week 24 visit .  Patients must be 
told not to take a dose the morning of the Week 24 
visit. Doses should be taken Updated language provide s more clarity of 
process for IP and when to take the dose 
on clinic visit days



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
23
Confidentialwith food.  During visits at 
the clinic or home, all assessments should be done predose, except where 
otherwise indicated.Patients should bring their IP with them for each visit (including any empty bottles).
1.3 Schedule of 
Assessments â€“ Main 
Study Footnote #12Amendment 1 wording
(additions in bold ):
Three 12 lead ECGs ( at least
1 minute apart) will be collected on Day 1 after at least 5 minutes of rest.  Single 12-lead ECGs will be collected at all other time points.Updated language provi des more guidance 
for collection of ECGs.
1.3 Schedule of 
Assessments â€“ Main 
Study Footnote #14
9.1.1 Right Heart 
CatherizationAdditional wording added at 
beginning of footnote #14:
RHC results from 4 weeks 
prior to the Screening visit may be used for entry provided the historical RHC includes all required information and provided that changes to the patientâ€™s PAH regimen were not made.New criteria allow for hemodynamics 
obtained during a recent RHC to be considered when determining a patientâ€™s 
eligibility for participation in the study.
1.3 Schedule of 
Assessments â€“ Main 
Study Footnote #17Original protocol wording: 
At Day 1 and Weeks 4
and 24, a predose PK sample will be collected (patients will take study medication in the clinic).  At Week 12, a postdose PK sample will be collected between 1 to 8 hours after the morning 
dose (patients will take the Clarification of collection of PK and PD
samples



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
24
Confidentialmorning dose at home before 
the clinic visit).
Amendment 1 new
wording:
At Day 1 and Week 4, a 
predose PK sample will be collected (patients will take study medication in the clinic). At Week 12, a postdose PK sample will becollected between 1 to 
8 hours after the morning dose (patients will take the morning dose at home before the clinic visit).   At Week 24, no study medication will be taken prior to the clinic visit and a PK sample will be collected. If the subject enrolls in the OLE, this PK sample will be collected prior to the first dose of study treatment in the OLE. 
Blood and spot urine samples 
for 5-HIAA (and urine samples for creatinine) willbe collected pre-dose on
Day 1 and at Weeks 4, 12, and 24.
1.3 Schedule of 
Assessments â€“ PK Sampling and Main 
Study Footnote #18Additional of PK sample for 
selexipag/ACT-333679 at 
Baseline and Week 4Additional PK assessments to further 
evaluate interaction between rodatristat 
ethyl and selexipag/ACT-333679
1.4 Schedule of Assessments â€“ OLE first 24 WeeksAddition of PK sample for 
selexipag/ACT-33679 at Week 4 of OLEAdditional PK assessments to further 
evaluate interaction between rodatristat ethyl and selexipag/ACT-333679



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
25
Confidential1.4 Schedule of 
Assessments â€“ OLE first 24 WeeksWording in italics will be 
deleted.  
Footnote 4: Placebo subjects 
from the Main Study will be 
re-randomized to active IP.  
As necessary, a 6month supply of IP will be 
dispensed. IP must be taken 
daily morning and evening.Removing wording to allow for flexibility 
of dispensing IP.
3 Objectives and 
EndpointsAddition of Objective and 
Endpoint to evaluate the effect of rodatristat ethyl on 
selexipag/ACT-333679 PKAdditional PK assessments to further 
evaluate interaction between rodatristat 
ethyl and selexipag/ACT-333679 
6.1Description of IP,
Table 3Updated wording in bold for 
the Physical Appearance of the IP:
 
White to off-white modified 
oval shaped tablet, 
debossed with â€œ2E8â€ on one 
sideUpdated to reflect the new tablet 
appearance.
6.2 Dose Regimen Additional wording added to 
section in bold:
The last dose of IP for the 
Main part of the study will be the last dose the night 
before the Week 24 visit (all 
Week 24 assessments will 
be collected post last dose).Clarification of dosing and timing.
6.4 Measures to 
Minimize the Bias:
Randomization and BlindingAdded words in bold :
The Investigator will have 
the ability, in the IRT 
system, to unblind a patient unless it will cause an 
unacceptable safety delay in 
the care of the patient, the Investigator should contact 
and discuss with the Medical Monitor first.Clarification of who can unblind a patient 
and how.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
26
Confidential6.6 Concomitant 
MedicationsNew wording in bold: 
(Note: Vaccines, including 
potential Covid-19 vaccine, are allowed but must be 
documented in the eCRF). Updated for clarity.
6.6.1 Rodatristat Drug 
Interaction PotentialAddition of data from 
rodatristat-selexipag interaction study and 
additional listing of narrow 
therapeutic substrates of 
CYP2C8Provide data from rodatristat-selexipag 
interaction study and guidance to 
investigator regarding CYP2C8 substrates.
7.1.7 Exclusion Criteria OLE exclusion criteria #6 is 
deleted in Amendment 1
6. Elevated ALT, AST, or 
TBL > 2X ULN Criteria is being taken out of Amendment 
as there is already stopping criteria for 
ALT/AST that is being followed
7.1.9 Open-Label 
Extension Treatment 
AssignmentAdditional wording added to 
the Amendment:
The first dose of IP in the 
OLE will be considered the first dose after all Week 24 
assessments in the Main 
Study are completed and all 
entry criteria are met.Clarification of dosing and timing in the 
OLE.
9.2.2.5 Other TestsPharmacogenetics and 
Optional Blood Sample for 
Future Research added to â€˜Other Testsâ€™ TableAdd lab samples to appropriate table
9.2.6 Pharmacogenetic 
SamplingWording is being added to 
the amendment to clarify the pharmacogenetic sample 
collection:
A separate and specific 
informed consent form will 
be provided to patients to 
allow the sponsor to obtain
and test a patientâ€™s blood Pharmacogenetic sampling wording added 
for clarification.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
27
Confidentialsample taken at the 
Baseline/Day1 visit for 
pharmacogenetic markers 
that may be predictive of 
the natural history of the 
disease, response to therapy and tolerability of therapy. 
If it is not collected at the 
Baseline/Day 1 visit, it may be collected at any time 
during the treatment 
period.  Providing this blood sample is optional 
and not required for participation in the study.
9.2.8 Suicidal Ideation 
and Behavior Risk MonitoringWording added in Bold :
Screening and Baseline 
assessments (within 1 
month) of suicidal 
ideation and behavior as well as potential treatment
emergent suicidal ideation 
and behavior will be monitored during the study 
using the C-SSRS.Clarifying the timeframe for Baseline 
collection of the C-SSRS
9.5 Pharmacokinetics Addition of selexipag/ACT-
33679 Pharmacokinetic SamplingAdditional PK assessments to further 
evaluate interaction between rodatristat ethyl and selexipag/ACT-333679
Appendix 1 â€“
Concomitant and 
Prohibited MedicationsRenaming of Section, 
clarified wording, and additional listing of narrow 
therapeutic substrates of CYP2C8Provide guidance to investigator regarding 
CYP2C8 substrates.
Appendix 12 REVEAL Lite 2.0 Risk CalculatorAdded the scoring and 
formula for REVEAL Lite 
2.0 risk calculatorAdded the scoring and calculator for 
REVEAL Lite 2.0 for calculations 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
28
ConfidentialSIGNATURE PAGE
Protocol RVT-1201-2002
A Phase 2b, Dose-Ranging, Randomized, Double-B lind, Placebo-Controlled, Multicenter Study 
of Rodatristat Ethyl in Patients w ith Pulmonary Arterial Hypertension
Sponsorâ€™s Approval
This protocol has been approve d by Altavant Sciences GmbH, as indicated by the signature 
below.
Company/Sponsor Signatory
Howard M. Lazarus, MD, FCCP
Chief Medical Officer
Altavant Sciences, Inc.
6501 Weston ParkwaySuite 330
Cary, North Carolina 27513
United States of AmericaTel: +1-203-297-5374Date



		
	


Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
29
ConfidentialINVESTIGATORâ€™S AGREEMENT
Protocol RVT-1201-2002
A Phase 2b, Dose-Ranging, Randomized, Double-B lind, Placebo-Controlled, Multicenter Study 
of Rodatristat Ethyl in Patients w ith Pulmonary Arterial Hypertension
I, the undersigned, have received  and read the Investigatorâ€™s Brochure for Rodatristat Ethyl. I
have read the RVT1201-2002 protocol and agree to conduct the study as outlined in this protocol 
and in accordance with the ethical principles se t forth in the Declaration of Helsinki, current 
Good Clinical Practice, a nd all applicable local laws and requ irements. I agree to maintain the 
confidentiality of all information received or  developed in connection with this protocol.
Printed Name of Investigator
Signature of Investigator
Date



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
30
ConfidentialMEDICAL CONTACT INFORMATION
Table 1: Contact Information
Role in Study Name Contact Information
Clinical Study Leader Watiri Kamau-Kelley
Sr. Director, Clinical OperationsAltavant Sciences, Inc.Watiri@altavant.com
+1-408-300-3316
Responsible Physician Howard M. Lazarus, MD, FCCP
Chief Medical OfficerAltavant Sciences, Inc.howard.lazarus@altavant.com
Phone:  +1-203-297-5374
North American Emergency ContactEd Parsley, DO
Medical Monitor
Altavant Sciences, Inc.ed.parsley@altavant.com
Phone: +1-713-899-2450
Rest of the World Emergency ContactGwyn D'Souza
Medical MonitorAltavant Sciences, Inc.gwyn.dsouza@altavant.com
Phone: 011 44 7887 822276
Drug Safety Physician/Serious Adverse Event ReportingPharmacovigilance (PVG) On discovery, all SAEs should 
be immediately reported (latest within 24 hours of knowledge of the event) to SPONSOR or 
Sponsorsâ€™ safety vendor by 
filling out the SAE form in the 
eCRF.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
31
ConfidentialTABLE OF CONTENTS
PROTOCOL AMENDMENT SUMMA RY OF CHANGES TABLE............................................2  
SIGNATURE PAGE ................................................................................................................. ....28  
INVESTIGATORâ€™S AGREEMENT.............................................................................................29  
MEDICAL CONTACT INFORMATION ....................................................................................30  
TABLE OF CONTENTS.............................................................................................................. .31 
LIST OF TABLES................................................................................................................. ........36  
LIST OF FIGURES ................................................................................................................ .......36  
LIST OF ABBREVIATIONS........................................................................................................37  
1. PROTOCOL SUMMARY..........................................................................................40  
1.1. Synopsis......................................................................................................................4 0 
1.2. Study Schematic .........................................................................................................49  
1.3. Schedule of Assessments â€“ Main Study .....................................................................50  
1.4. Schedule of Assessments â€“ Open-Labe l Extension â€“ (First 24 weeks of 
Open-Label Extension)...............................................................................................54  
1.5. Schedule of Assessments â€“ Open-Label Extension â€“ (Post 24 Weeks of the 
Open-Label Extension)...............................................................................................56  
2. INTRODUCTION ......................................................................................................57  
2.1. Background.................................................................................................................57  
2.2. Study Rationale...........................................................................................................58  
2.3. Benefit/Risk Assessment ............................................................................................58  
3. OBJECTIVES AND ENDPOINTS............................................................................61  
4. STUDY DESIGN .......................................................................................................63  
4.1. Overall Design............................................................................................................63  
4.2. Number of Patients .....................................................................................................63  
4.3. Treatment Assignment................................................................................................64  
4.4. Dose Adjustment Criteria ...........................................................................................64  
4.4.1.  Dose Reduction...........................................................................................................64  
4.4.1.1.  Diarrhea ......................................................................................................................6 4 
4.4.1.2.  Aminotransferase (Alanine aminotransfe rase or Aspartate Aminotransferase) 
Elevation.....................................................................................................................6 5 
4.5. Criteria for Study Termination ...................................................................................65  
4.6. Scientific Rationale for Study Design ........................................................................65  



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
32
Confidential4.7. Justification for Dose..................................................................................................66  
4.8. End of Study Definition..............................................................................................68  
5. STUDY POPULATION.............................................................................................69  
5.1. Inclusion Criteria ........................................................................................................69  
5.2. Exclusion Criteria .......................................................................................................70  
5.3. Other Eligibility Crit eria Considerations....................................................................73  
5.4. Lifestyle Considerations .............................................................................................73  
5.4.1.  Contraception..............................................................................................................73  
5.4.2.  Meals and Dietary Restrictions...................................................................................74  
5.4.2.1.  Tryptophan-Rich Foods..............................................................................................74  
5.4.2.2.  Food Requirements.....................................................................................................74  
5.5. Screen Failures............................................................................................................75  
6. INVESTIGATIONAL PRODUCT ............................................................................76  
6.1. Description of IP.........................................................................................................76  
6.2. Dose Regimen.............................................................................................................76  
6.3. Preparation/Handling/Storage/Accountability............................................................77  
6.3.1.  Investigational Product P ackaging and Labeling .......................................................77  
6.3.2.  Investigational Product Storage..................................................................................77  
6.3.3.  Investigational Product Administration......................................................................77  
6.3.4.  Investigational Pr oduct Accountability ......................................................................77  
6.3.5.  Investigational Product Handling and Disposal .........................................................78  
6.4. Measures to Minimize Bias: Randomization and Blinding........................................78  
6.5. Investigational Pr oduct Compliance...........................................................................79  
6.6. Concomitant Therapy .................................................................................................79  
6.6.1.  Rodatristat-Drug Inte raction Potential........................................................................80  
6.6.2.  Pulmonary Arterial Hy pertension Medications..........................................................81  
6.6.3.  Prohibited Medications  and Supplements ..................................................................82  
7. INTERVENTION AFTER THE END OF THE STUDY â€“ OPEN-LABEL 
EXTENSION..............................................................................................................83  
7.1. Rationale for the Open-Label Extension ....................................................................83  
7.2. Objective.....................................................................................................................8 3 
7.3. Endpoints ....................................................................................................................83  
7.3.1.  Safety endpoints..........................................................................................................83  



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
33
Confidential7.3.2.  Efficacy endpoints ......................................................................................................83  
7.4. Open-Label Extension Design....................................................................................84  
7.5. Number of Patients and Incl usion/Exclusion Criteria ................................................84  
7.6. Inclusion Criteria ........................................................................................................84  
7.7. Exclusion Criteria .......................................................................................................85  
7.8. Open-Label Extension Procedures .............................................................................85  
7.9. Open-Label Extension Treatment Assignment...........................................................86  
7.10.  Investigational Product Pr eparation, Handling, Storage, and Accountability............86  
7.11.  Dose Adjustment Criteria ...........................................................................................86  
7.12.  Criteria for Investigationa l Product/Study Termination.............................................86  
8. DISCONTINUATION OF INVE STIGATIONAL PRODUCT AND 
PATIENT DISCONTINUATION/WITHDRAWAL.................................................87  
8.1. Discontinuation of Investigational Product ................................................................87  
8.1.1.  Temporary Discontinuation........................................................................................88  
8.2. Patient Discontinuation/With drawal from the Study..................................................88  
8.2.1.  Investigational Product Discontinuation.....................................................................88  
8.2.2.  Study Discontinuation ................................................................................................88  
8.3. Lost to Follow up........................................................................................................89  
9. STUDY ASSESSMENTS AND PROCEDURES......................................................90  
9.1. Efficacy Assessments .................................................................................................90  
9.1.1.  Right Heart Catheterization ........................................................................................90  
9.1.2.  Time to Clinical Improvement....................................................................................91  
9.1.3.  Time to Clinical Worsening........................................................................................91  
9.1.4.  Six-Minute Walk Test/Six -Minute Walk Distance.....................................................91  
9.1.5.  Echocardiography.......................................................................................................91  
9.1.6.  Pulmonary Function Tests (PFTs)..............................................................................91  
9.1.7.  World Health Organization Functional Class.............................................................92  
9.1.8.  N-terminal pro-Brain Natr iuretic Peptide Level.........................................................92  
9.1.9.  Pulmonary Arterial Hypertension-Sy mptoms and Impact Questionnaire..................92  
9.1.10.  Registry to Evaluate Ea rly and Long-term Pulmonary Arterial Hypertension 
Disease Management Lite 2 Ri sk Assessment Calculator..........................................92  
9.1.11.  Actigraphy ..................................................................................................................92  
9.2. Safety Assessments.....................................................................................................93  



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
34
Confidential9.2.1.  Pregnancy Testing ......................................................................................................93  
9.2.2.  Physical Examinations................................................................................................93  
9.2.3.  Vital Signs ..................................................................................................................93  
9.2.4.  Electrocardiograms.....................................................................................................93  
9.2.5.  Clinical Safety Laboratory Assessments ....................................................................94  
9.2.5.1.  Hematology.................................................................................................................94  
9.2.5.2.  Coagulation.................................................................................................................94  
9.2.5.3.  Clinical Chemistry......................................................................................................94  
9.2.5.4.  Urinalysis....................................................................................................................9 5 
9.2.5.5.  Other Tests..................................................................................................................95  
9.2.6.  Pharmacogenetic Testing............................................................................................96  
9.2.7.  Optional Blood Sample for Future Research..............................................................96  
9.2.8.  Suicidal Ideation and Beha vior Risk Monitoring .......................................................96  
9.2.8.1.  Columbia Suicide Severity Rating Scale....................................................................97  
9.2.8.2.  Hospital Anxiety and Depression Scale .....................................................................97  
9.2.8.3.  Quick Inventory of Depressive Symptomatology ......................................................97  
9.3. Adverse Events, Adverse Events of Sp ecial Interest, and Serious Adverse 
Events ......................................................................................................................... 98 
9.3.1.  Adverse Events of Special Interest.............................................................................98  
9.3.2.  Time Period and Frequency for Collec ting Adverse Event, Adverse Events 
of Special Interest, Serious Adverse Event Information ............................................98  
9.3.3.  Method of Detecting Adverse Events, A dverse Events of Special Interest, 
and Serious Adverse Events .......................................................................................99  
9.3.4.  Follow-up of Adverse Events, Adverse Events of Special Interest, and Serious Adverse Events ..............................................................................................99
 
9.3.5.  Regulatory Reporting Requirements for Serious Adverse Events .............................99  
9.3.6.  Pregnancy ...................................................................................................................99  
9.4. Treatment of Overdose .............................................................................................100  
9.5. Pharmacokinetics......................................................................................................101  
9.6. Pharmacodynamics...................................................................................................101  
10. STATISTICAL CONSIDERATIONS .....................................................................102  
10.1.  Statistical Hypotheses...............................................................................................102  
10.2.  Sample Size Determination ......................................................................................102  
10.3.  Populations for Analyses ..........................................................................................102  



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
35
Confidential10.4.  Statistical Analyses...................................................................................................103  
10.4.1.  Efficacy Analyses .....................................................................................................103  
10.4.2.  Safety Analyses ........................................................................................................104  
10.4.3.  Other Analyses..........................................................................................................104  
10.5.  Interim Analyses.......................................................................................................104  
10.5.1.  Independent Data Monitoring Committee................................................................105  
11. REFERENCES .........................................................................................................106  
APPENDIX 1.  CONCOMITANT AND PROHIBITED MEDICATIONS..............................108  
APPENDIX 2.  DIARRHEA MANAGEMENT .......................................................................111  
APPENDIX 3.  LIVER SAFETY:  SUGGESTE D ACTIONS AND FOLLOW-UP 
ASSESSMENTS...............................................................................................112  
APPENDIX 4.  COLLECTION OF PREGNA NCY INFORMATION ....................................114  
APPENDIX 5.  REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS........................................................................................116  
APPENDIX 6.  SIX-MINUTE WALK TEST GUIDELINES ..................................................120  
APPENDIX 7.  BORG SCALE AND INSTRUCTIONS..........................................................124  
APPENDIX 8.  WORLD HEALTH ORGANIZATION FUNCTIONAL CLASSIFICATION OF PULMONARY HYPERTENSION ..........................126
 
APPENDIX 9.  PULMONARY ARTERIAL HYPERTENSION-SYMPTOMS AND IMPACTâ„¢ QUESTIONNAIRE ......................................................................127
 
APPENDIX 10.  COLUMBIA-SUICIDE SEVERITY RATING SCALE ...............................136  
APPENDIX 11.  HOSPITAL ANXIETY AND DEPR ESSION SCORE (HADS)...................142  
APPENDIX 12.  CLINICIAN-RATED QUICK INVENTORY OF DEPRESSIVE 
SYMPTOMATOLOGY ...................................................................................143  
APPENDIX 13.  REVEAL LITE 2.0 (BENZA ET AL., 2020) ................................................146  
APPENDIX 14.  ADVERSE EVENTS:  DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATION, FOLLOW UP, AND REPORTING ............147
 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
36
ConfidentialLIST OF TABLES
Table 1:  Contact Information....................................................................................................30  
Table 2:  Abbreviations and Specialist Terms ...........................................................................37  
Table 3:  Investigational Products..............................................................................................76  
LIST OF FIGURES
Figure 1:  Study Schematic .........................................................................................................49  
Figure 2:  Percentage Change from Baseline of Urine 5-HIAA: Creatinine Ratio 
5-HIAA on Days 7 and 14 following Twice Daily Repeat Oral 
Administration of Rodatristat Ethyl in Studies KAR5585-101 and 
RVT-1201-1001..........................................................................................................67  



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
37
ConfidentialLIST OF ABBREVIATIONS
The following abbreviations and specialist terms are used in this study protocol.
Table 2: Abbreviations and Specialist Terms 
Abbreviation or Specialist 
TermExplanation
AE adverse event
AESI adverse event of special interest
ALP alkaline phosphatase
ALT alanine aminotransferase
ANCOVA analysis of covariance
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
BID twice daily
BMI body mass index
BNP brain natriuretic peptide
BP blood pressure
CFR Code of Federal Regulations
CHD congenital heart defects
CI confidence interval
CNS central nervous system
CONSORT Consolidated Standard of Reporting Trials
C-SSRS Columbia Suicide Severity Rating Scale
CTCAE Common Terminology Crit eria for Adverse Events
CYP Cytochrome P450
DBP diastolic blood pressure
DM-IV Diagnostic and Statistical Manual of Mental Disorders â€“ 4thEdition
EC ethics committee
ECG electrocardiogram
eCRF electronic case report form
EDC electronic data capture
eGFR estimated glomerular filtration rate
FC functional class
FDA United States Food and Drug Administration
FEV 1 forced expiratory volume one second
FSH follicle stimulating hormone
GCP Good Clinical Practice
GGT gamma-glutamyl transferase
HADS Hospital Anxiety and Depression Scale
hCG human chorionic gonadotropin
5-HIAA 5-hydroxyindoleacetic acid
5-HT serotonin (5-hydroxytryptamine)
5-HTP 5-hydroxytryptophan
HIV human immunodeficiency virus
HR heart rate
HRCT high-resolution computed tomography
HRT hormone replacement therapy
ICF informed consent form



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
38
ConfidentialAbbreviation or Specialist 
TermExplanation
ICH International Conference on Harmonization
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IMP investigational medicinal product
IP investigational product
INR international normalized ratio
IRB Institutional Review Board
IRT interactive response technology
ITT intent-to-treat
IVRS interactive voice response system
IWRS interactive web response system
LQTS long QT syndrome
LVEDP left ventricular end diastolic pressure
LVEF left ventricular ejection fraction
MAOIs monoamine oxidase inhibitors
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCT monocrotaline
MCV mean corpuscular volume
MedDRA Medical Dictionary for Regulatory Activities
m-ITT modified intent-to-treat
mPAP mean pulmonary artery pressure
mRAP mean right arterial pressure
ms millisecond
NOAEL no observed adverse effect level
NT-proBNP N-terminal pro-Brain Natriuretic Peptide
OLE open-label extension
PAC pulmonary artery compliance
PAH pulmonary arterial hypertension
PCWP pulmonary capillary wedge pressure
PD pharmacodynamic
PFT Pulmonary Function Test
P-gp P-glycoprotein
PH pulmonary hypertension
PK Pharmacokinetic
PP per protocol
PR PR interval of the ECG
PRO patient-reported outcome
PT prothrombin time
PVG pharmacovigilance
PVR pulmonary vascular resistance
QD once daily
QIDS-C, -SR Quick Inventory of Depressive S ymptomatology, -Clinician Rated, -Self
Reported
QRS QRS interval of the ECG
QT QT interval of the ECG
QTc corrected QT interval



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
39
ConfidentialAbbreviation or Specialist 
TermExplanation
QTcF QT interval corrected for heart rate using Fridericiaâ€™s formula
RAP right arterial pressure
RBC red blood cell
REVEAL Registry to Evaluate Early and Long-Term PAH Disease Management
RHC right heart catheterization
RR RR interval of the ECG or Respiratory Rate
ROW rest of world
RV right ventricular
SAE serious adverse event
SAP Statistical Analysis Plan
SBP systolic blood pressure
SD standard deviation
SDS safety data sheet
6MWT/6MWD six-minute walk test / six-minute walk distance
SoA schedule of assessment
SOC standard of care
SU5416, SUGEN semaxanib
SUSARs suspected unexpected serious adverse reactions
SV stroke volume
SvO 2 Mixed venous oxygen saturation
TAPSE tricuspid annular plane systolic excursion
TBL total bilirubin level
TEAEs treatment-emergent adverse events
TLC total lung capacity
TPH tryptophan hydroxylase
TTCI time to clinical improvement
TTCW time to clinical worsening
ULN upper limit of normal
WBC white blood cell
WHO World Health Organization



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
40
Confidential1. PROTOCOL SUMMARY
1.1. Synopsis
Name of Sponsor/Company:
Altavant Sciences GmbH
Name of Investigational Product:Rodatristat ethyl
Name of Active Ingredient:Rodatristat ethyl
Protocol Number/Study Name:RVT-1201-2002 / ELEVATE 2
Title of Study:
A Phase 2b, Dose-Ranging, Randomized, Double-Bl ind, Placebo-Controlled, Multicenter Study of 
Rodatristat Ethyl in Patients with  Pulmonary Arterial Hypertension
Study region(s):
United States, Canada, Poland, United Kingdom, France,  Spain, Germany, Italy, Belgium, Bulgaria,
Ukraine, Czech Republic, Latvia, Austria, Bosn ia and Herzegovina, Republic  of Moldova, and Serbia
Ex-US sites are non-IND sites
Studied period (years):
Estimated date first pa tient enrolled: March 2021
Estimated date last patie nt completed: October 2022Phase of development:
2b
Rationale:
Rodatristat ethyl is an orally bi oavailable prodrug that is rapidl y converted to the active tryptophan 
hydroxylase (TPH) inhibitor rodatristat in the systemic  circulation of multiple nonclinical species and 
humans. The clinical doses and regimens selected for this study have been selected with the goal to 
achieve optimal rodatristat exposure and serotonin (5 HT ) lowering targets associated with efficacy in 
nonclinical models of pulmonary arterial hype rtension (PAH) and pharmacokinetic (PK) and 
pharmacodynamic (PD) data in healthy subjects.
Objectives
Primary Objective:
xTo evaluate the effect of rodatristat ethyl on the percent change from baseline of pulmonary 
vascular resistance (PVR), as measured by right heart catheterization (RHC) in patients 
with PAH
Secondary Objectives:
xTo evaluate the effect of rodatristat ethyl  on change from baseline on the following:
oWHO FC 
o6MWD
oN-terminal pro-Brain Natriuretic Peptide (NT-proBNP)



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
41
ConfidentialSafety Objectives:
xTo assess safety and tolerability of r odatristat ethyl in patients with PAH
Additional Objectives:
xTo evaluate the effect of rodatristat et hyl on change from baseline on the following:
oCardiopulmonary hemodynamics (cardiac i ndex, mean pulmonary artery pressure 
[mPAP], mean right atrial pressure  [mRAP], mean mixed venous oxygen 
saturation [SvO 2], and pulmonary artery compliance [PAC])
oTime to Clinical Worsening (TTCW) define d as the first occurrence of a composite 
end point of: 1. Death from any cause, 2. Hospitalization for worsening PAH (any hospitalization for worsening PAH, lung or heart and lung transplantation, atrial 
septostomy, or initiation of parenteral prostanoid therapy, 3. Disease progression 
defined as a decrease of more than 15% from Baseline in the 6-minute walk 
distance (6MWD) combined with World Health Organization (WHO) Functional 
Class (FC) III or IV symptoms at 2 consecutive visits separated by at least 14 days(adjudicated)
oDeath from any cause
oEchocardiographic measures of right atrial  size & right ventricular (RV) function
(tricuspid annular plan sy stolic excursion [TAPSE], tricuspid annular systolic 
velocity, and RV fractional area change)
oPulmonary Arterial Hypertension-S ymptoms and Impact Questionnaire 
(PAH-SYMPACT)
oRegistry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) 
Lite 2 score
PK/PD Objectives:
xTo assess the PK of rodatristat et hyl and metabolites using population PK 
xTo assess the effect of rodatristat ethyl o n plasma and urine 5-hydroxyindoleacetic acid 
(5-HIAA)
Exploratory Objectives:
xTime to Clinical Improvement (TTCI)
xActigraphy
xTo evaluate the effect of rodatristat ethyl on  the plasma concentration of selexipag and 
ACT-333679
See protocol Section 3for Endpoints.
Open-Label Extension Objectives:
The objective of the OLE is to evaluate the long-ter m safety, tolerability, and efficacy of rodatristat 
ethyl in patients with PAH.
See protocol Section 7.3for Open-Label Extension Endpoints.
Methodology/Overall Study Design:
This double-blind study will compare the efficacy, safet y, and tolerability of 2 doses of rodatristat ethyl 
to placebo in patients with PAH.  Eligible patients will be stratified during the randomization process 
based on the number of background PAH therapies th ey are receiving (1, 2 or 3) and use of selexipag 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
42
Confidential(yes/no).  The number of patients who are receiving a prostanoid infusion will be capped at 50% of the 
total number of patients enrolled.  The number of pa tients who are receiving selexipag will be capped at 
20% of the total enrolled .Patients will be randomized 1:1:1 to placebo, 300 mg BID, or 600 mg BID of 
rodatristat ethyl.
Patients who complete the Main Study will have the option to enroll into the OLE and continue to 
receive rodatristat ethyl (those randomized to placeb o will be re-randomized 1:1 to receive rodatristat 
ethyl 300 mg BID or 600 mg BID) for 6.5 years, until th e Investigator or patient chooses to stop the IP, 
any stopping criteria in the Main Study are met, IP becomes commercially available, or the Sponsor 
stops the study for lack of efficacy or a safety sign al (whichever preceding criteria comes first). In no 
case will a patient be allowed to exceed 10 years of exposure unless the product is approved for a 
chronic indication.
Disclosure Statement:
This is a parallel group treatment study with 3 a rms that is participant, Sponsor, and Investigator 
blinded.
Number of participants (planned):
Approximately 90 patients with PAH are expected to be enrolled at approximately 68study sites in the 
U.S., Canada, and Rest of World (ROW). 
Inclusion Criteria:
Patients are eligible to be included in the study only if all the following criteria apply:
1. Male and female patients must be at least 18 ye ars of age at the time of signing the informed 
consent.
a. Male patients and female partners must  agree to use contraception as detailed in
Section 5.4.1 of the protocol starting at Screening, during the treatment period, and for at 
least 100 days after the last dose of IP.  Male patients must refrain from donating sperm 
during this period.
b. Female patients of childbearing potential must agree to use contraception as detailed in 
Section 5.4.1 starting at Screening, during the treatment period, and for at least 4 weeks 
after the last dose of IP.
2. Body mass index (BMI) Â•18 kg/m2DQGÂ” 40 kg/m2
3. Patients with symptomatic PAH belonging to one  of the following 2018 Clinical Group 1 Sub-types:
a. Idiopathic PAH
b. Heritable PAH
c. Drug- or toxin- induced
d. PAH associated with:
1. Connective tissue disease
2. Congenital systemic to pulmonary shunt (a trial septal defect, ventricular septal 
defect, patent ductus arteriosus) repaired  at least one year prior to Screening
3. Human Immunodeficiency Virus (HIV) infection - if diagnosed with HIV, must 
have stable disease status defined as follows: 
a. stable treatment with HIV medications for at least 8 weeks prior to 
Screening 
b. no active opportunistic infection during the Screening Period 
c. no hospitalizations due to HIV for at least 4 weeks prior to Screening 



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
43
Confidential4. WHO FC II or III
5. Confirmed diagnosis of PAH and meet allthe following hemodynamic criteria by means of a 
screening RHC completed prior to randomization: 
a. mPAP of > 20 mmHg
b.395Â• 350 dyneâ€¢sec/cm5
c. Pulmonary capillary wedge pressure (PCWP) or  left ventricular end diastolic pressure 
/9('3RIÂ” 12PP+JLI395Â• 350 and < 500 dyneâ€¢sec/cm5, or PCWP/LVEDP 
Â”15PP+JLI395Â• 500 dyneâ€¢sec/cm5
6. 6MWD of 100 to 550 meters at Screening
7. Currently on a stable treatment regimen with one or more treatments approved for PAH. Stable 
therapy is defined as receiving the same medication(s) IRUÂ• 12 weeks prior to the screening RHC 
DQGDWDVWDEOHGRVHOHYHOIRUHDFKIRUÂ• 8 weeks prior to the screening RHC (see Protocol 
Section 6.6.2 for approved PAH medications). Any instances where doses of a medication have 
been missed prior to RHC must be discussed w ith the Medical Monitor prior to performing the 
RHC.
8. Meet the following criteria determined by pulmona ry function tests (PFTs) completed no more than 
24 weeks prior to Screening (performed  with or without bronchodilation):
a. Forced expiratory volume in one second (FEV 1Â•60% of predicted normal
b.Total lung capacity (TLC) Â•70% of predicted normal RU)9&Â•SUHGLFWHGLI7/&
LVQRWDYDLODEOH)RUVXEMHFWV ZLWK&7'DVVRFLDWHG3$+LI7/& LVÂ•RISUHGLFWHG
but  < 70% of predicte GRULI)9&Â•R f predicted but < 70% of predicted,  high 
resolution computed tomography [HRCT] obtai ned within 6 months of screening may 
be utilized to demonstrate li mited interstitial lung disease
9. If participating in an exercise program for pul monary rehabilitation, the program must have been 
LQLWLDWHGÂ• 12 weeks prior to Screening, and patient must  agree to maintain the current level of 
rehabilitation for the first 24 weeks of IP.  If not participating in an exercise training program for 
pulmonary rehabilitation, must agree not to enro ll in an exercise training program for pulmonary 
rehabilitation during the Screening Pe riod and the first 24 weeks of IP.
10. Willing and able to give written informed consent and to comply with the requirements of the study
for its duration.
Exclusion Criteria 
Patients are excluded from the study if any of the following criteria apply:
1. Women of childbearing potential who are pregnant , planning to become pregnant, or lactating or 
female/male patients unwilling to use eff ective contraception as defined in Section 5.4.1 .
Medical Conditions
2. WHO Pulmonary Hypertension (PH) Group 1 PAH associated with portal hypertension or 
schistosomiasis; PH due to left heart disease (WHO PH Group 2), lung diseases and/or hypoxia 
(WHO PH Group 3), chronic thromboembolic pulmonary hypertension (WHO PH Group 4), or 
PH with unclear multifactorial mechanisms (WHO PH Group 5).
3. PH associated with significant venous  or capillary involvement (PCWP > 15 mmHg), 
pulmonary capillary hemangiomat osis, portal hypertension, or unrepaired congenital heart 
defects (CHD).



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
44
Confidential4. Three or more of the following risk factors for left ventricular disease:
a. BMI > 30 kg/m2
b. Diagnosis of essential hypertension that is actively treatedc. Diabetes mellitus
d. History of significant coronary artery disease (e.g., chronic stable angina, history of 
coronary intervention within the last 3 m onths, or a stenosis > 70% at coronary 
angiography)
e.Atrial fibrillation 
f. Left atrial volume index (LAVi) > 41 mL/m2[or left atrial diameter (LA) > 4 cm if LAVi
unavailable]
5. Known genetic hypert rophic cardiomyopathy.
6. Known cardiac sarcoidosis or amyloidosis.
7. The patient has a history of, or currently has, a constrictive cardiomyopathy. 
8. Known history of any LVEF < 40% by echo cardiogram within 3 years of randomization 
(Note : a transient decline in LVEF below 40% that  occurred and recovered more than 6 months 
before the start of Screening and was associated w ith an acute intercurrent condition [e.g., atrial 
fibrillation] is allowed).
9. Hemodynamically significant valvular heart disease as determined by the Investigator, 
including:
a. greater than mild aortic and/or mitral stenosis and/or
b. severe mitral and/or aortic regurgitation (> Grade 3)
10. Severe arthritis, musculoskeletal problems, or  morbid obesity that, in the opinion of the 
Investigator, is the cause of the patientâ€™s func tional limitation and would affect the patientâ€™s 
ability to perform or complete the 6MWT.
11. Planned major surgery within the next 3 mont hs, including lung transplantation, major 
abdominal or major intestinal surgery.
12. End stage renal disease defined as receiving pe ritoneal dialysis, hemodialysis, or status after 
renal transplantation; or severe liver disease defined as Child-Pugh Class C, with or without 
cirrhosis
13. Known congenital long QT syndrome (LQT S) or known family history of LQTS 
14.'HSUHVVLRQWKDWLVFXUUHQWO\UDW HGDVVHYHUHGHILQHGDVDVFRU HRIÂ• 16 on the QIDS-C and/or 
Hospital Anxiety and Depression Scale [HADS] 'HSUHVVLRQDQGRU$Q[LHW\VFRUHÂ• 15), recent 
suicidal behavior (either preparatory acts/behav ior, aborted attempt, interrupted attempt, or 
actual attempt in the past 3 months per the Scr eening Columbia Suicide Severity Rating Scale 
[C-SSRS], or active suicidal ideation with intent to act (defined as C-SSRS category score of 
4 or 5 in the past month)
15. Patients with (during Screening):
a. Severe hypertension (SBP > 180 mmHg an d/or Diastolic Blood Pressure [DBP] 
> 110 mmHg), and patients with severe hypotension (SBP < 90 mmHg and/or DBP 
< 50 mmHg)
b. Hypertension or hypotension considered not c ontrolled in line with clinical standards
16. Clinically significant electrolyte abnorm ality (e.g., hypokalemi a, hypomagnesemia, or 
hypocalcemia) in the judgement of the Investigator.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
45
Confidential17. Current or prior history within the last 5 years of neoplasm (except for treated basal cell or 
squamous small cell carcinoma of the sk in with no evidence of recurrence).
18. Any concurrent clinically significant medical condition/disorder which in the Investigatorâ€™s 
opinion would interfere with the patientâ€™s ability  to comply with or complete the study or 
could affect the interpretation of the efficacy and safety variables.
Prior/Concomitant Therapy
19. Use of any of the following medications or supplements within 30 days prior to Screening:
a. Monoamine oxidase inhibitors (MAOIs; Refer to Appendix 1 )
b. 5-Hydroxytryptophan (5 -HTP) or L-tryptophan 
c. Telotristat ethyl
20. Patients currently taking one or more drugs known to prolong the QT interval and which are 
clearly associated with a known risk of Torsades de Pointe (see Appendix 1 ).
Diagnostic Assessments
21. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2at Screening as
determined by central laboratory.
22. 12-Lead electrocardiogram (ECG) results at Screening demonstrating QTcF interval 
> 450 ms for males or > 470 ms for females.
23. Elevated alanine transaminase (ALT), aspartate transaminase (AST)), or total bilirubin 
(TBL) > 2X upper limit of normal (ULN).
24. Any ECG or clinical laboratory abnormality which precludes safe pa rticipation in the study 
in the opinion of the Investigator.
Lifestyle
25. History of active substance use disorder (inc luding alcohol) within the past 2 years which, 
in the option of the Investigator, would limit th e ability of the patient to provide adequate 
informed consent or to comply with study requirements
26. Use of any investigational drug within 30 days or 5 half-lives (whichever is longer) prior to 
Screening or 90 days if an i nvestigational drug for PAH or anytime while on IP (including 
during OLE), unless local health author ity guidelines mandate a longer period ,or in 
consultation with the medical monitor, will not int erfere with the safety or efficacy of the 
study .
27. Any history of hypersensitivity to rodatr istat ethyl, any of its components, or any 
components in the placebo preparation (r efer to Rodatristat Ethyl IB, 2021).
28. Patient is deprived of their liberty by a judici al or administrative decision, or is receiving 
psychiatric care, and is admitted to  a health or social institution.
29. Patient is subject to legal protectio n or is unable to express consent.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
46
ConfidentialDuration of Treatment and Length of Study:
The treatment duration will be 24 weeks.  The study will last up to 32 weeks in duration for patients 
completing the study that do not enroll into the OLE:
xScreening period: up to 28 days
xFixed dose treatment period (including Baseline): 24 weeks
xSafety Follow-Up Visit: 4 weeks after the end of  dosing if the patient does not enroll into 
the OLE
OLE will continue for 6.5 years, until the Inves tigator or patient chooses to stop the IP, any 
stopping criteria in the Main St udy are met, IP becomes commerci ally available, or the Sponsor 
stops the study for lack of effica cy or a safety signal (whichever  preceding criteria comes first). 
In no case will a patient be allowed to exceed  10 years of exposure unless the product is 
approved for a chronic indication.
Investigational Product, Dosage , and Mode of Administration:
Patients will be enrolled into 1 of 3 treatment arms in  a 1:1:1 randomization, with 30 patients per arm, 
receiving placebo or IP, taken with food for 24 weeks as follows:  
xRodatristat ethyl 300 mg + matching place bo BID (1 x 300 mg + 1 x placebo BID)
xRodatristat ethyl 600 mg BID (2 x 300 mg BID)
xMatching placebo BID (2 x placebo BID)
In order to maintain the study blind, all patients will receive 2 tablets of either rodatristat ethyl and/or 
placebo in the morning and in the evening in one of the combinations noted above.
Temporary dosage reductions or discontinuations  will be allowed to manage adverse events 
(AEs)/Adverse events of special interest (AESIs), in cluding gastrointestinal AEs (e.g., diarrhea, nausea, 
or vomiting) and liver enzyme elevations occurri ng during the 24-week treatment period.  Use of 
antidiarrheal and/or anti-emetic medications will  be permitted as directed by the Investigator.
Patients randomized to a rodatristat ethyl arm in  the Main Study may continue at the dose level given 
during the Main Study in the OLE.  Patients random ized to placebo in the Main Study will be re-
randomized to one of the active rodatristat ethyl treatment arms (300 mg BID or 600 mg BID) during 
the OLE. Changing of treatment for all patients in the OLE, to receive either 300 mg BID or 600 mg 
BID, could depend on the timing and outcome of th e 24-week analysis from the Main Study.  
Tolerability and all accumulated safety and efficacy  data will be reviewed by the Independent Data 
Monitoring Committee (IDMC)  at regular intervals.
Non-Investigational Therapies:
Patients will remain on their prescribed, pre-existin g background PAH medications; doses of these 
medications should remain stable during the study.  All treatment modifications (changes in dose or 
regimen) will be documented.
Any changes to background PAH therapy during th e study should be based on clear medical need and 
should be first discussed with the Medical Monitor whenever possible.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
47
ConfidentialStatistical methods:
A detailed description of statistical methods will be provided in a separate Statistical Analysis Plan 
(SAP) that will be finalized prior to database lock.
Sample Size Justification:
The planned sample size is 90 patients with 30 patient s to be randomized into 1 of the 3 treatment arms 
in a 1:1:1 randomization. A sample size of 30 per group will provide at least 80% power at a 
significance level of 0.05 (2-sided hypothesis) to de tect a treatment difference of 0.75 times of standard 
deviation (SD) in the percentage change of PVR from baseline between an active arm and the placebo 
arm. For example, if the SD for PVR percent change from baseline is 24%, the study has 80% power to 
detect a difference of 18% between an active arm and the placebo arm.
Analysis Populations:Intent-to-Treat (ITT): All patients randomized into the study.  For all summaries based on the ITT 
population, patients will be assigned to the tr eatment arm to which they were randomized.
Safety: The Safety Population will consist of all patien ts who are randomized and received at least one 
dose of study medication. For all summaries based on th e safety population, patients will be assigned to 
the treatment arm corresponding to the dose they had received.
Modified Intent-to-Treat (m-ITT):  All Safety population patients that had an evaluable baseline and 
at least 1 post-baseline PVR measurement.
Per Protocol (PP): All m-ITT population patients who had no major protocol deviations.
Pharmacokinetic:
All Safety Population patients with rodatris tat ethyl or rodatristat concentration data.
Efficacy Analysis:Primary efficacy analyses will be perf ormed using the m-I TT and PP populations.
Percent change from baseline in PVR will be analyzed  using an analysis of covariance (ANCOVA) with 
baseline PVR as the covariate. Additional baseline characteristics may also be evaluated as 
covariates in the model. The estimated between-treatment differences, 95% confidence intervals
(CIs) and p-values will be presented. For patients who discontinue from the study early, the last 
observation carried forward method will be used to impute the PVR at Week 24.
Secondary efficacy analyses will be perfor med using the m-ITT and PP populations:
xChange in cardiac index, mPAP, mRAP, SvO2 at rest and PAC from baseline 
xTime to Clinical Worsening
xDeath from any cause
xChange in WHO FC from baseline
xChange in 6MWD from baseline 
xChange in NT-proBNP from baseline
xChanges in right atrial size & RV function: TAPSE, tricuspid annular systolic velocity, and
RV fractional area change from baseline
xChange in PAH-SYMPACT from baseline 
xChange in the REVEAL Lite 2 score
xChange in 5-HIAA (plasma an d spot urine concentration)



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
48
ConfidentialThe change from baseline endpoints will be anal yzed using an ANCOVA model with treatment as a 
fixed effect, randomization stratum and baseline assessment as covariates.  The estimated between treatment differences, 95% CIs and p-values will be presented.
The change in 6MWD from baseline will also be compared between groups using non-parametric 
analysis of covariance within the framework of the extended Cochran-Mantel-Haenszel Test.  For 
endpoints measured over time, a mixed effect of repeated measure model ma y be used as sensitivity 
analyses.  Details of statistical methods will be provided in the SAP.
The time from the first dose of IP
until to the first clinical worsening event will be  summarized using Kaplan-Meier estimates, and 
compared between treatment groups using the log-rank test.
Safety Analysis:
A summary of rodatristat exposure will be perform ed using the safety population.  The safety and 
tolerability of rodatristat ethyl will be  evaluated by assessment of AE in cidences and changes in clinical 
laboratory tests, vital signs measurements, ECG tr acings, and the use of concomitant medication during 
the study. Adverse events (AEs) will be mapped to a Medical Dictionary for Regulatory Activities 
(MedDRA)-preferred term and system organ classifi cation. The occurrence of treatment-emergent AEs 
(TEAEs) will be summarized by treatment grou p using MedDRA preferred terms, system organ 
classifications, and severity. Separate summaries of  treatment-emergent serious adverse events (SAEs) 
and AEs considered to be related to IP will be ge nerated. All AEs will be lis ted for individual patients
showing both verbatim and preferre d terms. Descriptive summaries of vital signs, ECG parameters, and 
clinical laboratory results will be prese nted by study visit and treatment group.
Pharmacokinetic Analysis
Population Pharmacokinetic Analysis:
A population PK approach will be utilized to characteri ze the PK of rodatristat ethyl and rodatristat.  A 
detailed description of the PK and any PK/PD analysis  methods used will be provided in the separate 
analysis plan.
Demographic and Baseline Characteristics: 
Demographic and baseline characteristics for the ITT population will be summarized using descriptive 
statistics.
Other Analyses:
Patient Reported Outcomes (C-SSRS, HADS and QI DS-C), PK concentration data , PD, and exploratory 
descriptive analyses will be described in the SAP finalized before database lock.
Independent Data Mo nitoring Committee:
The primary role of the IDMC which consists of inde pendent physicians with experience in the care of 
patients with PAH and the conduct of randomized cont rolled trials, and one non-vo ting biostatistician, is 
to ensure the safety of the patients enrolled in the study/OLE. A detailed description of IDMC 
procedures is provided in a separate data mon itoring committee charter maintained by the Sponsor.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
49
Confidential1.2. Study Schematic
Figure 1: Study Schematic
Abbreviations:  BID = twice daily; IP = investigational product




		
Clinical Study Protocol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
50
Confidential 1.3. Schedule of Assessments â€“ Main Study
Screenin g Baseline Treatment Follow-U p
Visit No. Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9
Study Week1
(Days)-4 Wks2
(D-28 to D-1) 
ClinicD1
ClinicWk 2 (D14)
Telemed/ 
Phone CallWk 4
(D28)
ClinicWk 8 ( D56)
Clinic or 
HomeWk 12
(D84)
ClinicWk 18 ( D126)
Clinic or HomeWk 24
(D168)
ClinicWk 28
(D196) 
FU3/ ET3,4
Clinic or Home
Screenin g/D e m o graph y/B a s e l i n e
Informed Consent X
Inclusion/Exclusion Criteria X X
Demographics X 
Height/Weight/BMI X X5X5X5X5X5X5
Medical History Including Cardiac 
and Pulmonary History/Current 
Conditions6X X 
PAH Medication History7 X X 
Pulmonary Function Tests (PFTs)
(unless completed in last 24 weeks)X 
FSH8 X
Urinar y Screen for Dru gs of Abuse X
Register Patient in IRT
Screenin g/Randomization X X 
Treatment 
Concomitant Medications X X X X X X X X X
Dispensing IP via IRT X X X 
Administer Rodatristat Ethyl or 
Placebo9 X X X X X X 
Morning Dose Taken in Clinic with 
Food9 X X 
Investigational Product 
Compliance/ Accountabilit yX X X X 
Safet y/Tolerabilit y Assessments
Adverse Events10 Ä¸X Äº
Pregnanc y Test (Serum/urine)11 XX X XX XX
Physical Examination X X X X X



		
Clinical Study Protocol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
51
Confidential Screening Baseline Treatment Follow-Up
Visit No. Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8 Visit 9
Study Week1
(Days)-4 Wks2
(D-28 to D-1) 
ClinicD1
ClinicWk 2 (D14)
Telemed/ 
Phone CallWk 4
(D28)
ClinicWk 8 ( D56)
Clinic or 
HomeWk 12
(D84)
ClinicWk 18 ( D126)
Clinic or HomeWk 24
(D168)
ClinicWk 28
(D196) 
FU3/ ET3,4
Clinic or Home
Vital Signs (BP, HR, RR, temp, 
oxygen saturation)X X X X X X X X 
12-Lead ECG12 X X X X X X X X 
Laboratory â€“ Hematology, 
Coagulation13, Chemistry,
urinal ysis,X X X  X X X X X 
Columbia-Suicide Severity Rating 
Scale (C-SSRS)X X X X X X X 
Hospital Anxiety and Depression 
Scale (HADS)X X X X X X X 
Quick Inventory of Depressive 
Symptoms (QIDS-C)X X X X X X X 
Efficacy-Related Assessments
6MWT X X X X X
Right Heart Catheterization (RHC)14 X XX14
Echocardiography15 XX X
WHO FC X X X X X
Plasma NT-proBNP level X X X X 
PAH Symptoms and Impact 
Questionnaire (PAH-SYMPACT)X X X 
Actigraphy16 Ä¸X Äº
Pharmacokinetics
Rodatristat PK Samplin g17 XXXX
Selexipa g PK samplin g18XX
Pharmacod ynamics
Urine 5-HIAA17 X X X X
Urine Creatinine17 X X X X
Plasma 5-HIAA17 XXXX
Other
Optional Blood for Future Research
SampleX X 
Pharmaco genetic Samples X X



		
Clinical Study Protocol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
52
Confidential 1Visits at Week 2 (Telemed/P hone Call) and Week 4 (clinic visit)  can occur within +/-2 days fro m the randomization date; Visits at  Weeks 8 (Telemed/Phone  call), 12 (clinic),
18 (clinic or home visit), 24 and 28/Follow Up (clinic) ca n occur within +/-5 days from the randomization date.
2Screening may be broken up into more than 1 visit, if necessary.  Once all screening procedures are complete and the Investigator  determines that the pati ent is eligible, the site 
must upload/send the required supporting documentation for approval by the Sponsor.
3Patients who early terminate from the IP should be asked to return for visits as scheduled for ongoing assessments through the Wee k 28 Visit.  Patients who withdraw consent 
should be asked to complete the Week 28 Visit for safety.  Patients who have not completed the study as planned (through Week 24) cannot participate in OLE.  Patients who 
withdraw consent will continue to be followed for vital status  from public records such as gov ernment vital statistics or obitu aries, as allowed by local law, or periodic contact 
(about every 6 to 12months). 
4Patients that complete the study (defined as completing all visits through Week 24) have  the option to enroll into the OLE (See Se ction 1.4).  Patients who complete through 
Week 24 but decide not to enroll into the OLE, should complete the Week  28 Follow-Up Visit. 
5Weight only (no height or BMI) will be performed at Day 1 and Weeks 4, 8, 12, 24, and 28. 
6Must have a confirmed diagnosis of PAH in patientsâ€™ medical history
7Background PAH therapy dose regimens must be stabilized for > 12 w eeks prior to the screening RHC and on stable dose(s) > 8 wee ks prior to the screening RHC to be eligible.
All changes and dose adjustments in ba ckground PAH therapy must be documented.
8Pregnancy tests not required for women who are surgically sterile. FSH required for women with amenorrhea < 2 years at the Scre ening Visit only to c onfirm postmenopausal 
status.
9IP must be taken daily, morning and evening until the night before  the Week 24 visit. Patients must be told not to take a dose the  morning of the Week 24 visit. Doses should be 
taken with food.  During visits at the clin ic or home, all assessments should be done predose, except where otherwise indicated.   Patients should bring thei r IP with them for each 
visit (including any empty bottles). 
10SAEs will be collected starti ng at informed consent form signing.  AEs w ill be collected starting at first dosing.
11Serum pregnancy tests will be performed at  Screening and urine pregnancy tests over th e rest of the study. A negative urine pre gnancy test must be completed before Day 1 
procedures.  If a positive result on a urine test, a serum pregnanc y test should be completed to confirm. Pregnancy tests will b e completed in women of child-bearing potential 
every 4 weeks while on study.  Weeks 8, 16 and 20 will be perform ed at home (with a kit given to  the subject by the site) and t he results will be confirmed with the subject by a 
phone call. Additional pregnancy tests should be  completed anytime menstruation is delayed and in women with infrequent or irregula r menstrual cycles.
12Three 12-lead ECGs (at least 1 minute apart) will be collected on Da y 1 after at least 5 minutes of rest.  Single 12-lead ECGs w ill be collected at all other time points. 
13Coagulation testing will be done at Screening, Weeks 12 and 24.
14RHC results from 4 weeks prior to the Screening visit may be us ed for entry provided the RHC includes all required information a nd provided that changes to the patientâ€™s PAH 
regimen were not made. If prior approval is obtained from the Sponsor,  the screening RHC may be performed on the same day as the  randomization procedures,  provided that all 
blood draws and other efficacy assessment s are conducted prior to the RHC procedure, and the RHC is performed prior to randomiz ation and IP dosing.  Week 24 RHC may
occur up to 7 days prior to or on the Week 24 Visit. If a patient terminates early, and at or afte r the Week 12 Visit, an RHC shou ld be performed at the Early Termination Visit.
15Echocardiography should be done in supine po sition after at least 5 minutes of rest.
16Patients will wear a wrist device for the entire duration of the study, but for endpoi nt assessments, focus will be on the 3 fol lowing periods: Day 1 to Week 4, 
Week 12 to Week 16, and Week 20 to Week 24.  All details of collection will be provided in the study manual.
17Rodatristat Ethyl and Rodatristat PK: At Day 1 and Week 4, a predose PK sample will be co llected (patients will  take study medicat ion in the clinic).  At Week 12, a postdose 
PK sample will be collect ed between 1 to 8 hours after the morning dose (patient s will take the morning dose in the clinic and the time of dose will be recorded â€“ all other 
assessments can be done pre or post dose).  At  Week 24, no study medication will be take n prior to the clinic visit (the last d ose in the Main Study will be the evening before the 
Week 24 visit) and a PK sample will be collected.  If the subject enrolls in the OLE, this PK sample will be collected prior to  the first dose of study treatment in the OLE. 
Blood and spot urine samples for 5-HIAA (and uri ne samples for creatinine) will be collected  pre-dose on Day 1 and at Weeks 4, 12, a nd 24. 
18Selexipag and ACT-333679 PK (for subjects using se lexipag at baseline only): At Day 1 and W eek 4, a predose PK sample will be col lected (patients will take selexipag in the 
clinic at these visits, and the PK  samples will be collected approxima tely 12 h after the prior dose) 
Additional unscheduled safety assessments may be conducted at any time during the study if the Investigator or Sponsor deems it necessary for the safety of the 
patient.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
53
ConfidentialAbbreviations:  5-HIAA = 5-hydroxyindolea cetic acid; 6MWT = 6-minute walk test; AEs = ad verse events; BMI = body mass index; BP = blood p ressure; 
C-SSRS = Columbia-Suicide Severity Rating Scal e; D = day; ECG = electrocardiogram; ET = early  termination; FSH = follicle stimulating hor mone; FU = follow up; 
HADS = Hospital Anxiety and Depression Scale; HR = heart rate; IP = i nvestigational product; IRT = intera ctive response technology; LFT s = liver function tests; mo = months; 
NT-proBNP = N-terminal pro-brain natriuretic peptid e; OLE = Open-Label Extension; PAH = pulm onary arterial hypertension; PAH-SYMPACT = Pulmonary Arterial 
Hypertension Symptoms and Impact Questionnaire; QIDS-C = Quick Inv entory of Depressive System-Clinic ian Rated; RHC = right heart ca theterization; RR = respiratory rate; 
SAE = serious adverse event; temp = temperature; WHO FC = W orld Health Organization Functional Class; Wk = week



		
Clinical Study Protocol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
54
Confidential 1.4. Schedule of Assessments â€“ Open- Label Extension â€“ (First 24 we eks of Open-Label Extension) 
Study Week1
(following Week 24 in Main Study)D1
Clinic
(Week 24 
Main Study) Wk 2 (D14)
Telemed/ 
Phone CallWk 4( D28)
ClinicWk 8 ( D56)
Clinic or 
Home Wk 12 ( D84)
ClinicWk 18 
(D126)
Clinic or 
HomeWk 24
(D168)
ClinicET2
Clinic or Home
Screenin g/D e m o graph y/B a s e l i n e
Informed Consent X 
Inclusion/Exclusion Criteria X
Weight X3X3X3X3X3
Treatment 
Concomitant Medications X X X X X X X X
Re-Randomization in IRT X 
Dispensing IP via IRT X X X 
Administer Rodatristat Ethyl XX X X XX X
Morning Dose Taken in Clinic 
with Food4 X X 
Investigational Product 
Compliance/ Accountabilit yX X X X X 
Safet y/Tolerabilit y Assessments
Adverse Events Ä¸X Äº
Pregnanc y Test (Serum/urine)5 XX X X X
Physical Examination X X X
Vital Signs (BP, HR, RR, temp, 
oxygen saturation)X X X X X X 
12-Lead ECG6 X X X X X X 
Laboratory â€“ Hematology, 
Coagulation7, Chemistry,
urinal ysis,X  X X X X X 
Columbia-Suicide Severity Rating 
Scale (C-SSRS)X X X X X 
Hospital Anxiety and Depression 
Scale (HADS)X X X X X 
Quick Inventory of Depressive 
Symptoms (QIDS-C)X X X X X 



		
Clinical Study Protocol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
55
Confidential Study Week1
(following Week 24 in Main Study)D1
Clinic
(Week 24 
Main Study) Wk 2 (D14)
Telemed/ 
Phone CallWk 4( D28)
ClinicWk 8 ( D56)
Clinic or 
Home Wk 12 ( D84)
ClinicWk 18 
(D126)
Clinic or 
HomeWk 24
(D168)
ClinicET2
Clinic or Home
Efficacy-Related Assessments
6MWT X X X
Right Heart Catheterization
(RHC)8 XX  
Echocardiography9 XX
WHO FC X X X
Plasma NT-proBNP level X X X 
PAH Symptoms and Impact 
Questionnaire (PAH-SYMPACT)X X 
Selexipag PK Sampling10XX
1Visits at Week 2 (Telemed/Phone Call) and Week 4 (clinic visit) can  occur within +/-2 days from th e randomization date; Visits at Weeks 8 (Telemed/Phone call), 12 (clinic),
18 (clinic or home visit), 24 and 28/Follow Up (clinic) can  occur within +/-5 days from the randomization date.
2Patients who withdraw consent shoul d be asked to complete the ET Visit for safety.  Patients who withdraw consent will continue to be followed for vital status from public 
records such as government vital statistics or obituaries, as allowed by local law, or periodic contact (about every 6 to 12mont hs).
3Weight only (no height or BMI) will be performed at Weeks 4, 8, 12, 24, and 28. 
4IP must be taken daily, morning and evenin g.  Doses should be taken with food.  During vi sits at the clinic or home, all assessm ents should be done predose, except where 
otherwise indicated.  Patients should bring their IP w ith them for each visit (including any empty bottles).
5Pregnancy tests not required for women who ar e surgically sterile. Pregnancy tests will be completed in women of child-bearing potential every 4 weeks while on study.  Weeks 
8, 16 and 20 will be performed at home (with a kit given to the subject by the site) and the results will be confirmed with the  subject by a phone call. Additional pregnancy tests 
should be completed anytime menstruation is delayed and in women with infreq uent or irregular menstrual cycles.
6Single 12-lead ECGs will be collected at all time points.
7Coagulation testing will be done at Weeks 12 and 24. 
8Week 24 RHC may occur up to 7 days prior to or on the Week 24 Visit.  If a patient terminates early, and at or after the Week 12 Visi t, an RHC should be performed at the Early 
Termination Visit.
9Echocardiography should be done in supine po sition after at least 5 minutes of rest. 
10Selexipag and ACT-333679 PK (for subjects using se lexipag at baseline only): At Day 1 and W eek 4, a predose PK sample will be col lected (patients will take selexipag in the 
clinic at these visits, and the PK samples will be  collected approximately 12 h after the prior dose)
Additional unscheduled safety assessments may be conducted at any time during the study if the Investigator or Sponsor deems it  necessary for the safety of the 
patient.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
56
ConfidentialAbbreviations:  5-HIAA = 5-hydroxyindolea cetic acid; 6MWT = 6-minute walk  test; AEs = adverse events; BMI = body mass index; BP = blood p ressure; 
C-SSRS = Columbia-Suicide Severity Rating Scal e; D = day; ECG = electrocardiogram; ET = early  termination; FSH = follicle stimulating hor mone; FU = follow up; 
HADS = Hospital Anxiety and Depression Scale; HR = heart rate; IP = i nvestigational product; IRT = intera ctive response technology; LFT s = liver function tests; mo = months; 
NT-proBNP = N-terminal pro-brain natriuretic peptid e; OLE = Open-Label Extension; PAH = pulm onary arterial hypertension; PAH-SYMPACT = Pulmonary Arterial 
Hypertension Symptoms and Impact Questionnaire; QIDS-C = Quick Inv entory of Depressive System-Clinic ian Rated; RHC = right heart ca theterization; RR = respiratory rate; 
SAE = serious adverse event; temp = temperature; WHO FC = World Health Organization  Functional Class; Wk = week
1.5. Schedule of Assessments â€“ Ope n-Label Extension â€“ (Post 24 Week s of the Open-Label Extension)
1As necessary, 6-month supply of IP will be dispensed.
2Patients should be instructed to bring their used, partial, and unused IP containers with them to every Clinic Visit to assess co mpliance and IP accountability.
3Pregnancy test will be required every 4 weeks, in women of childbear ing potential only.  Urine pregnancy kits will be provided to t he patient. Completion of the pregnancy test, 
and collection of adverse even ts and concomitant medications will be documented via telephone contact. Serum pregna ncy test to be done to confirm a positive urine test.
Additional pregnancy tests should be comple ted anytime menstruation is delayed and in women with infrequent or irregular menstr ual cycles.
4If a patient discontinues IP for any re ason a follow-up visit must be performed 4 weeks after the last dose of IP.
Abbreviations:  BP = blood pressure; HR = heart  rate; IP = investigational product; RT = inter active response technology; LFTs = liver fu nction tests; RR = respiratory rate; 
temp = temperature
Additional unscheduled safety assessments may be conducted at any time during the study if the Investigator or Sponsor deems it  necessary for the safety of the 
patient.Pregnancy Test Clinic Visits4Follow Up4
(4 weeks after last dose of 
IP)
Week Every 4 Weeks
(+/- 2 da ys)Every 24 Weeks
(+/- 4 da ys)
IP Dispensing via IRT1X
IP Compliance/ Accountability2X
Concomitant medications X X
Vital Signs (BP, HR, RR, temp, oxygen saturation) X X
Pregnancy Test (serum/urine)3X XX
Laborator y â€“ Hematolo gy, Coa gulation, Chemistr y(includin g LFTs) X X
Adverse Events X X X



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
57
Confidential 2. INTRODUCTION
2.1. Background
Pulmonary arterial hypertensi on (PAH) is a severe, incura ble disease characterized by 
remodeling of the pulmonary  arterial bed, leading to elevations  in resting mean pulmonary artery 
pressures, subsequent right ventricular hypert rophy, and eventually, ri ght heart failure and 
(Agarwal & Gomberg-Maitland, 2011 ).  Current standard-of-care therapies for PAH target 
3 different pathways â€“ namely, the endothelin- 1 pathway, the nitric oxide pathway, and the 
prostacyclin pathway â€“ and act primarily as vasodilators.  They reduce PAH symptoms and may 
slow disease progression, but they lack  compelling disease-modifying properties.
Several lines of evidence implicate sero tonin (5-hydroxytryptamine [5-HT]) in the 
pathophysiology of PAH where there are findings that  5-HT plasma levels are markedly elevated 
in PAH ( Humbert et al., 2002 ); tryptophan hydroxylase (TPH) 1, th e key rate-limiting enzyme in 
the biosynthesis of systemic  5-HT, is overexpressed in lung tissue of PAH patients 
(Eddahibi, 2006 ), and 5-HT acts on pulmonary artery  smooth muscle cells to induce 
vasoconstriction and proliferation ( MacLean & Dempsie, 2010 ).  In addition, 5-HT acts at the 
5-HT1B receptor and the 5-HT transporter to  mediate constriction and proliferation of 
pulmonary artery smooth muscle cells ( MacLean & Dempsie, 2010 ).  Finally, genetic deletion 
and pharmacological inhibition of TPH1 protects against the development of experimentally 
induced PAH ( Abid et al., 2012; Izikki et al., 2007 ) in nonclinical pharmacology models.  In 
aggregate, these findings indica te that modulation of the 5-HT  pathway by TPH1 inhibition is a 
novel approach that differentiate s itself mechanistically from cu rrent therapeutic options and 
offers the potential to  modify the underlying disease pathophysiology and progression of PAH
(Aiello et al., 2016; MacLean, 2018 ). 
A therapeutic strategy is needed to safely and effectively inhibit TPH1 activity in peripheral 
tissues, without unwanted central nervous system (CNS) effects th at result from inhibition of 
TPH2, the predominant TPH isoform in the CNS. 
Rodatristat ethyl is a peripherall y restricted TPH1/TPH2 inhibito r with little CNS penetration. 
Nonclinical data indicate that ne ither rodatristat ethyl nor rodatr istat cross the bl ood brain barrier 
to a pharmacologically relevant  level and do not lower brain levels of 5-HT in nonclinical 
pharmacodynamic studies in rats.  By limiting inhibition to TPH1 in the periphery, rodatristat 
ethyl may avoid potential untow ard CNS effects that could ot herwise be a consequence of 
inhibiting TPH2-mediated CNS 5-HT production ( Kim et al., 2015; Shi et al., 2008 ). 
Rodatristat ethyl is a prodrug that  is rapidly hydrolyzed to rodatristat, a potent TPH inhibitor that 
reduces peripheral 5-HT levels in the gut mucosa, lung, and serum in animal models of PAH.  In 
vitro, nonclinical, and human pha rmacokinetic (PK) studies to date have provided valuable 
information on the PK properties of  rodatristat ethyl and its active moiety, rodatristat. Rodatristat 
ethyl has low to moderate oral bioavailability in nonclinical speci es and is rapidly converted to 
rodatristat in vivo.  Both roda tristat ethyl and roda tristat are highly prot ein bound and little is 
excreted in the urine.  Biliary  excretion predominates in ra ts and no furthe r metabolism of 
rodatristat has been detected in human hepatocyte preparations. However, preliminary 
investigations have also identi fied a metabolite, M 15, in the plasma of dogs and humans after 



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
58
Confidential administration of rodatristat ethyl . After single-dose administrati on, the half-life of rodatristat 
ethyl and rodatristat are approximately 5 and 12 hours, respectively, reaching steady-state 
exposure, according to trough concentrations, by Day 5.  The highest exposures achieved in 
healthy subjects to date were reached on Day 7 following 800 mg twice daily (BID) doses of 
rodatristat ethyl.
Rodatristat ethyl was selected fo r development in the treatment of PAH based on a range of 
criteria, including achieving efficacy endpoint s in nonclinical in vivo models of PAH, 
pharmacokinetic (PK) parameters, and biomarker endpoints related to both changes in systemic 
5-HT levels and PAH pathology. 
Reductions in biomarkers  indicative of decreased 5-HT bios ynthesis were observed in healthy 
subjects receiving repeat twice daily (BID) oral doses (range 100 to 800 mg BID) of rodatristat 
ethyl over 14 days.  Rodatristat ethyl doses of either 400 or 800 mg BID achieved reductions in 
5-HT by Day 14 comparable to thos e associated with efficacy in  the rodent models of PAH. 
2.2. Study Rationale
Rodatristat ethyl is expected to  have efficacy for PAH.  Re sults from nonclinical pharmacology 
studies demonstrate that rodatris tat ethyl is a potent and selective inhibitor of TPH1 with the 
potential to ameliorate disease by halting or  reversing the pulmonary  vascular remodeling 
characteristically observed.  Th rough inhibition of TPH1, rodatrista t ethyl is expected to improve 
cardiopulmonary hemodyna mics, functional capacity, PAH sy mptoms, and right ventricular 
(RV) function via its novel antiproliferative and anti-re modeling mechanism of action.
This study will evaluate rodatristat ethyl doses of 300 mg BID and 600 mg BID. Dose selection 
was guided by the goal of demonstrating a dose/exposure efficacy relationship and was 
supported by nonclinical pharmacology, toxicology, and animal model efficacy data. Results 
from Phase 1 human studies suggest that these dosing regimens should be safe and generally 
well tolerated with dose-proportiona l differences in systemic dr ug exposure.  Further details 
regarding the dose rationale can be found in Section 4.7.
2.3. Benefit/Risk Assessment
Summaries of findings from both clinical and nonclinical studies conducted with r odatristat ethyl
as well as more detailed information about th e known and expected benefits and risks and 
reasonably expected adverse events (AEs) of rodatr istat ethyl may be found in the Investigatorâ€™s 
Brochure.  This section outlines the potential adve rse events of special interest (AESI; based 
either on preclinical or clinical data generated to date, the mechanism of action of rodatristat 
ethyl, or the prescribing information for telotris tat ethyl [a TPH inhibitor previously approved for 
the treatment of carcinoid syndrome-related diar rhea] and mitigation strate gies for this protocol.
The potential risk for QTc prolongation (described in the Investigatorâ€™s Br ochure) will be further 
evaluated in a definitive thorough QT study in the future. Until furthe r data are available in that 
regard, cardiac arrhythmia, related to an increas e in QT/QTc interval, will be treated as a 
potential AESI and has therefore also been incl uded in the table of potential risks below. 
Although any potential benefits to patients w ith PAH will not be known until the study is 
completed, the development of a drug with disease- modifying potential will certainly be of value 
to patients with this diagnosis.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
59
ConfidentialPotential Risk Mitigation Strategy
Impact on Eligibility Monitoring and Stopping 
Criteria OR Management Criteria
Severe constipation None Severe constipation 
(e.g., obstipation with manual evacuation indicated) and/or severe, persistent, or worsening abdominal pain would warrant withdrawal from the study.
Depression/other mood-related disturbance due to central depletion xExclusion of patients with active 
suicidal thinking or behavior at Screening/Baseline based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
xExclusion of patients with severe 
depression at Screening/Baseline based on the Quick Inventory of Depressive Symptoms Clinician-Rated (QIDS-C) or the Hospital Anxiety and Depression Scale (HADS)Withdrawal of patients with:
xAny significant worsening 
on postdose C-SSRS indicative of active suicidal ideation with intent to act or suicidal behavior
xSevere depression or 
anxiety based on a HADS Depression or Anxiety Score Â•15 or a QIDS-C
Total Score Â•16.
xAny severe psychiatric or 
CNS AE as determined by the Investigator.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
60
ConfidentialPotential Risk Mitigation Strategy
Impact on Eligibility Monitoring and Stopping 
Criteria OR Management Criteria
Hepatic enzyme elevationsExclude patients with alanine 
aminotransferase (ALT) / aspartateaminotransferase (AST) / gamma-glutamyltransferase (GGT) results greater than 2X
upper limit of normal (ULN) and/or TBL 
>2 XU L NWithdrawal criteria for abnormal liver function tests set at: 
xALT or AST > 3X ULN 
andTBL > 2X ULN (or 
international normalized ratio (INR) > 1.5)
xALT or AST > 3X ULN 
with appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia (> 5%)
xALT or AST > 5X ULN for 
>2w e e k s
xALT or AST > 8X ULN
Cardiac arrhythmia, 
related to an increase in QT/QTc intervalExclude patients with:
xQTcF > 450 ms (males) or > 470 ms 
(females)
xKnown congenital Long QT Syndrome 
(LQTS), or known family history of LQTS
xClinically significant electrolyte 
abnormality (i.e., hypokalemia, hypocalcemia, hypomagnesemia)
xConcomitant use of QT-prolonging 
drugs clearly associated with a risk of Torsades de Pointe (see Appendix 1 )Withdrawal criteria for 
abnormal/worsening QT interval prolongation:
xQTcF interval > 500 ms
xQTcF interval > 480 ms 
AND increase from baseline Â•60 ms
xQTcF interval > 480 ms 
associated with syncope, life-threatening arrhythmias, resuscitated cardiac arrest, or seizure



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
61
Confidential3. OBJECTIVES AND ENDPOINTS
Objectives Endpoints/Criteria for Evaluation
Primary Primary
xTo evaluate the effect of rodatristat ethyl on 
the percent change from baseline of 
pulmonary vascular resistance (PVR), as 
measured by right heart catheterization (RHC) 
in patients with PAHxPercent change from baseline to 24 weeks of 
PVR between an active arm and the placebo 
arm
Secondary
To evaluate the effect of rodatristat ethyl from 
baseline to Week 24 on the following:
RWHO FC
R6MWD
RN-terminal pro-Brain Natriuretic 
(NT-proBNP)Secondary
To evaluate the effect of rodatristat ethyl from 
baseline to Week 24 on the following:
oChange from baseline in WHO FC
oChange from baseline in 6MWD
oChange from baseline in NT-proBNP
To evaluate the effect of rodatristat ethyl from 
baseline to Week 24 on the following:To evaluate the effect of rodatristat ethyl from 
baseline to Week 24 on the following:
xSafety
RTo assess safety & tolerability of 
rodatristat ethyl in patients with PAH
xAdditional 
RHemodynamics (cardiac index, mean 
pulmonary artery pressure [mPAP],
mean right atrial pressure [mRAP],
mixed venous oxygen saturation 
[SvO2], and pulmonary artery 
compliance [PAC])
RTime to Clinical Worsening (TTCW) 
defined as the first occurrence of a 
composite end point of: 1. Death from any cause, 2. Hospitalization for worsening PAH (any hospitalization for worsening PAH, lung or heart and 
lung transplantation, atrial 
septostomy, or initiation of parenteral prostanoid therapy), 3. Disease progression defined as a decrease of more than 15% from baseline in the 
6-minute walk distance (6MWD) 
combined with WHO FC III or IV 
symptoms at 2 consecutive visits separated by at least 14 days 
(adjudicated).
RDeath from any causexSafety
RChange in safety parameters 
including AEs, vital signs, laboratory 
values, and electrocardiogram (ECG)
assessments
xAdditional 
RChange from baseline in cardiac 
index, mPAP, mRAP, SvO2 at rest 
and PAC
RChange from baseline in TTCW
RDeath from any cause
RChange from baseline in right atrial 
size & RV function (TAPSE, 
tricuspid annular systolic velocity, & RV fractional area change)
RChange from baseline in 
PAH-SYMPACT 
RChange from baseline in REVEAL 
Lite 2.0 Score
xPK/PD
RPopulation PK parameters of 
rodatristat ethyl, active metabolite 
rodatristat, M15, and other 
metabolites



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
62
ConfidentialObjectives Endpoints/Criteria for Evaluation
REchocardiographic measures of right 
atrial size & RV function (tricuspid 
annular plane systolic excursion 
[TAPSE], tricuspid annular systolic velocity, and RV fractional area change)
RPulmonary Arterial Hypertension-
Symptoms and Impact Questionnaire 
(PAH-SYMPACT)
RRegister to Evaluate Early and Long-
Term PAH Disease Management 
(REVEAL) Lite 2 score
xPK/PD
RTo assess the PK of rodatristat ethyl 
and metabolites
RTo assess the effect of rodatristat 
ethyl on plasma and urinary 5-HIAARChange from baseline in 
5-hydroxyindoleacetic acid (5-HIAA;
plasma and spot urine concentration)
Exploratory
To evaluate the effect of rodatristat ethyl from 
baseline to Week 24 on the following:Exploratory
To evaluate the effect of rodatristat ethyl from 
baseline to Week 24 on the following:
xTime to Clinical Improvement (TTCI)
xActigraphy
xTo evaluate the effect of rodatristat ethyl on 
the plasma concentration of selexipag and ACT-333679xA > 10% increase in 6MWD or 30 meters 
AND an improvement to or maintenance of WHO FC II symptomatology, in the absence 
of a deterioration in c linical condition or death 
during the 24 weeks of the Main Study
xChange from baseline in actual daily activity, 
(counts/minute) as determined by actigraphy:
RLight to vigorous activity/day
RModerate to vigorous activity/day
RTotal movement/day
RBest 6-minute walk effort
xPlasma selexipag and ACT-333679 trough 
concentration at baseline and Week 4



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
63
Confidential4. STUDY DESIGN
4.1. Overall Design
This study will compare the efficac y, safety, and tolerability of 2 dosing regimens of rodatristat 
ethyl to placebo in patients with PAH over a 24-week treatment period . Investigational product 
(IP) will be administere d on the background of stable PAH therapy. 
Approximately ninety (90) patients will be enro lled. Patients will be randomized 1:1:1 to 
placebo, 300 mg BID, or 600 mg BID of rodatristat ethyl. 
Eligible patients will be stra tified based on the number of background PAH therapies they are 
receiving (1 vs 2 vs 3) and selexipag use (Yes/N o).  The number of patients who are on a 
prostanoid infusion will be capped at 50% of th e total enrolled. The numbe r of patients who are 
receiving selexipag will be capped at 20% of the total enrolled.
The study will consist of a Screening Period ( up to 28 days in duration), a Baseline Period 
(Day 1), a 24-week Treatment Period (Main Study) , and for patients that early terminate or do
not enroll an Open-Label Extension (OLE), and a 4-week Follow-Up Period (approximately 
4 weeks after the last dose), for a total study duration of 32 weeks.
Patients who complete the Main Study will have the option to enroll into an OLE and continue to 
receive rodatristat ethyl (those randomized to placebo will be re-randomized 1:1 to receive 
rodatristat ethyl 300 mg BID or 600 mg BID) fo r 6.5 years, until the Investigator or patient 
chooses to stop the IP, any stopping criteria in th e Main Study are met, IP becomes commercially 
available, or the Sponsor stops the study for lack of efficacy or a safety signal (whichever 
preceding criteria comes first). In no case will a patient be allowed to exceed 10 years of 
exposure unless the product is a pproved for a chronic indication.
All participating patient s will be required to be on a st able background therapy for PAH with 
mono, dual or triple combination therapy (whic h may include currently approved prostanoid 
therapies) at the time of Screening. All patien ts will maintain their standard of care (SOC) 
regimen at entry for the durati on of the study. Refer to Section 6.6.2 for more details.
During the 24-week Treatment Period, in addition to the Day 1/Baseline Visit and a telemedicine 
or phone call at Weeks 2 and 8, pati ents will return to the study cen ter for safety, tolerability and 
efficacy-related assessments at  Weeks 4, 12, and 24, and a clinic or home visit at Week 18, as
specified in the Schedule of Events Table, Section 1.3, as well as Follow-up at Week 28 (as 
applicable). Female patients of childbearing potential will undergo pregnancy testing every 4 weeks and will be required to use 2 reliable methods of contr aception to reduce the risk of 
pregnancy, at Screening, during the course of the study, and for at leas t 4 weeks following the 
last dose of rodatristat ethyl. Additional pregnancy testing in women whose menstruation is delayed or who have infrequent or  irregular menstrual cycles shoul d be completed as warranted.
Further details for the O LE are found in Section 7.
4.2. Number of Patients
Approximately ninety (90) patients  with PAH are expected to be enrolled at approximately 
68 study sites in the United States, Canada, and Rest of World (ROW).



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
64
Confidential4.3. Treatment Assignment
Patients will be randomized to IP according to a computer-generated allocation schedule, 
prepared prior to th e start of the study.
At the Baseline Visit, eligible patients will be randomly allocated (1:1:1) to one of the following 
3 treatment groups:
Treatment Arm
NameTreatment Description
Rodatristat ethyl 
300 m g BID1 x 300 mg tablet + 1 x matching placebo BID
Rodatristat ethyl 
600 m g BID2 x 300 mg tablets BID
Placebo 2 x matching placebo tablets BID
In order to maintain the study bli nd, patients will take 2 tablets in the morning and 2 tablets in 
the evening in one of the combinations noted above.
4.4. Dose Adjustment Criteria
4.4.1. Dose Reduction
All determinations of rodatris tat ethyl dose reduction should be  discussed with the Medical 
Monitor prior to implementing unless time does not allow for safety.
Temporary dosage reductions or discontinuations  will be allowed to manage AEs/AESIs (or 
other instances to be discussed with the Me dical Monitor), including gastrointestinal AEs
(e.g., diarrhea, nausea, or vomiting) or liver enzyme increase occurring during the 24 weeks of 
the study.  Judicious use of antidiarrheal and/or  anti-emetic medications  will be permitted. One 
level of dose reduction is available.
To reduce the IP, the patient will be instructed to ta ke one tablet in the mo rning and one tablet in 
the evening from the appropriate dispensed bot tles during the dose reduc tion period per dosing 
instructions supplied in a sepa rate document.  If AEs continue, the patient may stop taking the IP
completely for up to 7 days before restarting.
4.4.1.1. Diarrhea
In the event the patient experiences dia rrhea, the dose may be reduced. The Common 
Terminology Criteria for Adverse Events (CTCAE) v ersion 4.0 grading will be used to grade the 
severity of all AEs and serious adverse events (SAEs) of diarrhea. Management 
recommendations for diarrhea are based on the CTCAE grades and are detailed in Appendix 2.
In general, the patient should be treated with anti-d iarrheal drugs such as loperamide as clinically 
indicated. In addition to direc tly treating any diarrhea, possibl e intermittent or permanent 
interruption of IP and dose reduction will be possible, de pending upon the frequency and 
severity of diarrhea.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
65
Confidential4.4.1.2. Aminotransferase (Alanine aminotrans ferase or Aspartate Aminotransferase)
Elevation
Management recommendations fo r ALT or AST elevations are based on U.S. Food and Drug 
Administration (FDA) Guidance for Liver Toxicity.
In general, all baseline or treatment-emerge nt ALT or AST elevations > 3X ULN should be 
confirmed within 48 to 72 hours with repeat assessments of ALT and AST as well as TBL,alkaline phosphatase (ALP), pr othrombin time/INR, and comple te blood count for eosinophil 
levels.  Further details for managing IP reducti on, restart, and discont inuation can be found in
Appendix 3 .
If at any time, the criteria as outlined in Section 8are met, the IP must be permanently 
discontinued.
4.5. Criteria for Study Termination
This study (including OLE) may be temporarily suspended or premat urely terminated if there is 
sufficient reasonable ca use. Written notification, documenti ng the reason for study suspension 
or termination, will be provided by the suspendi ng, or terminating party, to the Investigators,
Institutional Review Boards (IRB)/Ethics Com mittees (EC), regulatory authorities. If the study 
is prematurely terminated or suspended, the In vestigators will promptly  inform the IRB/ECs and 
will provide the reason(s) for the termination or suspension. Circumstances that may warrant termination or suspension include, but are not limited to: 
xDetermination of unexpected, significant,  or unacceptable risk to participants
xDemonstration of efficacy that would warrant stopping
xInsufficient compliance to  protocol requirements
xData that are not sufficiently  complete and/or evaluable
xDetermination of futility
The study may resume once concerns about safet y, protocol compliance, and data quality are 
addressed and the IRBs/ECs and competent author ities are satisfied. The study will only resume 
after prior submission and approva l of the substantial amendment (if required) by the competent 
authority.
4.6. Scientific Ration ale for Study Design
The design of this study will provide efficacy, safe ty, and dosing information to support proof of 
concept. Two rodatristat ethyl doses will be studied. Patients with idiopathic PAH and other 
Group 1 PAH sub-types will be included in this study.
Placebo-controlled randomized stud ies provide the most robust re sults and are thus considered 
the most appropriate design. However, approve d therapies for PAH are  available, making a
placebo-controlled rodatristat ethyl monotherapy study unethical. Therefore,  rodatristat ethyl (or 
placebo) will be evaluated in addition to st andard of care (SOC) P AH-specific treatments, 
i.e., this study will only include patients on stable, approved, and available treatments at baseline. 



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
66
Confidential Patients on prior monotherapy and combination re gimens to include up to 3 agents will be 
permitted to participate. Treat ment with oral, inhaled, or parenteral prostanoids will be 
permitted.  Any changes to background PAH th erapy during the study should be based on clear 
medical need. 
In prior studies of pati ents treated with PAH therapies, up to 24 weeks of treatment with study 
medication were considered necessary to demo nstrate efficacy based on potential impact on 
pulmonary hemodynamics.  This duration of exposure  will also allow for assessment of safety,
tolerability, and possible effects on exercise abil ity, patient reported outc omes, and biomarkers. 
The OLE will provide long term safety, tolerability, and efficacy of rodatristat ethyl in patients
with PAH. In order to minimize bias during the O LE, patients will remain blinded to original 
treatment assignment in th e Main Study.  Patients receiving ac tive rodatristat ethyl during main 
treatment period will continue at their origin ally randomized dose to generate additional 
long-term safety and efficacy data. Patients origina lly randomized to placebo will also have the 
opportunity to receive active rodatristat ethy l during the OLE, provi ding additional patient 
exposures for further assessment of safety and efficacy.
4.7. Justification for Dose
The dose levels selected are based on prior pharmacodynamic (PD) observa tions in nonclinical 
models of PAH and PK, PD, safety, and tolerability data in healthy subjects  receiving rodatristat 
ethyl for up to 14 days.
Disease-modifying effects of rodatristat ethyl were demonstr ated in the semaxanib (SU5416, 
SUGEN) hypoxia and the monocrotalin e (MCT) injury rat models of PAH.  In the MCT rat 
model, rodatristat ethyl decreased serum and lung 5-HT levels and reduced the extent of vascular 
remodeling. In the SU5416 hypoxia rat model, ro datristat ethyl signi ficantly reduced RV
systolic pressure, RV hypertrophy, the biomarker brain natriuretic peptide (BNP), and pulmonary 
vessel wall thickness and occlusions as measured  by histological analys is, without impacting 
systolic blood pressure (SBP). These benefits were observed at GRVHVRIÂ•  100 mg/kg, which 
results in approximately a 40% re duction in 5-HT biosynthesis ( IB, 2020 ). Based on these data,
a target reduction in 5-HT (as determined by ur inary 5-HIAA excretion rate ) of at least 40% was 
the basis for the doses selected in the current study.
After 14 day BID administration to  healthy subjects, rodatristat ethyl at doses of 400 to 800 mg 
BID resulted in 50 to 60% reductions in urin ary 5-HIAA.  Dose-dependent increases in 
gastrointestinal treatment-emergent AEs (TEAEs; notably nausea and diarrh ea) were noted with 
rodatristat ethyl, including an event of modera te diarrhea and an overa ll incidence rate of 
44% after administration of 800 mg BID ( IB, 2020 ).  Therefore, the highest dose regimen 
selected for the current study is rodatristat et hyl 600 mg BID which is expected the maintain the 
majority of the 5-HT lowering effect while minimizing potential of gastrointestinal TEAEs.
The lower dose regimen of rodatr istat ethyl of 300 mg BID was sele cted to evaluate a lower dose 
to aid in defining potential dose-re sponse relationships and is expected to result in approximately 
40% reduction in 5-HIAA, equivalent to the re ductions observed at efficacious doses in 
nonclinical models ( IB, 2020 ). 



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
67
Confidential Figure 2: Percentage Change from Baselin e of Urine 5-HIAA: Creatinine Ratio 
5-HIAA on Days 7 and 14 following Twi ce Daily Repeat Oral Administration 
of Rodatristat Ethyl in Studies KAR5585-101 and RVT-1201-1001 
Note:   Blue boxes and green boxes represent data from Day 7 and Day 14, respectively.  Data for subjects receiving 
placebo represent totality of data across BID cohorts.
Abbreviations:  5-HIAA = 5-hydroxyindoleacetic acid; BID = twice daily
Aside from the dose-dependent gastrointestinal TEAEs observed in healthy subjects receiving 
higher doses for 14 days, which have all been cons idered mild with the exception of 1 event of 
moderate diarrhea, no other safety concerns were  identified following sing le doses ranging up to 
2000 mg or following repeat dosing over 14 days of up to 800 mg administered BID to healthy 
subjects.  The majority of TEAEs for all dose re gimens evaluated to date have been mild and 
have resolved without requiring intervention or discontinuation of the IP. There have been no 
SAEs reported nor any dose-limiti ng toxicities identifi ed.  Mild, transient elevations in ALT 
were reported in 5 subjects who received either si ngle or multiple doses of  rodatristat ethyl (5 of 
136 subjects [3.7%]).  Further information can be found in th e Investigatorâ€™s Brochure. 
With respect to nonclinical toxico logy studies, rodatristat ethyl a nd rodatristat exposures at the 
no observed adverse effect level (NOAEL) in the 26-week rat (female  only) or 39-week dog 
toxicology studies are > 4-fold higher than the expected exposu re after at the higher dose 
regimen of 600 mg BID ( IB, 2020 ).  Due to adverse decreases in mean body weight gain (20 
to -41.7% relative to controls) and food consump tion at all dose levels in the 26-week study in 
male rats, the NOAEL could not be established.  Exposure at the lowest dose tested in this study 
was 4-fold higher than that anticipated at the higher dose regimen of 600 mg BID.  The major 
toxicities associated with oral rodatristat ethyl administration included mortality in rats preceded 
by clinical signs of toxicity a nd body weight loss occurring at exposures > 4-fold the highest 
exposure expected in the current study.  Fi ndings in both species were indicative of 
gastrointestinal changes including decreased body we ight and/or decreased rate of weight gain, 
decreased food consumption, diarrh ea/fecal change, dehydration, di stended abdomen (rats only), 




		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
68
Confidential intestinal dilation with mucosal thickeni ng and macrophage vacuolation (rats only), 
histopathologic findings of intestinal dilation with vac uolated macrophages, and increased 
mucosal thickness with regenerati on in the duodenum.  Observed liver enzyme elevations were 
not associated with adverse histopathology (h epatocellular necrosis ) and are considered 
monitorable.
Prior studies have demonstrated coadministra tion of rodatristat ethy l with food can increase 
systemic exposure of ro datristat ethyl and rodatristat from 1.1- to 1.8-fold.  Thus, the prior 
Phase 1 studies in healthy subjects evaluated rodatristat ethyl administered with a standard meal
(IB, 2020 ).  To maintain consistency with these studi es and therefore the expected PD effects, IP
will be administered BID with a standard meal.
Taken together, the nonclinical ph armacology and safety data, and pr ior clinical experience with 
rodatristat ethyl support the low and high BI D dose regimens (300 mg and 600 mg) to be 
evaluated in patients with PAH over the 24-week treatment period.
4.8. End of Study Definition
A patient is considered to have completed t he study if he/she has completed 24 weeks of 
treatment including the Week 24 visit and the Follow-up Visit (for patients that complete the study through Week 24 but decide not to rollover to the OLE), or the last scheduled procedureshown in the Schedule of Assessments(SoA; Section 1.3).   If the patient decides to continue 
into the OLE, subject must not participate in another interventional study until completing theET/final follow-up visit (4 weeks after the last dose of study drug) according to the Schedule of Assessments OLE (Section 1.4or1.5).
The end of the study for assessment of the primary endpoint is defined as the date of the last visit 
of the last patient in the Main Study or last scheduled procedure in the Main Study shown in the 
SoA for the last patient in the study globally, regardless of dura tion of participation in the OLE.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
69
Confidential5. STUDY POPULATION
5.1. Inclusion Criteria
Patients are eligible to be in cluded in the study only if all t he following criteria are met:
1. Male and female patients must be at least 18 years of age at the time of signing the 
informed consent.
a. Male patients and female partners of ch ildbearing potential must agree to use 
contraception as detailed in a Section 5.4.1 to the protocol starting at Screening,
during the treatment period, and for at leas t 100 days after the last dose of IP. Male 
patients must refrain from donating sperm during this period.
b. Female patients of childbearing potential must agree to use contraception as detailed 
in Section 5.4.1 starting at Screening, during the treatment period, and for at least 
4 weeks after the last dose of IP.
2. Body mass index (BMI) Â•18 kg/m2DQGÂ” 40 kg/m2
3. Patients with symptomatic PAH belonging to  one of the following 2018 Clinical Group 1
sub-types:
a. Idiopathic PAH
b. Heritable PAHc. Drug- or toxin-inducedd. PAH associated with:
1. Connective tissue disease2. Congenital systemic to pulm onary shunt (atrial septal defect, ventricular septal 
defect, patent ductus arteriosus) repaired  at least one year prior to Screening
3. Human immunodeficiency virus (HIV) i nfection - if diagnosed with HIV, 
must have stable disease status defined as follows: 
a. stable treatment with HIV medica tions for at least 8 weeks prior to 
Screening
b. no active opportunistic infecti on during the Screening Period 
c. no hospitalizations due to HIV for at  least 4 weeks prior to Screening
4. WHO FC II or III
5. Confirmed diagnosis  of PAH and meet allthe following hemodynamic criteria by means of a 
screening RHC completed prior to randomization:
a. mPAP of >20 mmHg b.395Â• 350 dyneâ€¢sec/cm
5
c. Pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic 
SUHVVXUH/9('3RIÂ” 12PP+JLI395Â• 350 and < 500 dyneâ€¢sec/cm5, or 
3&:3/9('3Â” PP+JLI395Â• 500 dyneâ€¢sec/cm5
6. 6MWD of 100 to 550 meters at Screening



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
70
Confidential7. Currently on a stable treatment regimen w ith one or more treatments approved for PAH. 
6WDEOHWKHUDS\LVGHILQHGDVUHFH LYLQJWKHVDPHPHGLFDWLRQVI RUÂ• 12 weeks prior to the 
VFUHHQLQJ5+&DQGDWDVWDEOHGRVHOHYHOIRUHDFKIRUÂ• 8 weeks prior to the screening RHC
(see Protocol Section 6.6.2 for approved PAH medications). Any instances where doses of a 
medication have been missed prior to RHC must  be discussed with th e Medical Monitor prior 
to performing the RHC.
8. Meet all of the following criteria determined  by pulmonary function te sts completed no more 
than 24 weeks prior to Screening (perfo rmed with or without bronchodilation): 
a. Forced expiratory volume in one second (FEV 1Â•60% of predicted normal, and
b. Total lung capacity (TLC) Â•70% of predicted normal RU)9&Â•SUHGLFWHGLI
TLC is not available; For subjects with CTD as VRFLDWHG3$+LI7/&LVÂ•RI
predicted but < 70% of predicted of LI)9&Â•RUSUHGLFWHGEXWRI
predicted, high resolution computed tomography [HRCT] obt ained within 6 
months of screening may be  utilized to demonstrate limited interstitial lung
disease
9. If participating in an exercise program for pulmonary rehabilitation, the program must have 
EHHQLQLWLDWHGÂ• 12 weeks prior to Screening, and patient must agree to maintain the current 
level of rehabilitation for the first 24 weeks of receiving IP.  If not participating in an 
exercise training program for pu lmonary rehabilitation, patient mu st agree not to  enroll in an 
exercise training program for pulmonary rehabi litation during the Sc reening Period and the 
first 24 weeks of receiving IP.
10. Willing and able to give written informed cons ent and to comply with the requirements of the 
study for its duration
5.2. Exclusion Criteria
Patients are excluded from the study if any of the following criteria are met:
1. Women of childbearing potential who are pr egnant, planning to b ecome pregnant, or 
lactating or female/male patients unwilling to use effective contrace ption as defined in 
Section 5.4.1
Medical Conditions
2. WHO pulmonary hypertension (PH) Group 1 PAH associated with portal hypertension or 
schistosomiasis; PH due to left heart dis ease (WHO PH Group 2), lung diseases and/or 
hypoxia (WHO PH Group 3), chronic throm boembolic PH (WHO PH Group 4), or PH 
with unclear multifactorial mechanisms (WHO PH Group 5)
3. PH associated with signif icant venous or capillary involvement (PCWP > 15 mmHg), 
pulmonary capillary hemangiomatosis, porta l hypertension, or unr epaired congenital 
heart defects (CHD)
4. Three or more of the fo llowing risk factors for left ventricular disease:
a. BMI > 30 kg/m2
b. Diagnosis of essential hypert ension that is actively treated
c. Diabetes mellitus



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
71
Confidentiald. History of significant coronary artery di sease (e.g., chronic stable angina, history 
of coronary intervention within the last 3 months, or a stenosis > 70% at coronary 
angiography)
e. Atrial fibrillationf. Left atrial volume index > 41 mL/m
2[or left atrial diameter (LA) > 4 cm if LAVi
unavailable]
5. Known genetic hypert rophic cardiomyopathy
6. Known cardiac sarcoidosis or amyloidosis
7. The patient has a history of, or currently has, a c onstrictive cardiomyopathy.
8. Known history of any left ventricular ej ection fraction (LVEF) < 40% by echocardiogram 
within 3 years of randomization ( Note: a transient decline in LVEF below 40% that 
occurred and recovered more than 6 months  before the start of Screening and was 
associated with an acute intercurrent condi tion [e.g., atrial fibr illation] is allowed).
9. Hemodynamically significant va lvular heart disease as dete rmined by the Investigator, 
including:
a. greater than mild aortic a nd/or mitral stenosis and/or
b. severe mitral and/or aort ic regurgitation (> Grade 3)
10. Severe arthritis, musculoskeletal problems, or  morbid obesity that, in the opinion of the 
Investigator, is the cause of the patientâ€™s  functional limitation and would affect the 
patientâ€™s ability to perform or complete the 6MWT.
11. Planned major surgery within the next 3 m onths, including lung transplantation, major 
abdominal or major intestinal surgery
12. End stage renal disease defined as receivi ng peritoneal di alysis, hemodialysis, or status 
after renal transplantation, or severe liver disease defined as Child -Pugh Class C, with or 
without cirrhosis
13. Known congenital LQTS or known family history of LQTS
14.'HSUHVVLRQWKDWLVFX UUHQWO\UDWHGDVVHYHUHGHILQHGDVDVFRU HRIÂ• 16 on the QIDS-C
and/or [HADS] Depression and/or Anxiety score Â•15), recent suicidal behavior (either 
preparatory acts/behavior, aborte d attempt, interrupted attempt,  or actual attempt in the 
past 3 months per the Screening C-SSRS), or active suicidal ideation with intent to act 
(defined as C-SSRS category scor e of 4 or 5 in the past month)
15. Patients with (during Screening):
a. Severe hypertension (SBP > 180 mmHg a nd/or Diastolic Blood Pressure [DBP] 
> 110 mmHg), and patients with severe hypotension (SBP < 90 mmHg and/or 
DBP < 50 mmHg)
b. Hypertension or hypotension considered not controlled in lin e with clinical 
standards
16. Clinically significant electrolyte abno rmality (e.g., hypokalemia, hypomagnesemia, or 
hypocalcemia) in the judgem ent of the Investigator
17. Current or prior history within the last 5 y ears of neoplasm (except for treated basal cell 
or squamous small cell carcinoma of the skin with no evidence of recurrence) 



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
72
Confidential18. Any concurrent clinically significant medical condition/disorder which in the 
Investigatorâ€™s opinion would interfere with the patientâ€™s ability to comply with or 
complete the study or could affect the interpretation of the efficacy and safety variables.
Prior/Concomitant Therapy
19. Use of any of the following medications or supplements within 30 days prior to 
Screening:
xmonoamine oxidase inhibitors (MAOIs; Appendix 1 )
x5-hydroxytryptophan (5-HTP) or L-tryptophan 
xtelotristat ethyl
20. Patients currently taking one or more drugs known to prolong the QT interval and which 
are clearly associated with a known risk of Torsades de Pointe (see Appendix 1 )
Diagnostic Assessments
21. Estimated glomerular filtrat ion rate (eGFR) < 30 mL/min/1.73 m2at Screening
22. 12-Lead ECG results at Screening demonstr ating QTcF interval > 450 ms for males or 
> 470 ms for females 
23. Elevated ALT, AST, or TBL > 2X ULN
24. Any ECG or clinical labora tory abnormality which precludes safe participation in the 
study in the opinion of the Investigator
Lifestyle
25. History of active substance use disorder (including alcohol) with in the past 2 years 
which, in the option of the Investigator, woul d limit the ability of th e patient to provide 
adequate informed consent or to  comply with study requirements
26. Use of any investigational drug within 30 days  or 5 half-lives (whichever is longer) prior 
to Screening, or 90 days if an  investigational drug for PAH, unless local health authority 
guidelines mandate a longer period, or in c onsultation with the me dical monitor, will not
interfere with the safety or efficacy of the study
27. Any history of hypersensitivity to rodatris tat ethyl, any of its components, or any 
components in the placebo preparation (ref er to current Rodatristat Ethyl IB).
28. Patient is deprived of their liberty by a judicial or administrative deci sion, or is receiving 
psychiatric care, and is admitted to  a health or social institution
29. Patient is subject to legal protect ion or is unable to express consent



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
73
Confidential5.3. Other Eligibility Criteria Considerations
To determine patient eligibility at Screening, a si ngle repeat of certain te sts such as laboratory 
values, vital signs, or ECGs will be allowed.
To assess any potential impact on patient eligibility with regard to  safety, the Investigator must 
refer to the rodatristat ethyl Investigatorâ€™s Brochu re for detailed information regarding warnings, 
precautions, contraindications, AEs, and other signif icant data pertaining to  the IP being used in 
this study.
5.4. Lifestyle Considerations
5.4.1. Contraception
Female patients of childbearing potential who have  a negative serum pregna ncy test at Screening 
and a negative urine pregnancy test at th e randomization visit must agree to use 
protocol-specified, highly effectiv e contraception starting at Screen ing and for the duration of the 
study and for at least 4 weeks following the last dose of IP as follows:
xUse 2 methods of contraception in comb ination defined as a condom plus an 
approved method of effective contraception from the following list from the time of 
informed consent:
Combined (estrogen and progestogen- containing) hormonal contraception 
associated with inhibition of ovulatio n: oral, intravaginal, transdermal
Progestogen-only hormonal contracepti on: oral, injectable/implantable, 
intrauterine hormone-releasing system
Implantable intrauterine device
Bilateral tubal ligation performed less  than 6 months prior to randomization
Partner with vasectomy
Sexual abstinence â€“ (refraining from hete rosexual intercourse). If study patient 
chooses this option, site staff must fo llow-up to reconfirm throughout the study.  
If patient becomes sexually ac tive, one of the above choices must be utilized and 
documented.
Female patients who are considered to have no childbearing potential (sur gically sterile defined 
as bilateral tubal ligation, hys terectomy, bilateral salpingect omy, or bilateral oophorectomy) for 
at least 6 months prior to randomization may participate and are not required to use 
contraception as defined above.
Female patients who are postmenopausal and > 4 5 years of age with am enorrhea for at least 
2 years may participate and are not require d to use contraception as defined above.
Postmenopausal women with amenor rhea for less than 2 years must have documented follicle 
stimulating hormone (FSH) levels > 35 IU/mL a nd negative pregnancy test at the Screening 
Visit.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
74
ConfidentialMale patients must agree to the following:
xNot to try to impregnate his partner from the Screening Visit until at least 100 days 
after the last dose of IP
xIf his female partner is of childbearing potential, agree to use 2 methods of 
contraception in combina tion defined as a condom pl us an approved method of 
effective contraception from  the following list from the time of informed consent 
until at least 100 days after the last dose of IP:
Combined (estrogen and progestogen- containing) hormonal contraception 
associated with inhibition of ovulatio n: oral, intravaginal, transdermal
Progestogen-only hormonal contracepti on: oral, injectable/implantable, 
intrauterine hormone-releasing system
Implantable intrauterine device
Bilateral tubal ligation performed less  than 6 months prior to randomization
Vasectomy
Sexual abstinence â€“ (refraining from hete rosexual intercourse). If study patient 
chooses this option, site staff must fo llow-up to reconfirm throughout the study.  
If patient becomes sexually ac tive, one of the above choi ces must be utilized and 
documented.
xUse condoms with partners that are pregnant until at least 100 days after the last dose 
of IP to ensure that the fetus is not exposed to the IP
xNot donate sperm for the duration of the st udy until at least 100 days after the last 
dose of IP
5.4.2. Meals and Dietary Restrictions5.4.2.1. Tryptophan-Rich Foods
As tryptophan-rich foods may increase 5-HT leve ls and interfere with biomarker assessments, 
patients will be asked to abstain from the follo wing foods for 48 hours before study visits on
Day 1 and at Weeks 4, 12, and 24:
xAvocado
xBananas
xEggplant
xKiwi fruit
xTree nuts, tree nut butters and tree nut pr oducts (e.g., hickory nuts, pecans, walnuts)
xPineapple
xPlums
xTomato and tomato products
5.4.2.2. Food Requirements
IP should be taken with f ood (at least a snack) at the morning and evening meals.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
75
Confidential5.5. Screen Failures
Screen failures are defined as patients who consen t to participate in the clinical study but are not 
subsequently randomized into the study. After ob taining informed consent, study site personnel 
will enter the patient into the Interactive Res ponse Technology (IRT), and the patient will be 
assigned a unique patient number. The IRT should be updated promptly for patients who do not 
meet the criteria for participation in  the study (screen failure) and reason.
A minimal set of screen failure information is required to ensure transp arent reporting of screen 
failure patients to meet the C onsolidated Standards of Reporti ng Trials (CONSORT) publishing
requirements and to respond to que ries from regulatory authorities. Minimal information is to be 
entered into the Electronic Data Capture (EDC ), including demography, sc reen failure details, 
eligibility criteria, and any SAE.
Individuals who do not meet the criteria for participation in th is study (screen failure) may be 
rescreened on a case-by-case basis. Approval fr om the Sponsor must be obtained prior to 
rescreening.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
76
Confidential6. INVESTIGATIONAL PRODUCT
IP is defined as any investigational medicin al product (IMP) or placebo, intended to be
administered to a study patient acco rding to the study protocol.
6.1. Description of IP
The IPs to be administered as part  of this study are described in Table 3 .
Table 3: Investigational Products
Arm Name 300 mg BID* 600 mg BID* Placebo*
Dose Formulation Tablet Tablet Tablet
Unit Dose Strength(s) 300 mg 300 mg N/A
Dosage Level(s) 1 x 300 mg tablet + 1 x 
placebo tablet BID2 x 300 mg tablets BID 2 x placebo tablets BID
Route of Administration Oral Oral Oral
IP Rodatristat ethyl Rodatristat ethyl Placebo
Physical Description White to off-white modified oval shaped  tablet, debossed with â€œ2E8â€ on one side
Manufacturer Patheon Pharmaceuticals
2100 Syntex Court
Mississauga, Ontario L5N 7K9Canada
Packaging and Labeling IP will be provided in bottles.  Each bottle will be labeled as required per country 
requirement.
*The components in rodatristat ethyl are provided in Section 3.2.2, Table 1 of the Investigatorâ€™s Brochure. The 
active and placebo are formulat ed with the same excipients.
Abbreviations:  BID = twice daily; IP = investigational product; N/A = not applicable
6.2. Dose Regimen
IP will be taken BID with food, approximately 12 hours apart.
Each patient will receive at least 4 bottles (1 kit) of IP at each clinic visit or by mail.  There is 
enough IP in each kit for 4 weeks of dosing, including overage.  The bottles of IP given at each clinic visit or by mail should be re turned at the subsequent clin ic visit for reconciliation and 
accountability.
The last dose of IP for the Main part of the st udy will be the last dose the night before the Week 
24 visit (all Week 24 assessments wi ll be collected post last dose).



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
77
Confidential6.3. Preparation/Handling/Storage/Accountability
The Investigator or designee must maintain accu rate records of receipt and the condition of the 
IP supplied for this study includi ng dates of receipt.  They must confirm appropriate temperature 
conditions have been maintained during trans it for all IP recei ved and any discrepancies are 
reported and resolved before use of the IP.
2. Only patients enrolled in the study may rece ive IP. Accurate records must be kept of 
when and how much IP is dispensed and admin istered to each patient in the study.  Any 
reason for departure from the in structions provided in the pr otocol for dispensing of IP 
must also be recorded.  IP may be supplied at  the site, from the site to the patient via a 
Sponsor-approved courier comp any, or from the depot dir ectly to the patient where 
allowed by local regulations and approved by the patient.
3. All IP at a study site must be stored in  a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to th e Investigator and authorized site staff.
4. The Investigator, institution, or  the head of the medical inst itution (where a pplicable) is 
responsible for IP accountabilit y, reconciliation, and record maintenance (i.e., receipt, 
reconciliation, and final disposition records).
5. Further guidance and informa tion for the final disposition of  unused IP are provided in 
the Study Reference Manual.
6. A Safety Data Sheet (SDS) describing o ccupational hazards and recommended handling 
precautions will be supplied to the Investigator.
6.3.1. Investigational Product Packaging and Labeling
IP will be packaged in an appropriately sized bottle and labeled per local regulations.
6.3.2. Investigational Product Storage
IP is to be stored at 15Â°C to 25Â°C (59Â°F to  77Â°F) in a dry place and protected from light.
6.3.3. Investigational Product Administration
Once a patient is confirmed as eligible for study participation, the patient will be randomized via 
the IRT and assigned a kit(s) of IP. For each scheduled  visit, the patient will be assigned new IP
kit(s).
6.3.4. Investigational Product Accountability
Accountability for the IP is  the responsibility of the Investigat or.  The study site must maintain 
accurate records including what kits were received and date, to whom the IP was dispensed, and all accounts of IP that is lost/m issing or discarded.  Additiona l details will be provided in a 
pharmacy or study reference manual.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
78
Confidential6.3.5. Investigational Product Handling and Disposal
Patients should return all IP (including empty, partial, and full bottles) at their regularly 
scheduled clinic visits.  Reconc iliation of all IP that was dispensed, returned, or lost must be 
accounted for with documentation for any IP that was lost or missing.
Returned IP may be re-issued if the patient is continuing in the study, returned to the drug depot,
or destroyed at the site as long as the site  has procedures in place for IP destruction where
allowed by local regulations. Otherwise, all retu rned IP will be returned to the depot at 
increments throughout the study after all IP has been accounted for and verified by the monitor.
Additional instructions for IP return and destruction will be  found in the pharmacy or study 
reference manual.
6.4. Measures to Minimize Bias : Randomization and Blinding
This is a double-blind study. The Sponsor, Investig ator, patient, and study site personnel will be 
blinded to all treatment group assignments. The I nvestigator will have th e ability, in the IRT 
system, to unblind a patient, and the decision will reside solely with the Investigator. Prior to 
unblinding, if safety allows, the I nvestigator should contact the Medical Monitor to discuss the 
reasons for unblinding.
Eligible patients will be stra tified during the rand omization process based on the number of 
background PAH therapies they are receiving (1, 2 or 3) and selexipag use. The number of 
patients who are receiving a prostanoid infusion will be capped at 50% of the total number of patients enrolled. The number of patients who are receiving selexipag will  be capped at 20% of 
the total number of patients enrolled. Patients w ill be randomized 1:1:1 to placebo, 300 mg BID, 
or 600 mg BID of rodatristat ethyl using an interactive randomization system.
At the time of Screening for entry into the O LE, all patients will be re-randomized to receive 
either 300 mg BID or 600 mg BID rodatristat ethy l in an open-label fash ion.  Patients will not 
know what they received in the Main Study until all patients have comple ted the Main Study and 
the database is locked.
At the time of randomization, in the Main Study, patients will be assigned a randomization 
number.  Once this number has been as signed, it cannot be reused/reassigned.
At the time of re-randomiza tion in the OLE, patients will be assigned a new randomization 
number.  Once this number has been a ssigned, it cannot be reused/reassigned.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
79
ConfidentialBlind Break 
(IVRS/IWRS)The Interactive Voice Response System (IVRS)/Interactive Web Response System (IWRS)
will be programmed with blind-breaking instructions.  Only in case of an emergency, when knowledge of the IP is essential for the clinical  management or welfare of a specific patient, 
may the Investigator unblind a patientâ€™s treatment assignment in IVRS/IWRS.  The 
Investigator has the sole responsibility for determining if unblinding of a patientâ€™s treatment 
assignment is warranted.  Patient safety must always be the first consideration in making 
such a determination.  If the Investigator decides that unblinding is warranted, the 
Investigator should make every effort to contact the Sponsor prior to unblinding a patientâ€™s treatment assignment unless this could delay emergency treatment of the patient.  If a 
patientâ€™s treatment assignment is unblinded, the Sponsor must be notified within 24 hours 
after breaking the blind without revealing the patientâ€™s study treatment assignment (unless 
important to the safety of patients in the study) and that the Investigator was unable to 
contact the Sponsor prior to unblinding.  The date and reason that the blind was broken must 
be recorded in the source documentation and electronic case report form (eCRF), as 
applicable.
6.5. Investigational Product Compliance
Patient compliance with IP will be assessed at ea ch visit by the site/study staff. Compliance will 
be assessed by direct questioning of the patient and counting returned tablets at each study visit 
to the study site.  Patients will be  reminded of the importance of taking their IP as directed at 
each visit including the Weeks 2 and 8 Phone Calls. Pa tients will be required to bring their IP
supplies with them to each study visit to the study site so that  a member of the study staff can 
check that the doses of IP were taken as directed.
Full compliance with the IP regimen, per s ubject, will be considered to be >80%.
Deviation(s) from the prescr ibed dosage regimen should be  recorded in the eCRF.
6.6. Concomitant Therapy
Any medication or vaccine (including over-the- counter or prescription medicines, vitamins,
and/or herbal supplements) that  the patient received in the 8 w eeks prior to en rollment, is 
receiving at the time of enrollment, or receives  during the study must be  recorded along with:
xReason for use
xDates of administration incl uding start and end dates
xDosage information in cluding dose and frequency
New and existing concomitant therapy(ies) may be considered on a case-by-case basis by the 
Investigator for treatment of a medical need. Any concomitant me dication should be recorded in 
the study records, including doses  administered, the dates and tim es of administration and the 
reason for administration.
The Medical Monitor should be c ontacted if there are any questi ons regarding concomitant or 
prior therapy. (Note: Vaccines, including potenti al Covid-19 vaccines, are allowed but must be 
documented in the eCRF). 



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
80
Confidential 6.6.1. Rodatristat-Drug Interaction Potential
In vitro experiments and in si lico modeling to evaluate the drug-drug interaction potential of 
rodatristat ethyl and rodatrista t have not identified any modera te or high risks for potential 
drug-drug interactions ( IB, 2020 ).  There is the potential for weak  interactions with substrates of 
the drug metabolizing enzymes cy tochrome P450 (CYP)2C8 and CYP3A, and drug transporters 
P-glycoprotein (P-gp) or organic an ion-transporting polypeptide (OATP). 
Selexipag, and active me tabolite ACT-333679, are substrates of  CYP2C8 and preliminary data 
from a selexipag-rodatristat clinical interaction stud y in healthy subjects are available.  In that 
study, steady-state rodatristat ethyl 600 mg BI D coadministered with single-dose selexipag 
400Î¼g increased selexipag AUC 1.18-fold and reduced ACT-333679 AUC by 40.5%.  These 
data suggest induction of CYP2C8 by rodatris tat ethyl/rodatristat. The magnitude of this 
interaction in PAH patients, a nd the clinical rele vance of these changes in exposure are 
unknown.  PK samples for assessment of sele xipag and ACT-333679 trough concentration at 
baseline and Week 4, in addition to safety a nd efficacy data, will be collected in this study to
further investigate this fi nding.  In the same study, a single-dose of selexipag 400 Î¼g had no 
relevant impact on the exposure of ro datristat ethyl or rodatristat.  
Preliminary safety data from th e study show a total of 33 TEAE s in 8 subjects during the study.  
There were no SAEs or deaths. Gastrointestinal  (GI) TEAEs were the mo st frequently reported 
TEAEs over all three periods with 25 GI TEAEs occurring in 6 subjects . All TEAEs were mild 
to moderate with the exception of one TEAE in  one subject of serious diarrhea on Day 6. This 
same subject was the only subject discontinued fr om the study.  This subject was discontinued by 
the Investigator due to prolonged GI TEAEs (n ausea, vomiting, stomachache, diarrhea) during 
the rodatristat ethyl alone dosi ng period (Days 5-9).   Nausea wa s the only TEAE reported in 2 or 
more subjects when selexipag was given alone. Diarrhea, headache, nausea and stomachache ZHUHUHSRUWHGLQÂ•VXEMHFWVD t approximately the same frequen cy during both rodatristat ethyl 
alone period and the selexipag and rodatristat ethyl coadmini stration period.  There were no 
changes in laboratory parameters, vital si gns, or ECGs of cl inical significance.
No concomitant medications based on these in vi tro and clinical findings are prohibited.   
The following information is provided as guidance for th e Investigator:
xPatients using systemic narrow therapeutic range substrates of CYP2C8, CYP3A and 
P-gp should be monitored during coadministration with IP.  See Appendix 1 for a list 
of relevant substrates, for example:
oNarrow therapeutic range CYP2C8 substrates (induction of CYP2C8 is 
possible): selexipag, trepostinil , pioglitazone, and torasemide.
oNarrow therapeutic range CYP3A substrates  (weak induction or  inhibition of 
CYP3A is possible): cyclosporine, ev erolimus, fentanyl, sirolimus, and 
tacrolimus;
oNarrow therapeutic range P-gp substrat es:  digoxin, monitor serum levels 
approximately 2 weeks after initiation of IP or if patient re ports any signs of 
toxicity; 



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
81
ConfidentialxRodatristat was also identified as a substrate of liver uptake transporters 
OATP1B1/1B3.  Strong inhibitors of OATP1B1/1B3 may increase circulating 
concentrations of rodatristat and may in crease adverse effe cts. Putative strong 
inhibitors of OATP1B1/1B3 are systemic at anazavir/ritonavir,  clarithromycin, 
cyclosporine, erythromycin, faldaprevir, gemfibrozil, glecaprevir/pibrebtasvir, 
lopinavir/ritonavir, rifampin, sofosbuvir/ velpatasvir/voxilaprevir, and telaprevir. 
Note: Hydroxymethylglutaryl-CoA re ductase inhibitors or â€˜s tatinsâ€™ also transported 
by OATP are not considered  strong inhibitors of OATP.
6.6.2. Pulmonary Arterial Hypertension Medications
The target population of patients with PAH will be receiving SOC t reatment which can consist of 
monotherapy, dual, or triple combin ation therapy that have been ta ken for at least 12 weeks prior 
to the Screening RHC.  These medications should be prescribed at doses considered 
therapeutically appropriate (e.g., maximum tolerated) and stable (i.e., no changes in dose or 
schedule) for at least 8 weeks prior to this RHC. Any instances where doses have been missed 
for > 2 consecutive days on more than one occasion or other regular lapses in compliance during 
this 8-week period prior to RHC must be discus sed with the Medical Monitor prior to performing 
the RHC.  Changes to these PAH medications mu st not be anticipated for the duration of the 
study.
No increases in background oral PAH doses or  addition of a new PAH medication(s) will be 
allowed. Decreases in background oral PAH ther apy dosing should only be considered in the 
event of suspected IP-related a dverse effects. The Medical Mon itor should be notified of any 
change to background PAH therapy.
Permissible oral, inhaled, and i njectable PAH medications include:
xTadalafil
xSildenafil
xAmbrisentan
xMacitentan
xBosentan
xRiociguat
xProstanoids
xProstacyclin receptor agonists (e.g., selexipag)



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
82
Confidential 6.6.3. Prohibited Medications and Supplements
The following drugs are prohibited: 
xDrugs which are known to prolong QT and whic h are also clearly associated with a 
known risk for Torsades de Poin te (per www.CredibleMeds.org ( Woosley, 2019 ), 
Refer to Appendix 1 ).
xMAOIs
xTelotristat ethyl 
x5-HTP or L-tryptophan supplements   
xInvestigational drugs (other than rodatristat ethyl) 
Refer to Appendix 1 for a complete list of concomitant medi cations that are prohibited in this 
study. 



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
83
Confidential7. INTERVENTION AFTER THE END OF THE STUDY â€“
OPEN-LABEL EXTENSION
7.1. Rationale for the Open-Label Extension
The purpose of the OLE is to provide continuous , uninterrupted access to rodatristat ethyl for
patients who participated in the main part of this study if the pa tient appears to benefit from the 
therapy (as determined by Investigator and patie nt).  The OLE will also provide active IP to 
patients who received pla cebo in the Main Study. 
7.2. Objective
xTo evaluate the long-term safety, tolerability, and efficacy of rodatristat ethyl in 
patients with PAH
7.3. Endpoints
7.3.1. Safety endpoints
xThe proportion of patients who disconti nue rodatristat ethyl due to an AE
xThe proportion of patients with SAEs
xThe proportion of patients with AEs
xThe proportion of patients with tr eatment-emergent Grade 3 or 4 AEs
xThe proportion of patients with treat ment-emergent Grade 3 or 4 laboratory 
abnormalities
7.3.2. Efficacy endpoints
xChange in PVR
xChange in cardiac index, mPAP, mRAP, SvO2 at rest and PAC from baseline 
xTime to Clinical Worsening
xDeath from any cause
xChange in WHO FC from baseline
xChange in 6MWD from baseline 
xChange in NT-proBNP from baseline
xChanges in right atrial size and RV functio n: TAPSE, tricuspi d annular systolic 
velocity, and RV fractional area change from baseline



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
84
Confidential7.4. Open-Label Extension Design
Patients in the Main Study that do not discontinue  prematurely and comple te up to and including 
the Week 24 Visit, have the option to rollover in to the OLE. Patients who continue into the OLE 
will be blinded to the treatment th ey received in the Main Study.  Patients who received active IP 
in the Main Study will remain on their regime n. Patients randomized to placebo in the Main
Study will be re-randomized to one of the 2 activ e rodatristat ethyl treatment arms (300 mg BID
or 600 mg BID) in the OLE.
Patients who participate in the OLE will continue to receive rodatristat ethyl for 6.5 years, until 
the Investigator or patient chooses to stop the IP, any stopping criteria in the Main Study are met, 
IP becomes commercially available, or the Sponsor  stops the study for lack  of efficacy or a 
safety signal (whichever preceding cr iteria comes first). In no case will a patient be allowed to 
exceed 10 years of exposure unless the pr oduct is approved for a chronic indication.
During the OLE patients will be followed by the Inve stigator according to clinical practice, with 
formal (per protocol) safety as sessments. These safety assessments  will include AEs, clinical 
laboratory tests, vital signs, and concomitan t medications. Female pati ents of childbearing 
potential will be required to use 2 reliable me thods of contraception to reduce the risk of 
pregnancy during the course of the study and for at least 30 days  following the last dose of 
rodatristat ethyl.
During the first 24 weeks of the OLE patients, will also undergo efficacy assessments.  These 
efficacy assessments will include 6MWT, RHC, echocardiogram, WHO FC, and plasma 
NT-proBNP level. Urine pregnancy tests will be  performed every 4 weeks in women of child-
bearing potential only, while the pa tient is on IP and once at 4 week s post dose.  If there is not a 
clinic visit, a urine pregnancy test will be sent ho me with the patient and results will be followed 
up with a phone call. Additional pregnancy testin g in women whose menstruation is delayed or 
who have infrequent or irregular menstrua l cycles should be conducted as warranted.
See SoA in Section 1.4and Section 1.5.
7.5. Number of Patients and Inclusion/Exclusion Criteria
The maximum number of patients enrolled in to the OLE will be the number of patients who 
complete the Main Study (Week 24).
7.6. Inclusion Criteria
1. Patient must have completed study assessm ents and procedures up to and including 
Week 24 in the Main Study.
2. Female patients of childbearing potential must  have a negative serum or urine pregnancy 
test at the Week 24 visit and must agree to use contraception as detailed in Section 5.4.1
for at least 4 weeks after the last dose of IP . A female patient of childbearing potential is 
defined in Appendix 4 .



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
85
Confidential3. Male patients are eligible to participate if  they do not have a fe male partner who is 
pregnant or who intends to become pregnant during the O LE. Male patients and female 
partners must agree to use cont raception as detailed in Section 5.4.1 of the protocol 
starting 4 weeks prior to the firs t dose of IP, during the treatm ent period, and for at least 
100 days after the last dose of IP. Male pa tients must refrain from donating sperm during 
this period.
4. Patient must agree not to pa rticipate in a clinical study in volving another investigational 
drug or device for PH/PAH while in the OLE ( does not include registry or observational 
studies).
5. Patient must be competent to understa nd the information given in the IRB- or 
Independent Ethics Committee (IEC)-approved Informed Consent Form (ICF) and must 
sign the form prior to the in itiation of any OLE procedures.
7.7. Exclusion Criteria
1. Patients who have demonstrated noncompliance w ith study visits or IP in the Main Study.
2. Planned major surgery within the next 3 m onths, including lung transplantation, major 
abdominal or major intestinal surgery. 
3. New major thrombo-embolic events deve loped after completion of the Main Study.
4. Time period > 8 weeks between  Week 24 of the Main Study and start of treatment in the 
OLE.
5. A disease or condition which in the opinion of  Investigator may put the patient at risk 
because of participation or limit the patients' ability to participate.
6. Alcohol or drug abuse that in the opinion of  the Investigator w ould interfere with 
participation.
7.8. Open-Label Extension Procedures
All assessments in the OLE will be performed as explained in the Main Study.  SoA for the OLE
are in Section 1.4and Section 1.5.
Patients rolling into the OLE will complete the Scr eening/Enrollment Visit after their final visit 
in the Main Study (Week 24). All procedures for Week 24 will be completed including the 
following for the OLE:
xObtain informed consent
xReview inclusion/ exclusion criteria
xComplete re-randomization procedures for all patients
xDispense IP and instruct patient to return all used and unused IP containers at next 
clinic visit
xInstruct Patient to call th e clinic or return prom ptly should an AE occur.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
86
Confidential7.9. Open-Label Extension Treatment Assignment
At the Screening/Enrollment Visit of the OLE, e ligible patients who receiv ed placebo during the 
main study will be randomly allocated (1:1) to  one of the following 2 treatment groups:
Treatment Arm 
NameTreatment Description
Rodatristat ethyl
300 m g BID1 x 300 mg tablet BID
Rodatristat ethyl
600 m g BID2 x 300 mg tablets BID
Abbreviation:  BID = twice daily
Patients who received active IP while in the Main  Study may remain on the same active dose in 
the OLE or may be provided with a new dose of  IP to receive either 300 mg BID or 600 mg BID 
depending on the timing and outcome of th e 24-Week analysis from the Main Study.
Tolerability and all accumulated safety and efficacy data will be  reviewed by the Independent 
Data Monitoring Committee (IDMC).
IP will be supplied without placebo. The first dose of IP in the OLE will be considered the first 
dose after all Week 24 assessments  in the Main Study are complete d and all entry criteria met.
7.10. Investigational Product Prepa ration, Handling, Storage, and 
Accountability 
All IP preparation, handling, storag e, and accountability will be the same as in the Main Study as 
in Section 6.
7.11. Dose Adjustment Criteria
Dose adjustment criteria are the same as  the Main Study and can be found in Section 6.
7.12. Criteria for Investigation al Product/Study Termination
All criteria for IP and study termination are th e same as in the Main Study and can be found in 
Section 8.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
87
Confidential8. DISCONTINUATION OF INVESTIG ATIONAL PRODUCT AND
PATIENT DISCONTINUATION/WITHDRAWAL
Unnecessary withdrawal of patients should be avoi ded, and all efforts should be made to retain 
patients in the study.
8.1. Discontinuation of Investigational Product
The Medical Monitor should be notified of any change to bac kground PAH therapy to determine 
any need for withdrawal. See Section 8.2for study withdrawal procedures.
Patients meeting any of the following liver chemis try criteria must be withdrawn (IP should be 
discontinued immediately) from the study by the Investigator:
xALT or AST > 3X ULN and TBL > 1.5X ULN or INR > 1.5
xALT or AST > 3X ULN with the appearance  of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, feve r, rash, and/or eosinophilia (> 5%)
xALT or AST > 5X ULN for more than 2 weeks
xALT or AST >8X ULN
If liver chemistry tests meet any of  the above criteria, repeat test ing should be performed within 
48 to 72 hours and the patient followed until resolution.
Patients meeting any of the following confirme d QT/QTc-related criteria must be withdrawn 
from the study by th e Investigator:
xQTcF interval > 500 ms
xQTcF interval > 480 ms AND increase from B DVHOLQHÂ• 60 ms
xQTcF interval > 480 ms associated with syncope, life-threatening arrhythmias, 
resuscitated cardiac arrest, or seizure
The Investigator must also disc ontinue/withdraw a patientâ€™s partic ipation in the study if any of 
the following criteria apply:
xPregnancy
xSignificant protocol violat ion/lack of compliance w ith the study and/or study 
procedures - non-compliance with IP for di scontinuation of patient is defined as 
< 50%.
xSevere constipation (e.g., obstipation with  manual evacuation indicated) and/or 
severe, persistent, or worsening abdominal pain
xAny significant worsening on postdose C-SSRS  indicative of active suicidal ideation 
with intent to act (defined as C-SSRS Su icidal Ideation category score of 4 or 5) or 
behavior (either preparatory acts/behavior, aborted attempt, interrupted attempt, or 
actual attempt)
x6HYHUHGHSUHVVLRQRUDQ[LHW\ED VHGRQD+$'6'HSUHVVLRQRU$Q[L HW\VFRUHÂ• 15, or 
a QIDS-&7RWDO6FRUHÂ• 16.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
88
ConfidentialxAny severe psychiatric or CNS AE as determined by the Investigator.
The Investigator may discontinue/w ithdraw a study patientâ€™s partic ipation in the study if any of 
the following criteria apply:
xBehavioral or ad ministrative reason
Any clinical AE, laboratory abnorma lity, or other medical condition or situation occurs such that 
continued participation in the study would not be in the best interest of the patient. When
applicable, patients should be informed of circum stances under which thei r participation may be 
terminated by the Investigator without their consent.
8.1.1. Temporary Discontinuation
Temporary discontinuation of IP of up to 7 day s will be allowed for extenuating circumstances
or to manage AEs.
8.2. Patient Discontinuation/Withdrawal from the Study
Patients may withdraw from the st udy at any time at his/her own request or may be withdrawn at 
any time at the discretion of th e Investigator for safety, behavioral, compliance, or administrative 
reasons.  This is expected to be uncommon.
If the patient withdraws consent for disclosure of future information, the Sponsor may retain and 
continue to use any data collected be fore such a withdrawal of consent.
Replacement patients may be enrolled in cons ultation with the Spons orâ€™s Medical Monitor.
8.2.1. Investigational Product Discontinuation
If a patient is permanently discon tinued from the IP, but agrees to  study visits, the patient will 
come in for the Early Termina tion Visit and continue attending clinic visits as scheduled through 
the 24-week visit (from first dose). A final follow-up visit will not be required.
If a patient prematurely discontinues IP prior to the Week 24 Visit, the Investigator will make 
every attempt to perform a RHC, as clinically  feasible, prior to or within 7 days of IP
discontinuation (but after at l east 12 weeks of IP), and prior to initiation of any new PAH 
medications.
8.2.2. Study DiscontinuationIf a patient who discontinues IP de cides to end all study participat ion, an Early Termination Visit
should be conducted, as shown in the SoA (Section 1.3), if possible. 
Patients who withdraw should be asked if they may be contacted  by the study site  by telephone 
unless they explicitly withdraw their consent to be followed up.
If a patient withdraws consent, he /she may request destruction of any samples taken and not 
tested, and the investigator must docu ment this in the site study records.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
89
Confidential8.3. Lost to Follow up
A patient will be considered lost to follow up if he or she repeatedly fails to return for scheduled 
visits and is unable to be contacted by the study site.
The following actions must be taken if a patient fa ils to return to the c linic for a required study 
visit:
xThe site must attempt to c ontact the patient and reschedule the missed visit as soon as 
possible and counsel the patie nt on the importance of main taining the assigned visit 
schedule and ascertain whether or not the pa tient wishes to and/or  should continue in 
the study.
xBefore a patient is deemed lost to follow up, the Investigator or  designee must make 
every effort to regain cont act with the patient (where possible, 3 telephone calls and,
if necessary, a certified letter to the patie ntâ€™s last known maili ng address or local 
equivalent methods). These contact attempts  should be documented in the patientâ€™s 
medical record.
xShould the patient continue to be unreachable , he/she will be considered to have 
withdrawn from the study.
xPatients who withdraw consent will continue  to be followed for vital status from 
public records such as government vital sta tistics or obituaries,  as allowed by local 
law, or periodic contact (about every 6 to 12 months).
Discontinuation of specific sites or of th e study as a whole are handled as part of Appendix 5 .



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
90
Confidential9. STUDY ASSESSMENTS AND PROCEDURES
Study procedures and thei r timing are summarized in the SoA in Section 1.3for the Main Study
and in Section 1.4and Section 1.5for the OLE.
Safety concerns should be discussed with the Sponsor immediatel y upon occurrence or 
awareness to determine if the patien t should continue or discontinue IP.
Adherence to the study design requ irements, including those specified  in the SoA, is essential 
and required for study conduct.
All screening evaluations must be completed an d reviewed to confirm that potential patients
meet all eligibility criteria. The Investigator will maintain a screening log to record details of all 
patients screened and to confirm eligibility or reco rd reasons for screening failure, as applicable.
Once all screening procedures are complete and the Investigator determines that the patient is 
eligible, the site must upload/send the requi red supporting documenta tion for approval by the
Sponsor. The required information will include the RHC report (including tracings), PFTs 
obtained (may use PFTs completed in the 24 we ek period prior to screening or obtained at 
Screening), the screening echocardiogram, as well  as specific information about the patientâ€™s 
medical history and disease state to further en sure the appropriateness of each patient being 
enrolled into this study. Approva l from the Sponsor must be obtained prior to randomization.
All assessments should be completed predose unless otherwise stated.
If assessments are scheduled for the same nominal time, then the assessme nts should occur in the 
following order whenever possible: ECGs, vita l signs, safety blood draws, PK blood draws.
Note: The timing of the assessments should allow th e blood draw to occur as close as possible 
to the nominal time but before dosing.
Repeat or unscheduled samples may be taken for sa fety reasons or due to technical issues with 
the initial samples.
9.1. Efficacy Assessments
The efficacy-related assessments, as outlined below,  will be obtained at time points indicated in 
the SoA in Section 1.3and Section 1.4.
9.1.1. Right Heart Catheterization
The RHC is a common procedure used to diagnose PAH.Cardiopulmonary hemodynamics will be assessed by RHC. All required RHC parameters must 
be collected using the same methods at  Screening/Randomization and Week 24. The 
Screening/Randomization RHC will be required to c onfirm the diagnosis of PAH, and data from 
this RHC will serve as the baseline value for the primary and secondary analyses of 
cardiopulmonary hemodynamic para meters. Since the study is enro lling treatment-experienced 
patients, results from a historic al RHC conducted prior to the Scr eening Visit are not expected to 
reflect the patientâ€™s current disease status un less it was performed within 4 weeks of the 
Screening visit, includes all re quired information, and provided th at changes to the patientâ€™s 
PAH regimen were not made subs equent to that catheterization.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
91
ConfidentialIf prior approval is obtained from the Sponsor , the screening RHC ma y be performed on the 
same day as the randomization procedures, provided that all bl ood draws and efficacy 
assessments are conducted prior to the RHC procedure, and the RHC is performed prior to 
randomization and IP dosing. The hemodynamic assessment will be conducted in the supine position under resting conditions. The original RHC tracings will be maintained at the site. The 
RHC tracings will have all personal health info rmation removed and will be labeled with the 
following: patient number, patient initials, protocol number, and date recorded. 
Full details available in RHC manual.
9.1.2. Time to Clinical Improvement
TTCI will be evaluated by a multicomponent  improvement score including WHO FC and 
6MWT measurements: a > 10% increase in 6MWD or 30 meters AND an improvement to or 
maintenance of WHO FC II sympto matology, in the absence of a deterioration in clinical 
condition or death during the 24 weeks of the Main Study.
9.1.3. Time to Clinical Worsening
TTCW is defined as the first occurrence of a co mposite end point of: 1. Death from any cause, 
2. Hospitalization for worsening PAH (any hospitaliz ation for worsening P AH, lung or heart and 
lung transplantation, atrial septos tomy, or initiation of parenteral  prostanoid therapy), 3. Disease 
progression defined as a decrease of more than  15% from baseline in the 6MWD combined with 
WHO FC III or IV symptoms at 2 consecutive visits separated by at least 14 days (adjudicated).
9.1.4. Six-Minute Walk Test/S ix-Minute Walk Distance
The 6MWT is a simple, commonly used, standard ized measure of functional exercise capacity 
and endurance. It is a commonly us ed measure of efficacy in PA H clinical studies. The change 
from baseline in 6MWD following intervention in dicates symptomatic improvement over that 
time-period. Improvement in 6MWD has been correlated with improvements in quality of life.
Refer to Appendix 6 .
9.1.5. Echocardiography
Patients will undergo resting card iac echocardiography at specif ied visits. Echocardiographic 
endpoints will include right atrial size and meas ures of RV function (TAPSE, tricuspid annular 
systolic velocity, and RV frac tional area change). There will be  a core imaging laboratory for 
centralized blinded ad judication of the echoc ardiographic endpoints.
Full details available in echocardiograph manual.
9.1.6. Pulmonary Function Tests (PFTs)
PFTs (performed with or without  bronchodilation) should be comple ted at Screening if there are 
no historical results from tests complet ed within 24 weeks prior to Screening.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
92
Confidential9.1.7. World Health Organization Functional Class
PAH functional disease severity is classified acco rding to WHO FC.  Patients are classified into 
1 of 4 functional classes on the basis of their degree of physical limi tation and associated 
symptoms. Refer to Appendix 7 for full description of each Functional Class.
9.1.8. N-terminal pro-Brain Natriuretic Peptide Level
NT-proBNP is a strong predictor of disease pr ogression and mortality in PAH patients. Current 
PAH treatment guidelines reco mmend measurement of NT-pro BNP levels for both risk 
assessment and longitudinal follow up. NT-proBNP le vels are also a good marker of response to 
treatment.
9.1.9. Pulmonary Arterial Hypertension-S ymptoms and Impact Questionnaire
The PAH SYMPACT Questionnaire is the first instrument for quantifying PAH symptoms and 
impacts. It is a brief, disease- specific patient-reported outc ome (PRO) instrument possessing 
good psychometric properties.
The questionnaire consists of two parts:
xDay 1 to Day 6: The Questionnaire asks 13 questions regarding the patientâ€™s PAH 
symptoms for the past 24 hours. The patient is required to complete these questions 
each day for Days 1 to 6.
xDay 7: The Questionnaire asks 12 questions regarding the patientâ€™s PAH symptoms 
for the past 24 hours and an additional 11 questions about the â€œI mpactsâ€ that best 
describes how the patientâ€™s life was affected by PAH.
Prior to departing the study site at the Screening Vis it, patients will be inst ructed and trained on 
how to complete the questionnaire. Patients will  start the PAH-SYMPACT questionnaire 6 days 
prior to the visit for which PAH-SYMPACT is co llected, with the Day 7 being completed on the 
day of the visit.
An example of the PAH SYMPAC T Questionnaire can be found in Appendix 9 .
9.1.10. Registry to Evaluate Early and Long -term Pulmonary Arterial Hypertension
Disease Management Lite 2 R isk Assessment Calculator
REVEAL Lite 2 includes 6 non-invasive variab les: FC, vital signs (SBP and HR), 6MWD, 
NT-proBNP, and renal insufficiency (by eGFR). REVEAL Lite 2 will be a calculated parameter
(by statistician) at Baseline and Week 24 of the Main Study and Week 24 of the OLE (this 
calculation will not be in the eCRF).
9.1.11. Actigraphy
Data on physical activity will be collected usi ng a small wrist-worn physical activity tracker
(monitor designed for documenting physical move ment) that will transmit all activity through the 
24 weeks of the Main Study.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
93
Confidential9.2. Safety Assessments
9.2.1. Pregnancy Testing
Serum pregnancy tests will be obtained for all female patients of childbearing potential at 
Screening and every 4 weeks while on IP. Urine  pregnancy tests will be obtained at all 
subsequent visits and must be  confirmed negative at  the Baseline Visit before randomization and 
IP dispensation. Additional pregnancy tests should be completed anytime menstruation is 
delayed and in women with infrequent or irregular menstrual cycles. A positive urine test will be 
confirmed by a serum test.
Serum pregnancy test and FSH levels will be obtained at the Screening Visit for any 
postmenopausal women with amenorrhea for < 2 years to confirm FSH level (must be
> 35 IU/mL). If FSH value is confirmed as postme nopausal at Screening, no further pregnancy 
tests are required.  If level doe s not confirm postmenopausal status , urine pregnancy tests will be 
required at all scheduled visits and patients must agree to us e an approved method of highly 
effective contraception (refer to Section 5.4.1 ).
Planned time points for all safety asse ssments are provided in the SoA (Section 1.3, Section 1.4,
and Section 1.5).
9.2.2. Physical Examinations
A complete physical examination will include, at  a minimum, assessments of the cardiovascular, 
respiratory, gastrointestinal and neurological systems. Height ( only at Screening) and weight 
will also be measured and recorded.
Investigators should pay special at tention to clinical si gns related to previous serious illnesses.
9.2.3. Vital Signs
Vital signs will be measured after 5 minutes re st and will include temperature, systolic and 
diastolic blood pressure, respir ation rate and oxygen saturation.
9.2.4. Electrocardiograms
Three 12-lead ECGs, one minute apart, will be obt ained after at least 5 minutes of rest at
Baseline. Single 12-lead ECGs will be performed at all other time points.
Each ECG performed during the study will be obtained using an ECG machine that 
automatically calculates the HR and meas ures PR, QRS, QT and QTcF intervals.
The corrected QT interval (QTc) using Fridericiaâ€™s formula (QTcF) will be used for each 
individual patient to determine study eligibility and for all on-study ECGs. The QTcF interval 
will be based on the ECG machineâ€™s algorithm.
Clinically significant ECG findings that are present prior to initia tion of IP, if not exclusionary, 
must be documented in the Me dical History section of the eC RF. Any clinically significant
abnormality that represents a change from baseline will be repor ted as an AE and followed until 
resolution.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
94
Confidential9.2.5. Clinical Safety Laboratory Assessments
A central laboratory will be used  for clinical safety laboratory assessments. The details for 
sample collection, preparation, a nd shipping to the central labo ratory will be provided in a 
separate lab manual. Reference ranges for all safe ty parameters will be provided to the site by 
the central laboratory respons ible for the assessments.
See the SoA (Section 1.3, Section 1.4, and Section 1.5) for timing and frequency.
Hematology, clinical chemistry, co agulation, urinalysis, and addition al parameters to be tested 
are listed below:
9.2.5.1. Hematology
Hematolo gyPanel
Platelet Count Red Blood Cell (RBC) Indices: Automated WBC 
Differential:
RBC Count Mean Corpuscular Volume 
(MCV)Neutrophils
White Blood Cell (WBC)
Count (Absolute)Mean Corpuscular Hemoglobin 
(MCH)Lymphocytes
Reticulocyte Count Mean Corpuscular Hemoglobin 
Concentration (MCHC)Monocytes
Hemo globin Eosinophils Basophils
Hematocrit
9.2.5.2. Coagulation 
Coagulation Panel
Prothrombin Time (PT)  
INR
Activated Partial Thromboplastin Time (aPTT)
Coagulation testing will be done at Screen ing, Week 12, and Week 24 for all patients on the 
Main Study and at Weeks 12 and 24 during the OLE in the first 24 weeks and every clinic visit 
post 24 weeks in the OLE. In addition, coagulation will be done at an unscheduled visit if there is an ALT result Â•3X ULN at any study visits. Refer to Appendix 3 .
9.2.5.3. Clinical Chemistry
Clinical Chemistr
y Panel
Blood Urea
Nitro genPotassium ALT Albumin
Creatinine Chloride Gamma-Glutamyl Transferase 
(GGT)Total Protein
Glucose Calcium Alkaline Phosphatase Urea
Sodium Bilirubin (Total) Bilirubin (Direct) (only if Total is 
elevated)AST 
Bicarbonate Magnesium Lipase (reflex if Amylase is 
>2 XU L N )Amylase



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
95
Confidential9.2.5.4. Urinalysis
Urinal ysis
Bilirubin, Glucose, Protein, Blood and Ketones, Leukocytes, Nitrites, pH, Specific Gravity and 
Urobilino gen by dipstick
Microscopic examination (if blood or protein is abnormal)
Microbiolo gy (at discretion of Investi gator based on urinal ysis results)
9.2.5.5. Other Tests
Other Tests
NT-proBNP
Urine Creatinine (for calculation of 5-HIAA) at each 5-HIAA collection time
Estimated Glomerular Filtration Rate (eGFR)
FSH (as needed at Screenin gfor confirmation of postmenopausal status)
Serum beta-hCG (pre gnanc y test; onl y at Screenin g)
Human Chorionic Gonadotropin (hCG) b yurine dipstick
Pharmaco genetic sample
Sample for Future Research sample
Drugs of abuse: amphetamines, barbiturates, benzodiazepines, cocaine metabolites, 
methadone, opiates, phenc yclidine, propox yphene (onl y at Screenin g)
The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE sec tion of the eCRF. The 
laboratory reports must be file d with the source documents. C linically significant abnormal 
laboratory findings are those which are not associated with the underl ying disease, unless judged 
by the Investigator to be more severe th an expected for the patient's condition.
All laboratory tests with  abnormal values consider ed clinically si gnificant during pa rticipation in 
the study or within 4 weeks after the last dose of IP should be repeated until the values return to 
normal or baseline or are no longe r considered clinica lly significant by th e Investigator or 
Medical Monitor.
If such values do not return to normal/baseline within a period of  time judged reasonable by the 
Investigator, the etiology should be  identified, and the sponsor notified.
All protocol-required laboratory assessments must be conducted in accordance with the 
laboratory manual and the SoA (Section 1.3, Section 1.4, and Section 1.5).
If laboratory values from non- protocol specified laboratory assessments performed at the 
institutionâ€™s local laboratory requi re a change in patient management  or are considered clinically 
significant by the Investigator (e .g., SAE or AE or dose modificati on), then the results must be 
recorded in the eCRF.
Additional unscheduled laboratory assessments may be conducted at  any time during the study if 
the Investigator or Sponsor deems it n ecessary for the safe ty of the patient.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
96
Confidential9.2.6. Pharmacogenetic Testing
A separate and specific informed consent form will be provided to patients to allow the sponsor 
to obtain and test a patientâ€™s b lood sample taken at the Baselin e/Day1 and the Week 24 visits for 
pharmacogenetic markers that may be predictive of the natural histor y of the disease, response to 
therapy and tolerability of thera py. If it is not collected at the Baseline/Day 1 visit, it may be 
collected at any time during the treatment period.  Providing th ese blood samples is optional and 
not required for participation in the study.
9.2.7. Optional Blood Sample for Future Research
In addition to the study-specific informed consent to be signed by each patient participating in 
the study, a separate, specific si gnature will be required to docu ment a patientâ€™s agreement to 
provide additional samples or to  allow the use of the remainder of their already collected 
biomarker specimens for optional non-genetic futu re research, once approved by local authorities 
as applicable according to specific local regulati ons.  The specimens collect ed for optional future 
research will be used to increase our knowledge  and understanding of th e biology pathogenesis, 
progression and/or treatment outcomes, including efficacy, AE s, and the process of drug 
absorption and disposition.  
A plasma sample will be obtained from all patients at the Day 1/Ba seline visit and at the end of 
the treatment or ET (as applicable) visit of the Main Study for future  research use.  Samples will 
be collected and archived by the sponsor for up to 10 years.
9.2.8. Suicidal Ideation and Behavior Risk Monitoring
Rodatristat ethyl acts to decrea se peripheral 5-HT levels and it was designed to not cross the 
blood-brain barrier; therefore, CN S 5-HT levels are not expected to be significantly impacted.
However, patients being treated with IP should be  monitored appropriately  and observed closely 
for suicidal ideation and behavior  or any other unusual changes in  behavior, especially at the 
beginning and end of the course of  treatment, or at the time of dos e changes, either increases or 
decreases. IP in patients who experience signs of  suicidal ideation or behavior following a risk 
assessment (see Section 8.1) must be stopped.
Screening and Baseline assessments ( within 1 month) of su icidal ideation and behavior as well as 
potential treatment-emergent suicidal ideation and behavior will be monitored during the study 
using the C-SSRS.
Suicidal ideation and behavior as well as mood a nd anxiety assessments, as detailed below, will 
be obtained at time points indi cated in the SoA in (Section 1.3).



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
97
Confidential 9.2.8.1. Columbia Suicide Severity Rating Scale
The C-SSRS is a valid, reliable, evidenced-based suicidal ideation and be havior rating scale,
which was developed by multiple institutions, including Columbia University with National 
Institute of Mental Health support,  to evaluate suicide risk ( CLP, 2016 ).  The
rater-/clinician-administered versio ns of the C-SSRS for research assess severity and intensity of 
suicidal ideation, types of suicidal  behaviors, and lethality of suic ide attempts at time points and 
over time periods that are t ypical for randomized control st udies. The C-SSRS has been 
identified by the FDA ( FDA, 2012 ) as acceptable for use in clinical  research and has been used 
extensively in clinical studies throughout the U.S. and around the world. 
Training should be completed by any study staff delegated to perfo rm this assessment.  Online 
training is available, and a certificate of completion is issued once the training is completed and must be filed at the site.  Tr aining must be current within th e previous 2 years. The sign-up and 
training portal can be found at the following link:   
https://cssrs.columbia.edu/training/training-research-setting/ An example of the C-SSRS can be found in Appendix 10.
9.2.8.2. Hospital Anxiety and Depression Scale
The HADS is a 14-item, self-rated measure designed to be used as a brief screen for depression 
(7 items) and anxiety (7 items) disorders among nonpsychiatric, medically ill, outpatient 
populations ( Zigmond & Snaith, 1983 ).  As a screening instrume nt, the HADS does not provide 
a definitive diagnosis, but is the first step in a multistage process of selecting individuals at 
elevated risk for disorder to be evaluated through clinical interview.
An example of the HADS can be found in Appendix 11.
9.2.8.3. Quick Inventory of De pressive Symptomatology 
The 16-item QIDS ( Rush et al., 2003 ) is designed to assess the se verity of depressive symptoms. 
The QIDS is available in the clinician-rated ( QIDS-C) and self-reported versions (QIDS-SR). 
Both versions assess all the criterion symptom domains designated by the American Psychiatry 
Association Diagnostic and Sta tistical Manual of Mental Di sorders - 4th edition (DSM-IV)
(APA, 1994 ) and the 5th edition adds reference to diagnose a majo r depressive episode. The 
QIDS-C version will be used in this study.  The QIDS-C is sensit ive to change with medications, 
psychotherapy, or somatic treatments,  making it useful for both rese arch and clinical purposes.  
The psychometric properties of the QIDS-C have been estab lished in various study samples.
An example of the QIDS-C can be found in Appendix 12.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
98
Confidential9.3. Adverse Events, Adverse Events  of Special Interest, and Serious 
Adverse Events
The definitions of an AE or SAE can be found in Appendix 14 .
AEs will be reported by the patient (or, when a ppropriate, by a caregiver, surrogate, or the 
patientâ€™s legally authorized representative).
The Investigator and any qualified designees ar e responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for follow up
of AEs that are serious, considered related to the IP or study procedures, or that caused the 
patient to discontinue the study (see Appendix 14 ).
9.3.1. Adverse Events of Special Interest
AESIs include:
Ð¬Severe constipation (and/or severe, pers istent, or worsening abdominal pain)
Ð¬Depression/other significant mood-related disturbance (active suicidal ideation or 
behavior, severe depressive and/or anxious symptoms, othe r severe psychiatric TEAE)
Ð¬Elevations in hepatic enzymes (see Appendix 3 )
Ð¬Diarrhea (see Appendix 2 )
9.3.2. Time Period and Frequency for Collecting Adverse Event, Adverse Events of 
Special Interest, Serious Adverse Event Information
All SAEs will be collected from the signing of  the ICF until the Follow-Up Visit at the time
points specified in the SoA (Section 1.3). All AEs will be collected from the first dose of IP.
Medical occurrences that begin before the start of IP but after obtaining in formed consent will be 
recorded on the Medical History/Current Medical  Conditions section of the eCRF not the AE 
section.
All SAEs will be recorded and reported to th e Sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix 14 . The Investigator will 
submit any updated SAE data to the Spons or within 24 hours of it being available.
Adverse events of special interest must be reported to the Sponso r should they meet the 
definition of an SAE, and a ll timelines for repor ting of SAEs should be adhered to.
Investigators are not obligate d to actively seek AEs or SA Es after conclusion of study 
participation. However, if the Investigator lear ns of any SAE, includ ing a death, at any time 
after a patient has been discharg ed from the study, and he/she  considers the event to be 
reasonably related to the IP or study participatio n, the Investigator mu st promptly notify the 
Sponsor.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
99
Confidential9.3.3. Method of Detecting Adverse Events, Ad verse Events of Special Interest, and 
Serious Adverse Events
The method of recording, evaluating, and a ssessing causality of AEs and SAEs and the 
procedures for completing and tran smitting SAE reports are provided in Appendix 14 .
Care will be taken not to introduce bias when  detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of  the patient is the preferre d method to inquire about AE
occurrences.
9.3.4. Follow-up of Adverse Events, Adverse Ev ents of Special Interest, and Serious 
Adverse Events
After the initial AE/SAE report, the Investigator is required to proactivel y follow each patient at 
subsequent visits/contacts. All SAEs, and non-serious AESIs (as defined in Section 9.3.1 ), will 
be followed until resolution, stabi lization, the event is otherwise e xplained, or the patient is lost 
to follow up (as defined in Section 8.3). Further information on follow- up procedures is given in
Appendix 14 .
9.3.5. Regulatory Reporting Requirements for Serious Adverse Events
Prompt notification by the Invest igator to the Sponsor of an SAE is essential so that legal 
obligations and ethical responsib ilities towards the safety of patients and the safety of an IP
under clinical inve stigation are met.
The Sponsor has a legal responsibility to notify both the local regulator y authority and other 
regulatory agencies about the safety of an IP under clinical inves tigation. The Sponsor will 
comply with country-specific regulatory requi rements relating to safety reporting to the 
regulatory authority, IRBs/IECs, and investigators.
Investigator safety reports must  be prepared for suspected unexpected serious adverse reactions
(SUSARs) according to local regulatory require ments and Sponsor policy and forwarded to 
investigators as necessary.
An investigator who receives an investigator safety report desc ribing an SAE or other specific 
safety information (e.g., summary or listing of SA Es) from the Sponsor will re view and then file 
it along with the Investigatorâ€™s Brochure and will  notify the IRB/IEC, if  appropriate, according 
to local requirements.
9.3.6. Pregnancy
Patients will be instructed that if they/their part ner become pregnant durin g the study, this should 
be reported to the Investigator. The Investigator  should also be notified of any pregnancy that 
occurs during the study but not confirmed until after completion of th e study for at least 
5 terminal half-lives (4 weeks) after the last dose. In the event that a patient/patientâ€™s partner is subsequently found to be pregnant  after being included in the st udy, then consent will be sought 
from the partner and, if granted, any pregnancy w ill be followed, and the status of the mother 
and/or child will be reported to the Sponsor after delivery.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
100
ConfidentialAny patient reporting a pregnancy during the study will be discontinued from the IP. The patient
will also be followed to determine the outcome of the pregnancy. Information on the status of 
the mother and child will be forwarded to th e Sponsor. Generally, follow up will be no longer 
than 6 to 8 weeks following the estimated deliver y date. Any premature termination of the 
pregnancy will be reported. Abnormal pregnanc y outcomes (e.g., spontaneous abortion, fetal 
death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.
If a pregnancy is reported, the Investigator should inform the Sponsor within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 4 .
9.4. Treatment of Overdose
Prior to this study, there has been no experience with rodatristat ethyl in patients with PAH. In 
healthy subjects, no safety concerns were id entified following single doses ranging from 100 mg 
to 2000 mg or following repeat dosing over 14 da ys of up to 800 mg administered BID or up to 
800 mg administered once daily (QD).
An overdose in this study is defined as a dose > 1200 mg on any single dosing occasion, or 
> 2400 mg in any 24-hour period.
Altavant Sciences GmbH does not recomm end specific treatment for an overdose.
In the event of an overdose, the Investigator should:
1. Contact the Medical Monitor immediately
2. Closely monitor the patient for any AE/SAE and laboratory abnormalities as applicable
3. Obtain an unscheduled plasma sample fo r PK analysis if requested by the Medical 
Monitor (determined on a case-by-case basis)
4. Document the quantity of the excess dose as  well as the duration of the overdose in the 
eCRF
Decisions regarding dose interruptions or modifi cations will be made by the Investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the patient.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
101
Confidential9.5. Pharmacokinetics
Blood samples for PK analysis of plasma rodatris tat ethyl, rodatristat, M15  metabolite, selexipag, 
and ACT-333679 will be collected by indwelling cannula or venipuncture at the time points 
indicated in the SoA (Section 1.3). Note, selexipag/ACT-333679 PK samples will only be
collected in subjects using sele xipag at baseline. The actual date  and time of each blood sample 
collection will be recorded.
The date and time of the dose of IP taken prior to the collection of each PK sample will be 
recorded and if the meal the dose was taken with  was high in fat, should also be recorded.
Sample analysis will be perform ed under the control of the Spons or. Plasma concentrations of 
rodatristat ethyl, rodatristat, M15, selexipa g, and ACT-333679 will be determined using 
validated liquid chromatography-tandem ma ss spectrometry (LC-MS/MS) methods. Raw data 
will be archived at the bioanalytical site(s). Once  the sample(s) has been analyzed for rodatristat 
ethyl, rodatristat, M15, selexipag, and ACT-333679, a ny remaining sample may be analyzed for 
other rodatristat-related metabolites and the results may be reported separately.
Samples will be collected into appropriate tube s as specified by the bi oanalytical laboratory. 
Details of blood collection, processing, storage, and shipment will be provided in the laboratory
manual.
Rodatristat ethyl and rodatristat concentration information that would unblind the study will not 
be reported to investigative sites or blinded personnel (including the Sponsor) until the study has 
been unblinded.
9.6. Pharmacodynamics
Blood samples for determination of plasma 5-HIAA will be colle cted by indwelling cannula or 
venipuncture at the time points in dicated in the SoA in Section 1.3. The actual date and time of 
each blood sample collection will be recorded.
Urine samples will be collected for determination of 5-HIAA (bioanalytical lab) and urine 
creatinine (central laboratory; for determinati on of creatine corrected 5-HIAA concentration) at 
the time points indicated in the SoA in Section 1.3and Section 1.4.
Sample analysis will be performed under th e control of the Sponsor. Plasma and urine 
concentrations of 5-HIAA will be determined  using a validated LC-MS/MS method. Raw data 
will be archived at the bioanalytical site.
Details of sample containers and processi ng will be contained in the laboratory manual.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
102
Confidential10. STATISTICAL CONSIDERATIONS
A detailed description of statistical methods will  be provided in a separa te Statistical Analysis 
Plan (SAP) and the SAP will be fina lized prior to database lock.
10.1. Statistical Hypotheses
No formal hypotheses are planned for the study.
10.2. Sample Size Determination
The sample size for this study was not based on a formal hypothesis testing. It is expected that 
30 patients per arm will provide sufficient da ta to assess the safety and efficacy. Power 
calculations were conducted to examine the pr obability of detecting a difference among 
treatment groups for th e percentage change of PVR from baseline.
A sample size of 90 patients with 30 patients to be  randomized into 1 of the 3 treatment arms in a 
1:1:1 randomization is planned. A sample size of 30 patients per arm will provide at least 
80% power at a significance level of 0.05 (2-sided hypothesis) to de tect a treatment difference of 
0.75 times of standard deviation (SD) in the percentage change from baseline of PVR from 
baseline between an active arm and the placebo arm. If the SD for PVR percent change is 24%, 
the study has 80% power to detect a differenc e of 18% between an active arm and the placebo 
arm.
10.3. Populations for Analyses
For purposes of analysis, the fo llowing populations are defined:
Population Description
Enrolled All patients who sign the ICF
Intent-to-Treat (ITT) All patients randomized into the study. For all summaries based 
on the ITT population, patients w ill be assigned to the treatment 
arm to which they were randomized.
Modified Intent-to-Treat (m-ITT): All safety population patients th at had an evaluable baseline
and completed at least 1 post-baseline efficacy assessment.Patients will be analyzed according to the treatment theyactuall
yreceived.
Per Protocol (PP) All m-ITT population patients who had no major protocol 
deviations and completed the Week 24 visit.
Safety All patients randomly assigned to IP and who take at least 1 dose 
of IP. Patients will be analyzed  according to the treatment they 
actually received.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
103
Confidential10.4. Statistical Analyses
The SAP will be developed and finalized before database lock and will describe the patient
populations to be included in the analyses a nd procedures for accounting for missing, unused, 
and spurious data. This section is a summary of th e planned statistical analyses of the primary 
and secondary endpoints.
10.4.1. Efficacy Analyses
Endpoint Statistical Analysis Methods
Primary Primary efficacy analyses will be performed using the m-ITT and PP 
populations.Percent change from baseline in PVR will be analyzed using an analysis of 
covariance (ANCOVA) with Baseline PVR as the covariate. Additional baseline characteristics may also be ev aluated as covariates in the model.
The estimated between-treatment di fferences, 95% confidence intervals
(CIs), and p-values will be presented. For patients who discontinue from the study early, the last-observation-carried -forward method will be used to impute 
the PVR at Week 24.
Secondary Secondary efficacy analyses will be  performed using the m-ITT and PP 
populations:Change in cardiac index, mPAP, mRAP, SvO2 at rest, and PAC from baseline to 
Week 24
xTTCW
xChange in WHO FC
xChange in 6MWD from baseline
xChange in NT-proBNP
xChange in right atrial size & RV function: TAPSE, tricuspid annular 
systolic velocity, and RV fracti onal area change from baseline
xREVEAL Lite 2 score
xChange in PAH-SYMPACT from Baseline to Week 24
xChange in 5-HIAA (plasma a nd spot urine concentration)
The change from baseline to Week 24 endpoints will be analyzed using an 
ANCOVA model with treatment  as a fixed effect, ra ndomization stratum and 
baseline assessment as covariates. The estimated between-treatment differences, 95% CIs, and p-va lues will be presented.
The change in 6MWD from baseline to Week 24 will also be compared between 
groups using non-parametric analysis of covariance within the framework of the 
extended Cochran-Mantel-Haenszel test. For endpoints meas ured over time, a 
mixed effect of repeated measure model may be used as sensitivity analyses.
Details of statistical methods will be provided in the SAP. The time from the 
first dose of IP until to the first clinical worsening event will be summarized using Kaplan-Meier estimates and compar ed between treatment groups using the 
log-rank test.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
104
ConfidentialEndpoint Statistical Analysis Methods
Exploratory Will be described in th e SAP finalized before database lock
10.4.2. Safety Analyses
Safety and tolerability will be evaluated by assessment of AE incidence and changes in clinical 
laboratory tests, physical examin ations, vital signs measuremen ts, ECG readings, and suicidal 
ideation and behavior ratings at various time points during the study.
The following AE summaries will be generated:
xAdverse events
xSerious adverse events
xAdverse events leading to discontinuation
xAdverse events by severity
xAdverse events by relationship to the IP
AE verbatim text will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA). All AEs, both serious and nonseri ous, will be listed. AE summaries by treatment 
group and consisting of the number a nd percent of patients reporting each event at least once will 
be generated.
Clinical values will be listed for each patient an d flagged high or low relative to the normal range 
where appropriate. Descriptive summary stat istics will be created by treatment and visit.
Other safety data (e.g., physical examination) w ill be summarized descriptively by treatment and
visit.
10.4.3. Other Analyses
Patient reported outcomes (HADS and QIDS-C), PK, PD, and exploratory descriptive analyses 
will be described in the SAP finalized before  database lock.  Population PK and any PK/PD
analyses will be documented in a separate an alysis plan and may be reported separately.
The planned analyses for the OLE portion of the study will be provided in the SAP.
10.5. Interim Analyses 
An external, multidisciplinary, IDMC will review the progress of the study and perform interim 
reviews of unblinded safety da ta at regular intervals and provide recommendations to the 
Sponsor whether the nature, frequency, and seve rity of AEs and AESIs associated with IP
warrant the early termination of the study in the best interests of  the patients, whether the study 
should continue as planned, or whether the study should continue with modifications. The 
IDMC may also provide recommendations as needed regarding study design. While the IDMC 
will be asked to advise the Sponsor regarding fu ture conduct of the study, including possible 
early study termination, the Sponsor retains final decision-making authority on all aspects of the 
study.
A separate SAP will describe the planne d interim analyses in greater detail.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
105
Confidential10.5.1. Independent Data Monitoring Committee
The primary role of the IDMC, which consists of  independent physicians with experience in the 
care of patients with PAH and the conduct of randomized, controlled st udies and one non-voting 
biostatistician, is to en sure the safety of the patients en rolled in the study, including the OLE.
Details of the IDMCâ€™s specific activities will be defined by a mutually agreed charter, which will 
define the IDMCâ€™s membership, c onduct and meeting schedule.  This  charter will be maintained 
by the Sponsor or designee.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
106
Confidential11. REFERENCES
Abid, S., Houssaini, A., Chevarin, C., Marc os, E., Tissot, C.-M., Gary-Bobo, G., Wan, F., 
Mouraret, N., Amsellem, V., Dubois-RandÃ©, J. -L., Hamon, M., & Adnot, S. (2012). Inhibition 
of gut- and lung-derived sero tonin attenuates pulmonary  hypertension in mice. American 
Journal of Physiology-Lung Cellular and Molecular Physiology ,303(6), L500â€“L508. 
https://doi.org/10.1152/ajplung.00049.2012
Agarwal, R., & Gomberg-Maitland, M. (2011). Curre nt therapeutics and practical management 
strategies for pulmonary  arterial hypertension. American Heart Journal ,162(2), 201â€“213.
https://doi.org/10.1016/j.ahj.2011.05.012
Aiello, R. J., Bourassa, P.-A., Zhang, Q., Dubins, J., Goldberg, D. R., Lombaert, S. D., Humbert, 
M., Guignabert, C., Cavasin, M. A., McKinse y, T. A., & Paralkar, V. (2016). Tryptophan 
hydroxylase 1 (TPH1) Inhibition Impacts Pulm onary Vascular Remodeling in Two Rat 
Models of Pulmonary Hypertension. Journal of Pharmacol ogy and Experimental 
Therapeutics ,360(2), jpet.116.237933. https: //doi.org/10.1124/jpet.116.237933
APA. (1994). American Psychiatric Association. Diagnos tic and Statistical Manual of Mental 
Disorders: DSM-IV . American Psychiatric Publishing, Inc.
ATS. (2012). ATS Statement: Guidelin es for the Six-Minute Walk Test. American Journal of 
Respiratory and Critical Care Medicine ,166(1), 111â€“117.
https://doi.org/10.1164/ajrccm.166.1.at1102
Benza, R., Kanwar, M., Raina, A., Scott, J., Zh ao, C., Selej, M., Elliott, C. and Farber, H., 2020.
Development and Validation of an Abridged Version of the REVE AL 2.0 Risk Score 
Calculator, REVEAL Lite 2, for Use in  Patients with Pulmonary Arterial 
Hypertension. Chest ,.
CLP. (2016). The Columbia Lighthouse Project . https://doi.org/cssrs.columbia.edu
Eddahibi, S. (2006). 055 Cross-talk between endo thelial and smooth muscle  cells in pulmonary 
hypertension: critical role for serotonin-induced sm ooth muscle hyperplasia. Revue Des 
Maladies Respiratoires ,23(5), 540. https://doi.org/10.1016/s0761-8425(06)71883-6
FDA. (2012). Guidance for industry: suicidal ideation and behavior: prospective assessment of 
occurrence in clinical trials . Center for Drug Evaluation and Research.
Humbert, M., Labrune, P., Sitbon, O., Gall, C. L ., Callebert, J., Herve, P., Samuel, D., Machado, 
R., Trembath, R., Drouet, L., Launay, J.-M., & Simonneau, G. (2002). Pulmonary arterial 
hypertension and type-I gl ycogen-storage disease: the serotonin hypothesis. European 
Respiratory Journal ,20(1), 59â€“65. https://doi.org/10.1183/09031936.02.00258702
IB. (2020). Rodatristat Ethyl Investigatorâ€™s Brochure .



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
107
ConfidentialIzikki, M., Hanoun, N., Marcos, E., Savale, L., Ba rlier-Mur, A. M., Saurini, F., Eddahibi, S., 
Hamon, M., & Adnot, S. (2007). Tryptophan hydroxylase 1 knockout and tryptophan 
hydroxylase 2 polymorphism: effects on hypoxi c pulmonary hypertension in mice. American 
Journal of Physiology-Lung Cellular and Molecular Physiology ,293(4), L1045â€“L1052. 
https://doi.org/10.1152/ajplung.00082.2007
Kim, J. J., Wang, H., Terc, J. D., Zambrowicz, B., Yang, Q. M., & Khan, W. I. (2015). Blocking 
peripheral serotonin synthesis by telotristat etipra te (LX1032/LX1606) re duces severity of 
both chemical- and infection-indu ced intestinal  inflammation. American Journal of 
Physiology-Gastrointesti nal and Liver Physiology ,309(6), G455â€“G465. 
https://doi.org/10.1152/ajpgi.00299.2014
Klinger, J. R., Elliott, C. G., Levine, D. J., Bo ssone, E., Duvall, L., Fagan, K., Frantsve-Hawley, 
J., Kawut, S. M., Ryan, J. J., Rosenzweig, E. B., Sederstrom, N., Steen, V. D., & Badesch, D. 
B. (2019). Therapy for Pulmonary Ar terial Hypertension in Adults. Chest ,155(3), 565â€“586.
https://doi.org/10.1016/j.chest.2018.11.030
MacLean. (2018). The serotonin hyp othesis in pulmonary hypertens ion revisited: targets for 
novel therapies (2017 Grover Conference Series). Pulmonary Circulation ,8(2), 1â€“9.
https://doi.org/10.1177/2045894018759125
MacLean, M. R., & Dempsie, Y. (2010). The Serotonin
Hypothesis of Pulmonary Hypertension 
Revisited .661, 309â€“322. https://doi.org/10.1007/978-1-60761-500-2_20
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, 
J. C., Ninan, P. T., Kornstein, S., Manber, R., Thase, M. E., Kocsis, J. H., & Keller, M. B.
(2003). The 16-Item quick inventory of depressive symptomato logy (QID S), clinician rating
(QIDS-C), and self-repo
rt (QIDS-SR): a psycho metric evaluation in patients with chronic
major depression. Biological Psychiatry ,54(5
), 573â€“583. https://doi.org/10.1016/s0006-
3223(02)01866-8
Shi, Z.-C., Devasagayaraj, A., Gu, K., Jin, H., Ma rinelli, B., Samala, L., Scott, S., Stouch, T., 
Tunoori, A., Wang, Y., Zang, Y., Zhang, C., Kimball, S. D., Main, A. J., Sun, W., Yang, Q., Nouraldeen, A., Yu, X.-Q., Buxton, E., â€¦ Liu, Q.  (2008). Modulation of Peripheral Serotonin 
Levels by Novel Tryptophan Hydroxylase Inhibitors  for the Potential Treatment of Functional 
Gastrointestinal Disorders. Journal of Medicinal Chemistry ,51(13), 3684â€“3687.
https://doi.org/10.1021/jm800338j
Woosley. (2019). CredibleMeds. https://doi.org/crediblemeds.org
Zigmond, A. S., & Snaith, R. P. (1983). The Hospital Anxiety and Depression Scale. Acta 
Psychiatrica Scandinavica ,67(6), 361â€“370. https://doi.org/10.1111/j.1600-
0447.1983.tb09716.x



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
108
Confidential APPENDIX 1. CONCOMITANT AND  PROHIBITED MEDICATIONS 
NARROW THERAPEUTIC RANGE SUBSTRATES OF CYTOCHROME P450 
(CYP)2C8, CYP3A, AND P-GLYCOPROTEIN (P-GP) Patients using the following systemic 
narrow therapeutic range substrates of CYP2 C8, CYP3A and P-gp are allowed but should be 
monitored during coadministration with IP.  
CYP2C8 Trepostinil 
Selexipag
Torasemide
Trimethoprim
Gemfibrozil
Rosiglitazone 
Pioglitazone 
CYP3A Alfentanil
Cyclosporine 
(dihydro)ergotamine
Everolimus 
Fentanyl 
Sirolimus
Tacrolimus
P-gp Digoxin
Dabigatran
Fexofenadin
e 
PROHIBITED MEDICATIONS
The following medications should not be used during the study: 
Class Drug Name
Generic Name
Monoamine Oxidase Inhibito rs (MAOIs) Isocarboxazid
Phenelzine
Selegiline
Tranylcypromine
Tryptophan Hydroxylase Inhi bitor Telotristat Ethyl
Marketed drugs known to prolong QT/QTc
AND which are also clea rly associated with 
a known risk of Torsades de Pointe 
source: www.CredibleMeds.org ( Woosley,
2021) Amiodarone (Cordarone and others) 
Anagrelide (Agrylin and others) 
Arsenic trioxide (Trisenox)Astemizole (Hismanal
Azithromycin (Zithromax and others
Bepridil (Vascor)Chloroquine (Aralen) 



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
109
ConfidentialClass Drug Name
Generic Name
Chlorpromazine (Thorazine and others) 
Chlorprothixene (Truxal)
Cilostazol (Pletal)  
Ciprofloxacin (Cipro and others)Cisapride (Propulsid)
Citalopram (Celexa and others) 
Clarithromycin (Biaxin and others)Cocaine (Cocaine)
Disopyramide (Norpace) 
Dofetilide (Tikosyn) Domperidone (Motil ium and others)
Donepezil (Aricept) 
Dronedarone (Multaq) Droperidol (Inapsine and others) 
Erythromycin (E.E.S. and others)
Escitalopram (Cipralex and others) Flecainide (Tambocor and others)
Fluconazole (Diflucan and others)
Gatifloxacin (Tequin)Grepafloxacin (Raxar)
Halofantrine (Halfan)
Haloperidol (Haldol and others) Hydroxychloroquine (Plaquenil and others)
Ibogaine
Ibutilide (Corvert) Levofloxacin (Levaquin and others)
Levomepromazine/methotri meprazine (Nosinan 
and others)
Levomethadyl acetate (Orlaam)
Levosulpiride (Lesuride and others)
Mesoridazine (Serentil)Methadone (Dolophine and others) 
Moxifloxacin (Aveloxand others) 
Ondansetron (Zofran and others)Oxaliplatin (Eloxatin) 
Papaverine HCl Intracoronary



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
110
ConfidentialClass Drug Name
Generic Name
Pentamidine (Pentam) 
Pimozide (Orap)
Probucol (Lorelco)
Procainamide (Pronestyl and others)Propofol (Diprivan and others)
Quinidine (Quinaglute and others)
Roxithromycin (Rul ide and others)
Sertindole (Serdol ect and others)
Sevoflurane (Ultane and others) 
Sotalol (Betapace and others)Sparfloxacin (Zagam) 
Sulpiride (Dogmatil and others)
Sultopride (Barnetil and others)Terfenadine (Seldane)
Terlipressin (Teripress and others)
Terodiline (Micturin and others)Thioridazine (Mel laril and others)
Vandetanib (Caprelsa)



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
111
ConfidentialAPPENDIX 2. DIARRHEA MANAGEMENT
CTCAE Grade Description IP S ymptom/Treatment
Mild = 1
(uncomplicated)Increase of < 4 stools 
per day over BaselineContinue same dose Consider anti-diarrheal 
medicines e.g., 4 mg 
loperamide followed by 
2 mg after each loose stool
or every 2-4 hours to a 
maximum of 16 mg/day until bowel movements cease for 
12 hours
Moderate = 2(uncomplicated)Increase of 4â€“6 stools 
per day over Baseline;
IV fluids indicated 
<2 4h o u r s ;
Not interfering with 
ADLIf Grade 2 diarrhea 
SHUVLVWVIRUÂ• 48 hours, 
IP should be 
interrupted until 
recovered to Grade Â”1
followed by dose reduction.
Dose re-escalation is 
possible within 4 weeks 
after start of reduced 
dose.Continue anti-diarrheal 
medicines, if Grade 2
persists fo UÂ•48 hours assess 
for dehydration and 
electrolyte imbalance, consider IV fluids and electrolyte replacement as 
clinically indicated.
Severe = 3
(complicated),QFUHDVHRIÂ• 7s t o o l s  
per day over Baseline;
Incontinence;
,9IOXLGVÂ• 24 hours;
Hospitalization;
Interfering with ADLIP interruption until 
recovery to Grade Â”1
followed by dose 
reduction.
In case of recurrence of 
Grade 3 diarrhea despite 
optimal symptomatic 
treatment and dose reduction, IP should be 
permanently 
discontinued.See Grade 2. 
Consider stool cultures and 
clostridium botulinum toxins to exclude any infection; aggressive IV fluid UHSODFHPHQWÂ• 24 hours,
hospitalization as clinically 
indicated, consider referral to a GI specialist to rule out potential differential 
diagnoses.
Life-threatening = 
4
(complicated)Life-threatening 
consequences 
(e.g., haemodynamic 
collapse)See Grade 3. See Grade 3.
Abbreviations:  ADL = activities of daily life; CTCA E = Common Terminology Criteria for Adverse Events; 
GI = gastrointestinal; IP = investigational product; IV = intravenous



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
112
ConfidentialAPPENDIX 3. LIVER SAFETY:  SUGGESTED ACTIONS AND 
FOLLOW-UP ASSESSMENTS
CTCAE Grade Description IP S ymptom/treatment
Mild = 1 AST or ALT> 1.5X ULN <3 XU L N Continue as planned No action taken
Moderate = 2 AST or ALTÂ•3X ULN and 
< 5X ULN and no signs of severe liver damageReduce to one pill 
BID or interrupt treatment (to be decided by Investigator, based on individual risk assessment.)Re-test ALT and AST, as 
well as ALP, TBL, and eosinophils within 48-72 hours, then at ~7 days, then at ~2 weeks, and assess for signs of severe liver damage:
xIf AST and ALT 
<3 XU L N  a f t e r  2 weeks, return to initial dose if reduced, restart at reduced dose if interrupted. Monitor labs (see above) every 2 weeks for at least 8 weeks.
xIf AST and ALT Â•3X ULN after 2 weeks 
or anytime thereafter, permanently discontinue study medication.
Severe = 3AST or ALT increase WRÂ•5X ULN and 
< 8X ULN and no signs of severe liver damageInterrupt treatmentRe-test ALT and AST, as well as ALP, TBL, and eosinophils within 48-72 hours, then at ~7 days, then at ~2 weeks, and assess for signs of severe liver damage:
xIf AST and ALT 
<3 XU L N  a f t e r  2 weeks, restart at reduced dose. Monitor labs (see above) every week for 4 weeks, then 



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
113
ConfidentialCTCAE Grade Description IP S ymptom/treatment
every 2 weeks for at 
least 8 weeks.
xIf AST and ALT Â•3X ULN after 2 weeks 
or anytime thereafter, permanently discontinue study medication.
Life-threatening 
=4AST or ALT increase 
WRÂ•8X ULN orsigns 
of severe liver 
damage:
-Increase of  liver
transa
minase s (ALT
RU$67Â• 3X
ULN)
and
Appearance of 
fatigue, nausea, vomiting, right upper abdominal quadrant pain or tenderness, fever, rash and/or eosinophilia (> 5%)
orTBL > 1.5X ULNorINR > 1.5Permanently 
DiscontinuePatients showing these 
laboratory abnormalities need to be followed up closely
Abbreviations:  ALP = alkaline phos phatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; 
BID = twice daily; CTCAE = Common Terminology Criteria  for Adverse Events; INR = international normalized 
ratio; IP = investigational product; ULN = upper limit of normal



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
114
ConfidentialAPPENDIX 4. COLLECTION OF PREGNANCY INFORMATION
Definitions
Woman of childbearing potential
A woman is considered fertile following menarc he and until becoming post-menopausal unless 
permanently sterile (see below).If fertility is unclear (e.g., amenor rhea in adolescents or athletes ) and a menstrual cycle cannot be 
confirmed before first dose of IP, additional evaluation should be considered.
Women in the following categories are not considered women of childbearing potential
1. Premenarchal
2. Premenopausal female with one of the following:
xDocumented hysterectomy
xDocumented bilateral salpingectomy
xDocumented bilateral oophorectomy
3. For individuals with permanent infertility due to an alternate medical cause other than
 the
above,
(e.g., MÃ¼llerian agenesis, androgen inse nsitivity), Investigator di scretion should
be applied to determining study entry.
4.Note: Documentation can come from the site personnelâ€™s review of the patientâ€™s medical
records, medical examination, or medical history interview.
5.
Postmenopausal female
xA postmenopausal state is defined as no mens es for 12 months without an alternative
medic
al cause.
A high follicle stimulating hormone (FSH ) level in the postmenopausal range may 
be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement th erapy (HRT). However, in the absence 
of 12 months of amenorrhea, confirmati on with more than one FSH measurement 
is required.
xFemales on HRT and whose menopausal status is in doubt will be required to use one 
of the non-estrogen hormonal hi ghly effective contraception methods if they wish to 
continue their HRT during the study. Otherwi se, they must discontinue their HRT to 
allow confirmation of postmenopausa l status before study enrollment.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
115
ConfidentialCollection of Pregnancy Information
Male patients with partners who become pregnant
xThe Investigator will attempt to collect pr egnancy information on any male patientâ€™s 
female partner who becomes pregnant while the male patient is in this study. This 
applies only to male patients who receive the investigational product.
xAfter obtaining the necessary signed inform ed consent from the pregnant female 
partner directly, the Investigator will record pregnanc y information on the appropriate 
form and submit it to the Sponsor within  24 hours of learning of the partnerâ€™s 
pregnancy. The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mother and child will be forwarded to the 
Sponsor. Generally, the follow up will be no longer than 6 to 8 weeks following the estimated delivery date. Any termination of the pregnancy will be reported regardless 
of fetal status (presence or absence of a nomalies) or indication for the procedure.
Female Patients who become pregnant
xThe Investigator will coll ect pregnancy information on any female patient who 
becomes pregnant while participating in th is study. Information will be recorded on 
the appropriate form and s ubmitted to the Sponsor within 24 hours of learning of a 
patient's pregnancy.
xThe patient will be followed to determin e the outcome of the pregnancy. The 
Investigator will collect follow-up information on the patient and the neonate, and the 
information will be forwarded to the Sponsor. Generally, follow up will not be 
required for longer than 6 to 8 weeks beyond the estimated delivery date. Any 
termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for the procedure.
xWhile pregnancy itself is not considered to be an adverse event (AE) or serious 
adverse event (SAE), any pregnancy comp lication or elective termination of a 
pregnancy will be reported as an AE or  SAE. A spontaneous abortion is always 
considered to be an SAE and will be reported as such. Any poststudy 
pregnancy-related SAE considered reasonabl y related to the i nvestigational product
by the Investigator will be reported to  the Sponsor as described in Section 9.3.5 .
While the Investigator is not obligated to actively seek this information in former 
study patients, he or she may learn of  an SAE through spontaneous reporting.
xAny female patient who becomes pregnant  while participating in the study will 
discontinue the inves tigational product and be withdrawn from the study.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
116
ConfidentialAPPENDIX 5. REGULATORY, ETHI CAL, AND STUDY OVERSIGHT 
CONSIDERATIONS
Regulatory and Ethical Considerations
xThis study will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived fro m international guide lines including the 
Declaration of Helsinki and Council for International Organi zations of Medical 
Sciences International Ethical Guidelines
Applicable International Conferen ce on Harmonisation (ICH) Good Clinical 
Practice (GCP) Guidelines
Applicable laws and regulations
xThe protocol, protocol ame ndments, ICF, Investigator Brochure, and other relevant 
documents (e.g., advertisements) must be submitted to an IRB/IEC by the 
Investigator and reviewed and approved by the IRB/IEC before the study is initiated.
xAny amendments to the pr otocol will require IR B/IEC approval before 
implementation of changes made to the st udy design, except for changes necessary to 
eliminate an immediate hazard to study patients.
xThe Investigator will be res ponsible for the following:
Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/IEC
Notifying the IRB/IEC of serious advers e events or other si gnificant safety 
findings as required by IRB/IEC procedures
Providing oversight of the conduct of th e study at the site and adherence to 
requirements of 21 Code of Federal Regul ations (CFR), ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for c linical studies (if a pplicable), and all 
other applicable local regulations
Financial Disclosure
Investigators and sub-investigators will provide the Sponsor with suffic ient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the ap propriate regulatory aut horities. Investigators are 
responsible for providing information on financial interests du ring the course of the study and for 
1 year after completion of the study.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
117
ConfidentialInformed Consent Process
xThe Investigator or his/her representative will explain the nature  of the study to the 
patient or his/her legally authorized represen tative and answer all questions regarding 
the study.
xPatients must be informed that their pa rticipation is voluntar y. Patients or their 
legally authorized representative will be re quired to sign a statement of informed 
consent that meets the require ments of 21 CFR 50, local re gulations, ICH guidelines, 
Health Insurance Portability and Accountab ility Act requirements,  where applicable, 
and the IRB/IEC or study center.
xThe medical record must include a statem ent that written informed consent was 
obtained before the patient was enrolled in  the study and the date  the written consent 
was obtained. The authorized person obtaini ng the informed consent must also sign 
the ICF.
xPatients must be reconsented to the most current version of the ICF during their 
participation in the study.
xA copy of the ICF must be provided to the patient or the patientâ€™ s legally authorized 
representative.
Patients who are rescreened ar e required to sign a new ICF.
Data Protection
xPatients will be assigned a unique identifi er by the Sponsor. Any patient records or 
datasets that are transferred to the Sponsor  will contain the identifier only; patient
names or any information which would make  the patient identif iable will not be 
transferred.
xThe patient must be informed that his/her pe rsonal study-related da ta will be used by 
the Sponsor in accordance with local data  protection law. The level of disclosure 
must also be explained to the patient.
xThe patient must be informed that his/ her medical records may be examined by 
Clinical Quality Assurance auditors or ot her authorized personnel appointed by the 
Sponsor, by appropriate IRB/IEC member s, and by inspectors from regulatory 
authorities.
Data Quality Assurance
xAll patient data relating to the study will be  recorded on printed or electronic case 
report form (CRF) unless transmitted to the Sponsor or designee electronically 
(e.g., laboratory data). The Investigator is re sponsible for verifyi ng that data entries 
are accurate and correct by physically or electronically signing the CRF.
xThe Investigator must maintain accurate documentation (source data) that supports 
the information entered in the CRF.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
118
ConfidentialxThe Investigator must perm it study-related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide  direct access to source data documents.
xMonitoring details describing strategy (e.g., ri sk-based initiatives in operations and 
quality such as Risk Management and Mitigation Strategies and Analytical 
Risk-Based Monitoring), methods, respons ibilities and requirements, including 
handling of noncompliance issues and mon itoring techniques (central, remote, or 
on-site monitoring) are provide d in the Monitoring Plan.
xThe Sponsor or designee is responsible fo r the data manageme nt of this study 
including quality ch ecking of the data.
xThe Sponsor assumes accountability for ac tions delegated to other individuals 
(e.g., Contract Research Organizations).
xStudy monitors will perform ongoing source da ta verification to confirm that data 
entered into the CRF by authorized site  personnel are accurate, complete, and 
verifiable from source documents; that the safety and rights of  patients are being 
protected; and that the st udy is being conducted in accord ance with the currently 
approved protocol and any other study ag reements, ICH GCP, and all applicable 
regulatory requirements.
xRecords and documents, including signed IC Fs, pertaining to the conduct of this 
study must be retained by the Investigator  for 2 years after last  marketing approval
unless local regulations or in stitutional policies require a longer retention period. No 
records may be destroyed during the reten tion period without the written approval of 
the Sponsor. No records may be transferre d to another location or party without 
written notification to the Sponsor.
Source Documents
xSource documents provide evidence for the existence of the patient and substantiate 
the integrity of the data collected. Source documents are filed at the Investigatorâ€™s site.
xData reported on the CRF or entered in th e electronic CRF that are transcribed from 
source documents must be consistent with the source documents or  the discrepancies 
must be explained. The Investigator may need  to request previous  medical records or 
transfer records, depending on the study. Al so, current medical records must be 
available.
xDefinition of what constitutes source da ta can be found in the Monitoring Manual.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
119
ConfidentialStudy and Site Closure
The Sponsorâ€™s designee reserves the right to clos e the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required docum ents and study supplies 
have been collected and a study-site  closure visit has been performed.
The Investigator may init iate study-site closure at any time , provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the S ponsor or Investigator may include but are 
not limited to:
xFailure of the Investigator to comply w ith the protocol, the requirements of the 
IRB/IEC or local health authorities, th e Sponsor's procedures, or GCP guidelines
xInadequate recruitment of pa tients by the Investigator
xDiscontinuation of further inve stigational product development
Publication Policy
xThe results of this study may be published or  presented at scientif ic meetings. If this 
is foreseen, the Investigator agrees to submit all manuscripts or abstracts to the 
Sponsor before submission. This allows  the Sponsor to protect proprietary 
information and to provide comments.
xThe Sponsor will comply with the requir ements for publication of study results. In 
accordance with standard editorial and ethi cal practice, the Sponsor will generally 
support publication of multicenter studies only in their entire ty and not as individual 
site data. In this case, a coordinating investigator will be designated by mutual 
agreement.
xAuthorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
120
ConfidentialAPPENDIX 6. SIX-MINUTE WALK TEST GUIDELINES
The six-minute walk test (6MWT) should be performed in accordance with the American 
Thoracic Society Guidelines. Please refer to the ATS guidelines and the following general 
procedures for conducting the 6MWT:
Testing Location:
xThe 6MWT should be performed indoors, along a long, flat, straight, enclosed corridor 
with a hard surface that is seldom travele d.  The location should be quiet and free of 
distractions and drafts.
xThe walking course must be 30 meters in le ngth (any deviations from this must be 
reviewed with and approved by the Medica l Monitor/Sponsor prio r to initiating the 
study). A 100-foot hallway is, therefore, requ ired. The length of the corridor should be 
marked every 3 meters. The turnaround points s hould be marked with a cone (such as an 
orange traffic cone). A starting line, which marks the beginning and end of each 60 meter
lap, should be marked on the floor  using brightly colored tape.
Required Equipment:
xCountdown timer (or stopwatch)
xMechanical lap counter
xTwo small cones to mark the turnaround points
xA chair that can be easily m oved along the walking course
xWorksheets (to be provided) on a clipboard
xA source of oxygen
xSphygmomanometer
xAutomated electronic defibrillator
Testing:
Patient Preparation:
xComfortable clothi ng should be worn
xAppropriate shoes for wa lking should be worn
xPatients should use their usual walking ai ds during the test (cane, walker, etc.)
xThe patientâ€™s usual medical regimen should be continued on testing days
xA light meal is acceptable before early morni ng or early afternoon tests, at least 2 hours 
before testing
Patients should not have smoke d or exercised vigorously with in 2 hours of beginning the test



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
121
ConfidentialTesting Conditions:
xThe patient should sit at rest in a chair, lo cated near the starting position, for at least 
10 minutes before the test st arts. During this time, check for contraindications, measure 
pulse and blood pressure and make sure that clothing and sh oes are appropriate.
xTo reduce the variability of the 6MWTs, it is of utmost importance that the eligibility tests 
(Screening and Baseline) and all follow ing 6MWTs are performed under the same 
conditions:
RThe same tester should ad minister the 6MWT for a given patient throughout the trial 
whenever possible
RThe same time of day for conducting the 6MWT for a given patient should be used 
whenever possible to minimize intra-day variability
RPatients who used walking aids at the eligibility tests (Screening and Baseline,
e.g., cane or walker) need to use the same  walking aids at every subsequent 6MWT
xSite staff will need to document if a walking aid (and what type) was used at
each test, if applicable
xIf the patient
normally requires supplemental oxy gen when walking, then the test should be 
performed on the patientâ€™s â€œusualâ€ walking oxyg en flow rate at Ba seline and during all 
subsequent 6MWTs whenever possible.  If the patient usually breathes room air while 
walking, they should perfor m the test on room air.
RPatients who add supplemental oxygen after the Baseline Visit s hould walk without 
oxygen during subsequent walk tests when ever possible so that data will be 
comparable to baseline conditions. However, if this is not possible (from a patient 
safety perspective) then the 6MWT may be conducted with the supplemental oxygen 
and this should be noted in the electronic case report form (eCRF).
RFor patients on supplemental oxygen at Baseline, if the oxygen flow rate must beincreased during the trial due to wors ening gas exchange, 6MWTs should be 
conducted using the same oxygen flow rate that was used at the Baseline Visit 
whenever possible.  However, if this is not possible (from a patient safety 
perspective) then the 6MWT may be conducte d at the increased flow rate and this 
should be noted in the eCRF.
RIf the patient reduces or discontinues supplemental oxygen use during the study, the 
patient should still perform th e 6MWT with the same oxygen flow rate that was used 
at the Baseline Visit.
Instructions for the Patient and Test Administrator:
xA â€œwarm-upâ€ period should not be  performed before the test
xSet the lap counter to zero and the timer to 6 minutes.  Assemble all necessary equipment and 
move to the starting point.
xThe Tester/Investigator should st and near the starting line duri ng the test but should not walk 
with the patient.  Patients will be instructed to walk al one, not run, from one end of the 



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
122
Confidentialwalking course to the other, at their own pace, wh ile attempting to cover as much ground as 
possible in 6 minutes.
xThe tester should not influence the walking pace of the patient.
xDuring the walk, the patients will be allowed to stop intermittently  and stand or sit, or lean 
against the wall, to rest if the patient can no longer continue, but they should resume walking 
as soon as they feel able to do so (see below for instructive language th at should be used in 
this instance). The clock must con tinue to run during the brief rests.
xThe Tester can stop the test at any time for safety-related reasons  (e.g., chest pain, intolerable 
dyspnea, leg cramps, pale or ashen-looking appearance).
Patient Instructions Before the Test - The person administering the test will use the following 
dialog with the patient immediately before the test (repeat the entire set of instructions if the 
patient does not seem to understand):
Râ€œThe object of this test is to walk as far as possible for 6 minutes. You will walk back 
and forth in this hallway. Six minutes is a long time to walk, so you will be exerting 
yourself. You will probably get out of br eath or become exhausted. You are 
permitted to slow down, to stop, and to re st, as necessary. You may lean against the 
wall while resting but resume walking as soon as you are able. You will be walking
back and forth around the cones. You s hould pivot briskly around the cones and 
continue back the other way without he sitation. Now Iâ€™m going to show you. Please 
watch the way I turn without hesitation.â€ ( The tester then demonstrates by walking 
one lap and pivots around a cone briskly ). 
Râ€œAre you ready to do that? I am  going to use this counter to  keep track of the number 
of laps you complete. I will c lick it each time you turn ar ound at this starting line. 
Remember that the object is to walk AS FAR AS POSSIBLE fo r 6 minutes, but donâ€™t 
run or jog.â€ ( The tester should position the patient  at the starting line and ask the 
patient if he/she has any questions about th e test and should confirm that the patient 
understands what he/she is expected to do.  Re peat the entire set of  instructions if the 
patient does not seem to understand).
Râ€œStart now, or whenever you are ready.â€
xPatient Instructions During the Test â€“ As soon as the patient starts  to walk, start the timer. 
The person administering the test  should not walk with the patie nt.  The Tester should not 
talk to anyone during the tes ting. Only standardized phrases for encouragement can be used 
during the test.  To best ensure reproducibility  and consistency of the testing, standardized 
phrases should be used every minut e according to the following pattern:
RAfter the 1stminute, tell the patient the follow ing (in even tones): â€œYou are doing 
well. You have 5 minutes to go.â€
RWhen the timer shows 4 minut es remaining, tell the pati ent the following: â€œKeep up 
the good work. You have 4 minutes to go.â€
RWhen the timer shows 3 minutes  remaining, tell the patien t the following: â€œYou are 
doing well. You are halfway done.â€
RWhen the timer shows 2 minut es remaining, tell the pati ent the following: â€œKeep up 
the good work. You have only 2 minutes left.â€



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
123
Confidential RWhen the timer shows only 1 minute rema ining, tell the patient: â€œYou are doing well. 
You have only 1 minute to go.â€ 
RDo not use other words of encouragement or  body language to get the patient to speed 
up.
RIf the patient is slowing down, stops or expr esses that he/she wants to stop, the tester 
should say: â€œYou can lean agai nst the wall if you would lik e; then continue walking 
whenever you feel able.â€ Do not stop the timer.
RIf the patient stops before the 6 minutes are up and refuses to con tinue (or the Tester 
decides that they should not continue), wheel  the chair over  for the patient to sit on, 
discontinue the walk, and note on the worksh eet the distance, the time stopped, and 
the reason for stopping prematurely. 
RWhen the timer is 15 sec onds from completion, say this: â€œIn a moment Iâ€™m going to 
tell you to stop.  When I do, just stop right  where you are, and I will come to you.â€  
When the timer rings (or buzzes ), say this: â€œStop!â€  Walk over to the patient.  Mark 
the spot where they stopped. 
RIf the patient walked for less than 6 minutes (i.e., stops prior to 6 minutes and does 
not start again), record the time walked as well as the distance.
xPost-Test Procedures:
RThe Tester will record the number of laps from the counter and the additional distance 
covered (the number of meters  in the final lap).  Calculate the total distance walked, 
rounding to the nearest meter, a nd record it on the worksheet.
RFollowing the 6MWT, the Tester will always  obtain and record the post-walk Borg 
Dyspnea Score.
Reference:  (ATS, 2012 )



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
124
ConfidentialAPPENDIX 7. BORG SCALE AND INSTRUCTIONS
Instructions:  Use this rating scale to report how strong your perception is. It can be exertion, 
pain or something else. First l ook at the verbal expressions. Start with them and then the 
numbers. Of these ten (10) or â€Ext remely strongâ€, â€œMaximalâ€ is a v ery important in tensity  level. 
This is the most intense percep tion or feeling yo u have ever had.
If your experience or feeling is â€œVery weakâ€, you should  say â€œ1â€, if it is â€œModerateâ€, say â€œ3â€. 
Note that â€œModerateâ€ is â€œ3â€ and thus weaker th an â€œMediumâ€, â€œMeanâ€ or â€œMid dleâ€. If the 
experience is â€œStrongâ€ or â€œHeavyâ€ (it feels â€œDifficu ltâ€) say â€œ5â€. Note that â€œStrongâ€ is abou t half 
of â€œMaximalâ€. If your feeling is â€œVery strongâ€, choose a numbe r from 6 to 8. If your perception 
or feeling is stronger than  â€10â€, - â€œExtremely strongâ€, â€œMaximalâ€ â€“ you can use a larger numb er, 
e.g. 12 or still higher (thatâ€™s why â€œAbsolute maximumâ€ is marked with a dot.
It's very important that you re port what you actually experience or feel, not what you think you 
should rep ort. Be as spontaneous and honest as possible and try to avoid u nder- or 
overestimatin g. Look at the verbal de scriptors and  then choose a number.
When rating exertion give a numb er that correspo nds to how hard and strenuou s you perceive the 
work to be. The perception of exer tion is mainly felt as strain a nd fatigue in your muscles and as 
breathlessness or any aches.
0 â€Nothing at allâ€, means that you donâ€™t feel any exertio n wh atsoever, no muscle fatig ue, no  
breathlessness or di fficulties breathing.
1 â€œVery weakâ€ means a very light exertion. As taking  a shorter walk at yo ur own  pace.
3 â€œModerateâ€ is somewhat but no t especially hard. It feels go od and not difficult to go on.
5 â€œStrongâ€. The work is hard and tiring , but con tinuing isn't terribly diff icult. Th e effo rt and  
exertion is about half as intense as â€œMaximalâ€.
7 â€œVery strongâ€ is quite strenu ous. You  can still go on, but you really have to pu sh yourself and 
you are very tired.
10 â€œExtremely strong â€“ Maximalâ€ is an extremely strenuou s level. For most people th is is the 
most strenuous exertion they have ever experienced previous ly in their lives.
Æ”,VÂ´$EVROXWHPD[LPXPÂ´IRUH[DPSOHÂ´Â´RUHYHQPRUH
Any questions?
Borg CR10 scaleÂ®
Â© G. Borg, 1998, 2007English



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
125
ConfidentialBorg Scale




		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
126
Confidential APPENDIX 8. WORLD HEALTH ORGANIZATION FUNCTIONAL 
CLASSIFICATION OF PULMONARY HYPERTENSION
Reference:  (Klinger et al., 2019 ) CLASS DESCRIPTION
Class IPatients with pulmonary hypertensi on (PH) but without resulting 
limitation of physical activity.  Ordina ry physical activity does not cause 
undue dyspnea or fatigue, chest pain, or near syncope. 
Class IIPatients with PH resulting in slight limitation of physical activity. They 
are comfortable at rest.  Ordinary physical activity causes undue dyspnea 
or fatigue, chest pain, or near syncope. 
Class IIIPatients with PH resulting in marked limitation of physical activity.  They 
are comfortable at rest.  Less than ordinary activity causes undue dyspnea 
or fatigue, chest pain, or near syncope. 
Class IVPatients with PH with inability to car ry out any physical activity without 
symptoms.  These patients manifest signs of right-heart failure.  Dyspnea 
and/or fatigue may even be present at rest. Discomfort is increased by any physical activity. 



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
127
ConfidentialAPPENDIX 9. PULMONARY AR TERIAL HYPERTENSION-
SYMPTOMS AND IMPA CTâ„¢ QUESTIONNAIRE




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
128
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
129
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
130
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
131
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
132
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
133
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
134
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
135
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
136
ConfidentialAPPENDIX 10. COLUMBIA-SUICIDE  SEVERITY RATING SCALE
BASELINE/SCREENING VISIT




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
137
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
138
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
139
ConfidentialSINCE LAST VISIT




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
140
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
141
Confidential




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
142
ConfidentialAPPENDIX 11. HOSPITAL ANXIET Y AND DEPRESSION SCORE 
(HADS)




		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
143
ConfidentialAPPENDIX 12. CLINICIAN-RATED QUICK INVENTORY OF 
DEPRESSIVE SYMPTOMATOLOGY
NAME: ______________________________________________ TODAY'S DATE: _______________
Please circle one response to each item that be st describes the patient for the last seven days.
1. Sleep Onset Insomnia:
0 Never takes longer than 30 minutes to 
fall asleep. 
1 Takes at least 30 minutes to fall 
asleep, less than half the time. 
2 Takes at least 30 minutes to fall 
asleep, more than half the time. 
3 Takes more than 60 minutes to fall 
asleep, more than half the time.
2. Mid-Nocturnal Insomnia:
0 Does not wake up at night. 
1 Restless, light sleep with few 
awakenings.
2 Wakes up at least once a night, but 
goes back to sleep easily. 
3 Awakens more than once a night and 
stays awake for 20 minutes or more, 
more than half the time. 
3. Early Morning Insomnia:
0 Less than half the time, awakens no 
more than 30 minutes before necessary.
1 More than half the time, awakens more 
than 30 minutes before need be.
2 Awakens at least one hour before 
need be, more than half the time.
3 Awakens at least two hours before 
need be, more than half the time.
4. Hypersomnia: 
0 Sleeps no longer than 7-8 hours/night, 
without naps. 
1 Sleeps no longer than 10 hours in a 24 
hour period (include naps). 
2 Sleeps no longer than 12 hours in a 24 
hour period (include naps). 
3 Sleeps longer than 12 hours in a 24 
hour period (include naps).
Enter the highest score on any
1 of the 4 sleep items (1â€“4 above) _____5. Mood (Sad):
0 Does not feel sad.
1 Feels sad less than half the time.2 Feels sad more than half the time.
3 Feels intensely sad virtually all the 
time.
6. Appetite (Decreased):0 No change from usual appetite. 
1 Eats somewhat less often and/or 
lesser amounts than usual. 
2 Eats much less than usual and only 
with personal effort. 
3 Eats rarely within a 24-hour period, 
and only with extreme personal effort or with persuasion by others.
7. Appetite (Increased):
0 No change from usual appetite. 
1 More frequently feels a need to eat 
than usual.
2 Regularly eats more often and/or 
greater amounts than usual.
3 Feels driven to overeat at and between 
meals.
8. Weight (Decrease) Within The Last Two 
Weeks: 
0 Has experienced no weight change.
1 Feels as if some slight weight loss 
occurred.
2 Has lost 2 pounds or more. 
3 Has lost 5 pounds or more. 
9. Weight (Increase) Within the Last Two 
Weeks: 
0 Has experienced no weight change.
1 Feels as if some slight weight gain has 
occurred.
2 Has gained 2 pounds or more. 
3 Has gained 5 pounds or more.



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
144
ConfidentialEnter the highest score on any 1 of the 4 
appetite/weight change items (6â€“9
above) _____
10. Concentration/Decision Making: 
0 No change in usual capacity to 
concentrate and decide. 
1 Occasionally feels indecisive or notes 
that attention often wanders.
2 Most of the time struggles to focus 
attention or make decisions.
3 Cannot concentrate well enough to 
read or cannot make even minor 
decisions.
11. Outlook (Self):
0 Sees self as equally worthwhile and 
deserving as others. 
1 Is more self-blaming than usual. 
2 Largely believes that he/she causes 
problems for others. 
3 Ruminates over major and minor 
defects in self.
12. Suicidal Ideation: 
0 Does not think of suicide or death.
1 Feels life is empty or is not worth 
living.
2 Thinks of suicide/death several times a 
week for several minutes.
3 Thinks of suicide/death several times a 
day in depth, or has made specific plans, or attempted suicide.
13. Involvement: 
0 No change from usual level of interest 
in other people and activities.
1 Notices a reduction in former 
interests/activities.
2 Finds only one or two former interests 
remain.
3 Has virtually no interest in formerly 
pursued activities.14. Energy/Fatiguability:
0 No change in usual level of energy.
1 Tires more easily than usual.
2 Makes significant personal effort to 
initiate or maintain usual daily 
activities.
3 Unable to carry out most of usual daily 
activities due to lack of energy.
15. Psychomotor Slowing: 
0 Normal speed of thinking, gesturing, 
and speaking.
1 Patient notes slowed thinking, and 
voice modulation is reduced.
2 Takes several seconds to respond to 
most questions; reports slowed 
thinking.
3 Is largely unresponsive to most 
questions without strong 
encouragement.
16. Psychomotor Agitation: 
0 No increased speed or disorganization 
in thinking or gesturing.
1 Fidgets, wrings hands and shifts 
positions often.
2 Describes impulse to move about and 
displays motor restlessness. 
3 Unable to stay seated. Paces about 
with or without permission. 



		
Clinical Study Protocol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
145
ConfidentialEnter the highest score on either of
the 2 psychomotor items (15 or 16 
above) ____
Scoring Interpretation
Enter the highest score on any 1 of the 4 sleep items
(1 â€“ 4)_____ Normal 0 â€“ 5
Item 5 _____ Mild 6 â€“ 10
Enter the highest score on any 1 appetite / weight item
(6 â€“ 9)_____ Moderate 11 â€“ 15
Item 10 _____ Severe 16 â€“ 20
Item 11 _____ Very Severe 21+
Item 12 _____
Item 13 _____
Item 14 _____
Enter the highest score on either of the 2 psychomotor items
(15 and 16)_____
Total Score (Range 0 â€“ 27) _____
Â”1986, 2000 UT Southwestern Medical Center, Dallas



		
Clinical Study Protoc ol Protocol RVT-1201-2002 
Altavant Sciences GmbH Effective: 19JAN2022 
146
Confidential APPENDIX 13. REVEAL LITE 2.0 (BENZA ET AL., 2020 ) 
REVEAL Lite 2 is based on REVEAL 2.0, but includes  only six noninvasive and modifiable parameters: 
 1.  New York Heart Association (NYHA)  or WHO functional class (FC);  
FC I = -1, FC II = 0, FC III = +1, FC IV = +2
 2. Systolic BP;  
SBP < 110 mm Hg = + 1,   ^WÑˆÏ­Ï­Ï¬ÑÏ¬
 3. Heartrate 
,ZÑ…ÏµÏ²ÄÆ‰ÅµÑÐ½Ï­Í•,ZÑ‡ÏµÏ²ÑÏ¬
 
4.  6-min walk distance(6MWD);  ÑˆÏ°Ï°Ï¬ÅµÅÅ¶Ñ -2, 
320 - 440 min = -1
165 â€“ 319 = 0<165 min = +1 5. Brain natriuretic peptide (BNP)/N-terminal prohormone of brain natriuretic peptide (NT-proBNP);   
BNP < 50 pg/mL OR NT-proBNP < 300 pg/mL =  -2
BNP 50 â€“ 199 pg/mL = 0
BNP 200 - 799 pg/mL = +1 EWÑˆÏ´Ï¬Ï¬Æ‰ÅÍ¬Åµ>KZEd -Æ‰ÆŒÅ½EWÑˆÏ­Ï­Ï¬Ï¬Æ‰ÅÍ¬Åµ>Í—Ð½Ï®
 
6. Renal insufficiency: if estimated glomerular filtration rate [eGFR] <60 mL/min/1.73 m2 or reported 
as â€œrenal insufficiency,â€ as assessed by the principal investigator when eGFR was unavailable +1 ); If ÑˆÏ²Ï¬ÆšÅšÄžÅ¶ÆÄÅ½ÆŒÄžÅÆÏ¬  
 
For the REVEAL Lite 2 assessment (w ith scores ranging from 1 to 14);
 
a score between 1 and 5 was considered low risk,
a score of 6 or 7 was considered intermediate risk, 
Ä‚ÆÄÅ½ÆŒÄžÅ½Ä¨Ï´Å½ÆŒÅšÅÅÅšÄžÆŒÇÄ‚ÆÄÅ½Å¶ÆÅÄšÄžÆŒÄžÄšÅšÅÅÅšÆŒÅÆÅ¬Í˜



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
147
ConfidentialAPPENDIX 14. ADVERSE EVENTS:  DEFINITIONS AN D PROCEDURES 
FOR RECORDING, EVALUA TION, FOLLOW UP, AND 
REPORTING
Definition of Adverse Event
Adverse Event Definition
xAn adverse event (AE) is any untoward medical occurr ence in a patient, temporally associated with 
the use of investigational product (IP), whet her or not considered related to the IP.
xNOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use 
of IP.
Events Meeting the Adverse Event Definition 
xAny abnormal laboratory test results (hematology, clin ical chemistry, or urinalysis) or other safety 
assessments (e.g., electrocardiogram, radiological s cans, vital signs measurements), including those 
that worsen from Baseline, considered clinically significant in the medical and scientific judgment
of the investigator (i.e., not relate d to progression of underlying disease).
xExacerbation of a chronic or intermittent pre-ex isting condition including either an increase in 
frequency and/or inte nsity of the condition.
xNew conditions detected or diagnosed after IP ad ministration even though it may have been present 
before the start of the study.
xSigns, symptoms, or the clinical sequel ae of a suspected drug-drug interaction.
xSigns, symptoms, or the clinical sequelae of a suspected overdose of either IP or a concomitant 
medication.  Overdose per se will not be reported as an AE/serious adverse event (SAE) unless it is 
an intentional overdose taken with possible suicid al/self-harming intent.  Such overdoses should be 
reported regardless of sequelae.
xâ€œLack of efficacyâ€ or â€œfailure of expected pharmaco logical actionâ€ per se will not be reported as an 
AE or SAE. Such instances will be captured in the efficacy assessments. However, the signs, 
symptoms, and/or clinical sequelae resulting from l ack of efficacy will be reported as AE or SAE if 
they fulfil the definition of an AE or SAE.
Events NOT Meeting the Adverse Event Definition 
xAny clinically significant abnormal laboratory fi ndings or other abnormal safety assessments 
which are associated with the underlying disease,  unless judged by the Investigator to be more 
severe than expected for the patientâ€™s condition.
xThe disease/disorder being studied or expect ed progression, signs, or symptoms of the 
disease/disorder being studied, unless more se vere than expected for the patientâ€™s condition.
xMedical or surgical procedure (e.g., endoscopy, appendectomy): the condition that leads to the 
procedure is the AE.
xSituations in which an untoward medical occurr ence did not occur (social and/or convenience 
admission to a hospital).
xAnticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at 
the start of the study that do not worsen.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
148
ConfidentialDefinition of Serious Adverse Event
If an event is not an AE per definition above, then  it cannot be an SAE even if serious conditions 
are met (e.g., hospitalization for signs/symptom s of the disease under study, death due to 
progression of disease).
A serious adverse event is defined as any untoward medical occurrence that, at any dose:
1. Results in death
2. Is life-threatening
The term 'life-threatening' in the definition of 'serious ' refers to an event in wh ich the patient was at risk 
of death at the time of the event. It does not refer to  an event, which hypothetically might have caused 
death, if it were more severe.
3. Requires inpatient hospitalization or pr olongation of existing hospitalization
In general, hospitalization signifies that the patient h as been detained (usually  involving at least an 
overnight stay) at the hospital or em ergency ward for observation and/or  treatment that would not have 
been appropriate in the physicianâ€™s office or outpatient setting. Complications that occur during 
hospitalization are AEs.  If a complication prolongs hospitalization or fulfills an y other serious criteria, 
the event is serious. When in doubt as to whether â€œhospitalizationâ€ occurred or was necessary, the AE 
should be considered serious.
Hospitalization for elective treatment of a pre-exis ting condition that did not worsen from Baseline is 
not considered an AE.
4. Results in persistent disability/incapacity
xThe term disability means a substantial disrup tion of a personâ€™s ability to conduct normal life 
functions.
xThis definition is not intended to include experi ences of relatively minor medical significance such 
as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma 
(e.g., sprained ankle) which may interfere with or prevent everyday life functions but do not 
constitute a substantial disruption.
5. Is a congenital anomaly/birth defect
6. Other situations:
xMedical or scientific judgment should be ex ercised in deciding whether SAE reporting is 
appropriate in other situations such as important  medical events that may not be immediately life
threatening or result in death or hospitalizati on but may jeopardize the patient or may require 
medical or surgical intervention to prevent one of  the other outcomes listed in the above definition.
These events should usually  be considered serious.
xExamples of such events include invasive or  malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronc hospasm, blood dyscrasias, or convulsions that do 
not result in hospitalization, or devel opment of drug dependency or drug abuse.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
149
ConfidentialRecording and Follow Up of Adverse Ev ents and/or Serious Adverse Events
Adverse Event and Seriou s Adverse Event Recording
xWhen an AE/SAE occurs, it is the responsibility of the Investigator to review all documentation 
(e.g., hospital progress notes, laboratory reports , and diagnostics reports) related to the event.
xThe Investigator will then record all relevant AE/SAE information in the case report form.
xIt is not acceptable for the Investigator to send photocopies of the patientâ€™s medical records to 
Sponsor in lieu of completion of the AE/SAE case report form page.
xThere may be instances when copies of medical re cords for certain cases are requested by Sponsor.
In this case, all patient identifiers, with the excep tion of the patient number, will be redacted on the 
copies of the medical records before submission to Sponsor.
xThe Investigator will attempt to establish a diagnos is of the event based on signs, symptoms, and/or 
other clinical information. Whenever possible, th e diagnosis (not the individual signs/symptoms) 
will be documented as the AE/SAE.
Assessment of Intensity
The Investigator will make an assessment of in tensity for each AE and SAE reported during the study 
and assign it to 1 of the following categories: 
xMild: An event that is easily tolerated by the patient, causing minimal discomfort, and not 
interfering with everyday activities.
xModerate: An event that causes sufficient di scomfort and interferes with normal everyday 
activities.
xSevere: An event that prevents normal everyday ac tivities. An AE that is assessed as severe 
should not be confused with a SAE. Severe is a category utilized for rating the intensity of an 
event; and both AEs and SAEs can be assessed as severe.
xAn event is defined as â€˜seriousâ€™ when it meets at least 1 of the predefined outcomes as described in 
the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
xThe Investigator is obligated to assess the re lationship between IP and each occurrence of each 
AE/SAE.
xA â€œreasonable possibilityâ€ of a relationship convey s that there are facts, evidence, and/or 
arguments to suggest a causal relationship, ra ther than a relationship cannot be ruled out.
xThe Investigator will use clinical j udgment to determine the relationship.
xAlternative causes, such as underlying disease(s), concomitant therapy, and other risk factors, as 
well as the temporal relationship of the event to IP administration will be considered and 
investigated.
xThe Investigator will also consult the Investig atorâ€™s Brochure and/or Product Information, for 
marketed products, in his/her assessment.
xFor each AE/SAE, the Investigator must document in the medical notes that he/she has reviewed 
the AE/SAE and has provided an assessment of causality.
xThere may be situations in which an SAE h as occurred and the Investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important that the 
Investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to the Sponsor.



		
Clinical Study Protoc ol Protocol RVT-1201-2002
Altavant Sciences GmbH Effective: 19JAN2022
150
ConfidentialAssessment of Causality
xThe Investigator may change his/her opinion of causality in light of follow-up information and 
send a SAE follow-up report with the updated causality assessment.
xThe causality assessment is one of the criteria used when determining regulatory reporting 
requirements.
Follow Up of Adverse Events and Serious Adverse Events
xThe Investigator is obligated to perform or ar range for the conduct of s upplemental measurements 
and/or evaluations as medically indicated or as  requested by the Sponsor to elucidate the nature 
and/or causality of the AE or SAE as fully as po ssible. This may include additional laboratory tests 
or investigations, histopathological examinati ons, or consultation with other health care 
professionals.
xIf a patient dies during participation in the st udy or during a recognized follow-up period, the 
Investigator will provide the Sponsor with a copy of any post-mort em findings including 
histopathology.
xNew or updated information will be recorded in the originally completed case report form.
xThe Investigator will submit any up dated SAE data to the Sponsor wi thin 24 hours of receipt of the 
information. 
Reporting of Serious Adverse Events
Serious Adverse Event Reporting to the Spons or via an Electronic Data Collection Tool
xThe primary mechanism for reporting an SAE to the Sponsor will be the electronic data collection 
tool.
xIf the electronic system is unavaila ble, then the site will use the paper SAE data collection tool (see 
next section) in order to report the event within 24 hours).
xThe site will enter the SAE data into the elect ronic system as soon as it becomes available.
xAfter the study is completed at a given site, the el ectronic data collection tool will be taken off-line 
to prevent the entry of new data or changes to existing data.
xIf a site receives a report of a new SAE from  a study patient or receives updated data on a 
previously reported SAE after the electronic data co llection tool has been taken off-line, then the 
site can report this information on a paper SAE fo rm (see next section) or to the Sponsorâ€™s medical 
monitor/SAE coordinator by telephone.
xContacts for SAE reporting can be foun d on the Contact Information page.
Serious Adverse Event Reporting to th e Sponsor via Paper Case Report Form
xEmail transmission of the SAE paper case report  form is the preferred method to transmit this 
information to the Sponsorâ€™s Medical  Monitor or the SAE Coordinator.
xIn rare circumstances and in the absence of f acsimile equipment, notifi cation by telephone is 
acceptable with a copy of the SAE data collection tool sent by overnight mail or courier service.
xInitial notification via telephone does not replace the need for the Investigator to complete and sign 
the SAE case report form pages within the designated reporting time frames.
xContacts for SAE reporting can be found on the Contact Information page.



		